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Summary 
Introduction: Chronic wounds do not progress through the normal wound healing 
process and represent a significant burden to healthcare systems and to the 
hundreds of thousands of patients in the UK who suffer with them. There are 
significant challenges in both understanding the underlying biology and 
developing novel therapies to encourage healing of chronic wounds. nWASP is a 
regulator of the actin cytoskeleton through interactions with the Arp2/3 complex 
and is involved in a variety of roles particularly at the cell membrane in protrusion 
and vesicle formation. This study investigates the expression pattern of nWASP in 
chronic wound tissues and explores, through both in vitro and in vivo models, the 
cellular and molecular impact of nWASP activity on the function of cells involved 
in wound healing and also in cancer cells. 
Methods: Clinical cohorts from patients with chronic wounds and lung cancer 
were tested for the expression of nWASP expression through qPCR analysis. Cell 
models, based on keratinocytes (HaCaT) and vascular endothelial (HECV) cells 
were employed to evaluate the influence of nWASP on cellular functions that are 
key to the healing process genetic knockdown and/or using nWASP-specific 
inhibitors. Resulting cellular signalling changes was explored by way of protein 
kinase arrays and Western blotting and in vivo models were used to assess the 
therapeutic values of topical application of nWASP inhibitors in wound healing. A 
similar approach was employed using lung cancer cell models. 
Results: nWASP was found to be significantly elevated at the transcript level in 
human non-healing chronic wound tissues compared with healing tissues. nWASP 
inhibitors, namely wiskostatin and 187-1, and knockdown, altered the spreading 
and attachment behaviour of HaCaT cells. Several protein signalling pathways 
affected by nWASP inhibition were identified, in particular TrkB signalling and 
downstream PLCγ1 phosphorylation were shown to be impaired by nWASP 
inhibition in HaCaT cells. Healing of hole-punch wounds in the ears of db/db mice, 
a diabetic model which exhibit impaired wound healing, was improved by topical 
and systemic nWASP inhibitor treatment. In the context of lung cancer, nWASP 
expression was significantly correlated with the survival of the patients. Invasive 
behaviour was found to be impaired in the more invasive SK-MES-1 cell line with 
motility and migration being affected in A-549 cells following nWASP inhibitor 
treatment. Decreased paxillin activity in membrane focal adhesions was shown 
following nWASP inhibition and knockdown. 
Conclusions: This study suggests that nWASP activity may be related to the non-
healing behaviour of chronic wounds and that its activity can affect function of 
keratinocytes and endothelial cells. Together with the findings in the in vivo 
models, it strongly points nWASP as a therapeutic target in non-healing wounds. 
nWASP is also a potential biomarker and therapeutic target in human lung cancer, 
in which it influences the aggressive behaviour of lung cancer cells. The study has 
identified that TrkB, PLCγ1 and paxillin signalling can be controlled by nWASP 
activity. 
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1.1. Wound Healing 
Wound healing can be described as the repair of cutaneous tissue damage or 
breakdown. It is an extremely complex biological process consisting of a complex 
cascade of events, each requiring the coordination of a variety of signalling 
pathways and cell types. The multifaceted process of wound healing has been 
reviewed many times in great depth (Shaw and Martin, 2009, Velnar et al., 2009, 
Li et al., 2007) and is commonly broken down into the stages of coagulation and 
haemostasis, inflammation, proliferation and remodelling. Coagulation and 
haemostasis occur immediately after injury and a blood clot forms. Inflammation 
then occurs where cell types such as neutrophils and macrophages are recruited 
to the wound. They act to prevent infection and remove debris in preparation for 
reepithelialisation during the proliferation phase where keratinocytes migrate to 
close the wound. Angiogenesis and production of a new matrix also occurs during 
the proliferation stage. Remodelling of scar tissue following wound closure then 
follows and can take years. This complex process is orchestrated by signals from 
numerous cell types using growth factors, cytokines and other signalling methods 
(Barrientos et al., 2008, Behm et al., 2012). The phases of wound repair vary in 
duration and are not linear events but overlap as the collaboration of many cell 
types and signalling pathways takes place to achieve healing (Figure 1.1). This 
process is described in greater depth in the following sections. 
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Figure 1.1: The wound healing process. The normal wound healing process 
consists of several overlapping stages which occur over varying time points 
depending on the nature of the wound. Image adapted from Shield HealthCare. 
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1.1.1. Coagulation and Haemostasis 
The immediate response to acute tissue damage to the skin involves the 
coagulation and haemostasis stages which have the primary aim of stopping blood 
loss and protecting the vascular system from further damage. Vasoconstriction 
occurs in the minutes following tissue damage as a neuronal reflex at the site of 
injury and blood loss. This involves a contraction of vascular smooth muscle cells 
in the circular muscle layer which can rapidly prevent or reduce blood loss in 
transversally injured vessels whilst a clot at the wound site forms as a longer-term 
prevention for exsanguination. 
Coagulation is initiated when platelets come into contact with extracellular matrix 
(ECM) components at the site of injury, signalling them to release clotting factors. 
These are generally precursors of proteolytic enzymes and work together in the 
coagulation cascade to form a clot (Palta et al., 2014) consisting of fibronectin, 
fibrin, vitronectin, thrombospondin and the platelets themselves. Thrombin is an 
important coagulation factor which acts to convert fibrinogen to insoluble strands 
of fibrin in the clot. The clot acts to further limit blood loss whilst also creating a 
scaffold for infiltrating cells, forming a reservoir of growth factors and acting as a 
provisional matrix for reepithelialisation in the later phases of wound healing. 
Platelet activity also initiates signalling cascades which are important for the 
progression of the wound healing process through growth factors and cytokines 
such as platelet derived growth factor (PDGF), transforming growth factor-(TGF-
, epidermal growth factor (EGF) and insulin-like growth factors (Hart, 2002). 
These signals can direct the activity of other cell types such as neutrophils, 
endothelial cells and fibroblasts in the subsequent stages of wound healing. 
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1.1.2. Inflammation 
Following the immediate response of coagulation and haemostasis, the 
inflammatory response is initiated which mainly accomplishes protection from 
microorganisms through an influx of leukocytes to the area of injury. Neutrophils 
are recruited initially to the wound site by chemoattractive signals such as TGF-
peptides, and platelet products that are present during the early wound 
response. Once neutrophils have migrated to the wound environment, integrin 
receptors on their surface enhance cell-matrix interactions. This allows them to 
fulfil their main function of preventing/removing infection through the 
phagocytotic removal of tissue debris, foreign particles and bacteria and the 
destruction of these particles through the release of oxygen derived free radical 
species and proteolytic enzymes (Wilgus et al., 2013). Upon the removal of 
infection and debris, neutrophil activity must be reduced for progression to the 
next stage in the wound healing process. The neutrophil population is eliminated 
from the wound through apoptosis or extrusion to the wound surface as slough 
which appears as a yellow, fibrinous tissue. High levels of neutrophil activity in the 
first part of the inflammatory phase usually only lasts a few days but 
contamination that prolongs neutrophil presence within the wound may delay 
healing.  
During the later part of the inflammatory phase, typically around 48-72 hours 
following injury, monocytes are also attracted to the wound by similar signalling 
agents to neutrophils such as PDGF and TGF-ECM degradation products, such 
as collagen and elastin breakdown products and thrombin are also specific 
chemotactic signals for monocytes. These monocytes undergo phenotypic 
changes to form larger phagocytic macrophages which become the predominant 
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cell type at work in the later stages of inflammation. Macrophages act 
phagocytotically to remove tissue debris at the wound site, kill pathogenic 
organisms and remove neutrophils (Koh and DiPietro, 2011). They are also key 
signalling cells, providing a reservoir of potent growth factors including TGF- 
EGF, fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), 
fibronectin and collagen (Schnoor et al., 2008). These cytokines are critical for the 
recruitment, activation and direction of fibroblasts, keratinocytes and endothelial 
cells in the next stage of wound healing, highlighting the pivotal role macrophages 
have in the transition between inflammation and wound closure. A reduction in 
macrophage activity in healing wounds can impair the process due to disrupted 
fibroblast proliferation and maturation, delayed angiogenesis and poor 
debridement (see section 1.2.3.1).  
Lastly, lymphocytes also enter the wound site in the late inflammatory stage, 
according to signals such as interleukin-1 (IL-1) and immunoglobulin breakdown 
products, where their activity is required for optimal healing of dermal wounds 
(Hart, 2002).  
1.1.3. Proliferation and remodelling 
Once haemostasis and inflammation has been achieved and there is no further 
bleeding, risk to immunity or injury a healing acute wound will begin the 
proliferative stage where the physical lesion closes. As with the haemostasis and 
inflammation stages, this phase is not distinct but part of the continuous series of 
overlapping stages of wound healing and, like the previously described stages, 
consists of numerous events requiring the coordination of several pathways and 
cell types. Unlike the previous stages, which occur from the moment of injury and 
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for a short while afterwards lasting perhaps 3 or 4 days, the proliferative stage 
may last for up to 2 weeks or more depending on the size of the wound. During 
this proliferation period the synthesis of a new permanent ECM and the 
movement of keratinocytes are the predominant activities (Stephens and Thomas, 
2002). A more detailed breakdown of the processes that contribute to this 
activity, which can be categorised into matrix production, angiogenesis, 
reepithelialisation and remodelling is given below. 
1.1.3.1. Matrix production 
Fibroblasts are the main cell type responsible for matrix deposition following 
tissue injury. Fibroblasts in the areas surrounding the wound proliferate following 
injury and then migrate into the wound site when stimulated by the signalling 
factors previously mentioned, such as TGF-and PDGF which are released by 
platelets and inflammatory cells. They proliferate when at the injury site and 
produce proteins such as fibronectin, hyaluronan, proteoglycans and procollagens 
which they deposit to restore the matrix (Bainbridge, 2013). Collagens are the 
foundation of the intracellular matrix within the wound, with type 3 collagen 
more common in wound and granulation tissues (at around 40%) than in 
unwounded dermis where type 1 collagen makes up the majority of the collagen 
composition, at around 80% (Bailey et al., 1975). After prolonged proliferation and 
protein production by fibroblasts a collagen rich ECM accumulates which acts to 
support cell migration and offers strength and integrity to the tissues. Fibroblasts 
then alter their phenotype to become myofibroblasts. These cells extend 
pseudopodia which connect to components in the reconstituted ECM and 
contribute to wound contraction as they retract. Following wound closure, 
redundant fibroblasts are abolished through apoptosis (Desmouliere et al., 1995). 
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1.1.3.2. Angiogenesis 
Angiogenesis, or the formation of new blood vessels, is critical in wound healing 
and occurs throughout all phases of the wound healing process. Due to damage to 
the vascular system immediately following injury, only tissue at the wound edge 
has access to a vascular supply through perfusion by uninjured vessels and 
diffusion through undamaged interstitium. For the vascular system at the wound 
to be reinstated, capillary sprouts initially form at the edges of the wound clot and 
then invade to form a microvascular network of new capillaries which offers a 
blood supply to the wound site (Tonnesen et al., 2000). Factors that are secreted 
during the haemostasis phase as previously described can stimulate blood vessel 
remodelling. Angiogenic factors such as FGF, vascular endothelial growth factor 
(VEGF), PDGF, angiogenin, TGF-and TGF-and the action of inhibitory factors 
such as angiostatin and steroids can act synchronously on proliferating resident 
endothelial cells to activate mitosis, promote locomotion and stimulate further 
signalling with endothelial growth factors. Hypoxia in tissues can also cause 
signalling molecules to be produced to induce endothelial cell growth and 
proliferation (Michiels et al., 2000). In response to angiogenic signalling, resident 
endothelial cells respond by producing proteases to degrade the basal lamina in 
the parent vessel allowing access to the ECM. Chemotaxis as the cell travels 
through the matrix in response to the environmental stimuli then happens 
alongside proliferation, remodelling and differentiation. 
1.1.3.3. Reepithelialisation 
The reepithelialisation stage of the wound healing process, where cells migrate 
over the wound site to restore the epithelial surface, is an essential part of wound 
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healing and is used as the defining parameter of its success. Without successful 
reepithelialisation, a wound is not considered healed. This process is impaired in 
all types of chronic wounds which are discussed in more detail later in this 
chapter. 
Keratinocytes are the major components of the epidermis which divide and 
differentiate to form different layers which together form an effective protective 
barrier for the body. The cells in the basal layer are responsible for the continuous 
renewal of the epidermis through mitotic division. These basal cells differentiate 
and form the spinous and granular layers as they proceed up away from the 
dermis, and eventually the flattened, keratin-rich cells of the corneum layers 
which are shed. In healthy epidermal tissues, there is stability in the renewal of 
the epidermis maintained by a balance between cell proliferation in the basal 
layers and a loss of cells at the stratum corneum (desquamation). During the 
maturation of keratinocytes and their transition between each layer, the shape, 
position, and expression of keratins, structural proteins and lipids varies 
(Bouwstra et al., 2003, Baroni et al., 2012). 
Upon injury, activation of keratinocytes occurs following signalling from several 
cytokines and growth factors present in the wound site as a result of the activity 
of other cell types including neutrophils and macrophages, as previously 
described. This active phenotype is marked by changes to cell surface receptors, 
cytoskeletal structures and keratin 6 and 16 expression (Coulombe, 1997). This 
change in phenotype then allows keratinocytes to migrate over the newly formed 
matrix from the wound edge until the layer of cells is complete and the wound is 
closed. A representation of the layers of the epidermis and the movement of cells 
during wound healing is shown in Figure 1.2. 
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Figure 1.2: Structure of the epidermis and reepithelialisation. Schematic illustration of the epidermis made up largely of keratinocytes which divide and 
differentiate to form the basal, spinous, granular and cornified layers as they mature. During reepithelialisation, basal keratinocytes proliferate and migrate 
across the newly formed wound bed. 
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Keratinocytes must undergo several stages of functional change during the 
reepithelialisation stage of wound healing (Pastar et al., 2014). Initially, 
keratinocytes at the wound edge must loosen their adhesion to each other and to 
the basal lamina and must develop a mobile and flexible phenotype which will 
permit migration over the new matrix. Hemidesmosomes and desmosomes, the 
structures which maintain contacts with the surrounding substratum and cells 
respectively, must therefore be disassembled (Heng, 2011). As the first migratory 
keratinocytes move over the new matrix, cells behind this leading edge begin to 
proliferate. As with the previously discussed stages of wound healing, the control 
of the migration and proliferation of keratinocytes during the reepithelialisation 
process is carefully regulated by a variety of signalling molecules and regulatory 
proteins. Growth factors, cytokines, chemokines, keratins, matrix 
metalloproteinases (MMPs), integrins, and extracellular macromolecules can all 
coordinate different aspects of migration through inducing polarisation, altering 
adhesion or controlling actin dynamics (Pastar et al., 2014). In particular, growth 
factors, such as EGF, and cytokines, such as IL-1 and IL-6, can modulate migratory 
and proliferative phenotypes of keratinocytes (Barrientos et al., 2008). 
Several cellular processes occur during cell migration of keratinocytes during 
reepithelialisation (Vicente-Manzanares et al., 2005, Trepat et al., 2012) beginning 
with signal attenuation where cytokines and other signalling molecules are sensed 
by the cell and polarisation is initiated where a leading edge is formed. Receptors, 
particularly G-protein couple receptors, and other membrane bound proteins 
such as integrins (Schwartz, 2010) sense the surroundings and can respond to a 
wide range of possible stimuli through signal transduction, leading to changes in 
cell motility (Cotton and Claing, 2009). Actin-rich membrane structures, sheet-like 
lamellipodia or finger-like filopodia, extend from the leading edge in the direction 
12 
 
of migration and adhesions between the actin cytoskeleton and the extracellular 
matrix or neighbouring cells stabilise protrusions and form traction sites to allow 
the cell to move over them. The attachment and movement of keratinocytes 
through fibrin and the newly deposited ECM in the wound is facilitated by MMPs. 
The transmission of contractile forces through the adhesions between the cell 
cytoskeleton and the environment allows the cell to pull the cytoplasm and cell 
body behind the protrusions towards the leading edge. Myosin motors cause this 
contraction by reorganising actin bundles within the cell that are connected to the 
adhesions (Case and Waterman, 2015). As the advance of the cell in the direction 
of signalling takes place through the projection of membrane structures, their 
adhesion and the traction applied through them to move the cell body forwards is 
followed by the release of connections at the rear of the cell. Optimal adhesion 
dynamics, where there is a coordinated balance in the formation of adhesions at 
the leading edge of the cell and disassembly at the rear, is key in allowing the 
motility of migrating cells (Mierke, 2013, Velnar et al., 2009, Palecek et al., 1997, 
Holly et al., 2000). Furthermore, cell-cell adhesion has been shown to promote 
sustained sheet-like keratinocyte migration during wound healing (Nardini et al., 
2016). The various key elements of migration which are critical for the effective 
migration of keratinocytes and hence wound closure are shown in Figure 1.3. 
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Figure 1.3: The principles of cell migration. Cell migration consists of several 
stages dependent on the reorganisation of the actin cytoskeleton. In response to 
an extracellular signal cell polarisation occurs and a leading-edge forms (A) where 
actin-rich membrane protrusions (lamellipodia) extend from the cell body (B) and 
new adhesions form (C) allowing the cell to gain traction and the cell body to 
move towards the signal (D). Attachments on the trailing end of the cell are then 
released as the cell migrates. Image adapted from (Ladoux and Nicolas, 2012). 
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Final contraction and closure of the wound leads to the resolution stage where 
scar remodelling occurs. 
1.1.3.4. Remodelling 
Remodelling of the wound is the final phase of wound healing and consists of the 
development of the new epithelium and scar tissue formation and remodelling 
(Velnar et al., 2009). This phase occurs once the wound site has been temporarily 
repaired to ensure protection from infection from outside the body and can last 
for years in some cases. Remodelling of a wound is tightly regulated to achieve 
the optimum balance between the synthesis and breakdown of components of 
the wound site to achieve the best possible tensile strength. Degradation of 
temporary components of the wound, such as hyaluronic acid and fibronectin, 
occurs and a balance between the synthesis and degradation matrix constituents 
such as collagen is also important. 
The end tensile strength of a wound will not reach that of the previous 
unwounded tissue and depends on several factors. Collagen fibre accumulation 
correlates with the strength of the tissue but the location of the wound and 
duration from wounding also influences the strength of the resulting tissue (Bayat 
et al., 2003). Degradation of collagen is carried out by MMP enzymes which are 
produced by neutrophils, macrophages and fibroblasts and regulated by inhibitory 
factors. A gradual increase in the activity of the inhibitors causes a shift towards 
the accumulation of matrix factors due to the decreased activity of MMPs. During 
the wound remodelling stage, collagen bundles mature to become more 
organised, orientated and cross-linked. Additionally, fibroblast and macrophage 
activity is reduced by apoptosis, vascular growth declines and metabolic activity at 
the injury site decreases. Following successful progression through the wound 
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healing process an acute injury site will become a mature scar with high tensile 
strength. 
Effective wound healing depends on the timely coordination of many diverse 
processes, cell types, signalling pathways and structures that have been described 
briefly above. The process described here is a rudimentary portrayal of how an 
acute wound may heal but in reality the cell types, pathways and timescales 
involved may vary considerably depending on the site of the injury, extent of the 
tissue damage and many other factors. For example, a surgical incision will 
generally result in limited disruption to the epithelial and connective tissues and 
with reduced risk of infection will often result in timely and effective tissue repair. 
In comparison, healing of an open wound with extensive loss of tissue is more 
complex, will take more time and may result in more apparent scarring. In 
addition to changes to the severity, location or size of the wound, many other 
factors can affect the effectiveness of the wound healing process and may lead to 
a poor outcome and, in some cases, chronic wound development. 
1.2. Chronic wounds 
Wounds can be classified based on aetiology as acute, which typically occur 
suddenly, following trauma or burns, or following surgery. In most cases, acute 
wounds close predictably through the series of events described above, within a 
reasonable time period. However, underlying pathological complications or other 
numerous factors that impair the normal healing process can cause chronic or 
non-healing wounds to form. The vast majority of these can be classified as 
venous ulcers, diabetic ulcers, pressure ulcers and arterial insufficiency ulcers 
(Kirsner, 2016). Although the exact definition of a chronic wound is often 
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deliberated in the literature it is generally accepted that a chronic wound is one 
that does not heal predictably within a reasonable timescale. 
1.2.1. Risk factors and causes 
Due to the complex nature of the wound healing process there are many factors 
that can be affected which can interfere with progression of a healing wound. 
These may lead to conditions that aren’t conducive to the regeneration and repair 
of tissues so leading to chronic wound formation. A better understanding of the 
underlying causes of chronic wound development and the factors that can alter 
the effectiveness of wound healing may lead to the development of therapeutic 
approaches which can treat the problem of chronic wounds. Some of these 
factors, including infection, age, diabetes, oxygenation, vascular compromise and 
growth factor imbalance to name a few (Guo and Dipietro, 2010), are discussed in 
this section.  
Local factors such as oxygenation can affect wound healing and be responsible for 
chronic wound development. Oxygen has long known to be critical for prevention 
of infection, the control of angiogenesis and affecting keratinocyte and fibroblast 
behaviour during reepithelialisation and matrix synthesis (Bishop, 2008, Rodriguez 
et al., 2008). Local hypoxia in the wound site following injury, due to vascular 
disruption and high oxygen consumption by active cells, can stimulate wound 
healing through encouraging cytokine and growth factor production. However, 
prolonged hypoxic conditions in the wound, which can occur in systemic 
conditions such as diabetes, advanced age and vascular disease where poor tissue 
oxygenation results from impaired vascular flow, can impair healing. Chronic 
wounds are markedly hypoxic compared with control tissues (Tandara and 
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Mustoe, 2004). Fibrin cuffs, deposits of fibrin around the capillary beds leading to 
intravascular pressure and tissue hypoxia, are thought to contribute to impaired 
wound healing in patients with venous disease (Vasudevan, 2014). 
Infection is another local factor that can affect wound healing progression. 
Microorganisms are able to access the underlying tissues following injury and are 
routinely removed during the inflammation stage of healing. Ineffective or 
incomplete decontamination can prolong the inflammatory stage and lead to 
chronic wound formation. This prolonged inflammation can cause a shift in 
protease content within the wound with increased MMP activity, which can 
degrade the ECM, and an imbalance in growth factor activity, delaying and 
impairing wound closure (Edwards and Harding, 2004, Menke et al., 2007). 
Biofilms, complex communities of bacteria which aggregate in an extracellular 
polysaccharide matrix, can develop on chronic wounds and can form a protected 
microenvironment which is more resistant to conventional antibiotic treatment 
(Davis et al., 2008). As such, the presence of biofilms on chronic wounds can 
impair the immune response and removal of infection from the wound site so 
impairing the progressing of healing. 
Numerous systemic factors can influence wound healing including age, sex 
hormones, diabetes, various medications including chemotherapy drugs, obesity, 
alcohol consumption, smoking and diet, which are discussed at great length by 
Guo and Dipietro in their review, (Guo and Dipietro, 2010), and briefly in the 
following section. 
Every phase of healing has been shown to undergo age-related changes including 
increased secretion of inflammatory mediators, delayed infiltration of 
macrophages and impaired macrophage function, reduced growth factor 
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secretion, delayed angiogenesis, collagen deposition and reepithelialisation and 
decreased wound strength to name a few (Gosain and DiPietro, 2004). Overall, 
advanced age is found to delay, rather than impair, the wound healing process 
and is a major risk factor for impaired wound healing, a problem which is 
increasing due to the aging population of the UK. 
Diabetes is well-known to be a significant risk factor for the development of 
chronic wounds, in particular diabetic foot-ulcers which are estimated to occur in 
15% of diabetes sufferers (Reiber et al., 1999). Neuropathy (nerve damage) is 
commonly experienced in diabetes patients and may be causative to the 
occurrence of breakages to the skin, especially on the feet. The numerous known 
physiologic factors that then contribute to wound healing deficiencies in diabetic 
individuals account for the high incidence of chronic wounds. These factors 
include hypoxia from insufficient perfusion and angiogenesis leading to impaired 
wound healing as previously discussed. Hyperglycaemia lead to the production of 
advanced glycation end-products (Huijberts et al., 2008, Peppa et al., 2009) and 
also adds to oxidative stress through excessive reactive oxygen species (ROS) 
production (Vincent et al., 2004) both which are associated with impaired wound 
healing. These common problems associated with diabetes cause changes to the 
wound healing process, including impaired growth factor production, 
angiogenesis, macrophage function, epithelialisation, balance between ECM 
components and MMP remodelling and collagen accumulation, and lead to high 
chronic wound incidence amongst diabetes sufferers (Brem and Tomic-Canic, 
2007, Guo and Dipietro, 2010). 
Obesity is also a risk factor for chronic wound development with increases in 
pressure ulcers in obese individuals as a result of poor perfusion and 
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hypovascularity. This combined with friction from skin-on-skin contact, skin folds 
harbouring microorganisms, ischaemia in subcutaneous adipose tissues and 
stress, which are all common problems associated with obesity, means that obese 
individuals are predisposed to the risk of impaired wound healing (Wilson and 
Clark, 2004, Anaya and Dellinger, 2006). 
In summary, numerous factors can affect the progression of the wound healing 
process and certain conditions such as advanced age, diabetes and vascular 
diseases which can increase the incidence of one or more of these factors can 
predispose individuals to the risk of chronic wound development. The influences 
of the factors leading to chronic wound development are not mutually exclusive 
and may have a role in multiple phases of the complex wound healing process. 
Multiple underlying properties and molecular changes to the wound healing 
process can be affected by the factors discussed in this section, some of which are 
represented in Figure 1.4. 
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Figure 1.4: Schematic comparing cellular differences in acute and chronic wounds. The normal cellular content and processes which occur in acute wound 
healing are shown (left) and compared with processes often found in the chronic wound environment (right). Image from: medicalgraphics.de. 
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1.2.2. Incidence, cost and impact of chronic wounds 
Numerous studies have been carried out to estimate the prevalence of chronic 
wounds both in the UK and worldwide. It is estimated that 1-2% of the population 
in developed countries will acquire a chronic wound during their lifetime 
(Gottrup, 2004). Chronic wound incidence is predicted to increase due to the 
increasing populations of obese, diabetic and aged individuals amongst other 
factors (Sen et al., 2009). The ongoing nature of chronic wounds and the 
significant care required to manage them (see section 1.2.3) means there is a 
significant cost to healthcare systems worldwide associated with chronic wound 
care. Estimates of the cost to the NHS for caring for patients with a chronic wound 
are up to £3.1bn per year – which accounted for about 3% of the total 
expenditure on health (estimates for 2005/2006) (Posnett and Franks, 2008). This 
financial burden is predicted to increase by at least a third, due to the forecasted 
increase in the UK population aged 65 and over and diabetes incidence, by 2027 
(Posnett and Franks, 2007, Posnett and Franks, 2008). In the UK the cost to the 
NHS of treating patients with venous ulceration, pressure ulcers  and foot ulcers is 
estimated to be £168-198m, £1.8-2.6bn and £300m per year respectively (Posnett 
and Franks, 2007). The prevalence and incidence of chronic wounds is found to be 
variable over numerous studies which examine different types of chronic wounds 
in a variety of settings. Some of the findings of these studies reporting the 
incidence and impact of the distinct types of chronic wounds are described below. 
1.2.2.1. Pressure ulcers 
Approximately 1 in 5 hospital inpatients are estimated to have a pressure ulcer in 
hospitals across Europe at any time (Clark, 2004), but they also affect many 
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individuals in residential and nursing homes where prevalence is not well 
documented (Bennett et al., 2004). Most cases of pressure ulcers occur over areas 
where skin covers bone, such as sacral, ischial and trochanteric pressure ulcers 
and in the lower extremities on  the heel and feet (Vasconez et al., 1977, Cannon 
and Cannon, 2004). Cost of treating a pressure ulcer is estimated to be up to 
£10,551 (2004 estimate) per patient for more severe ulcers. The increasing aging 
population in the UK will increase lead to an increase in chronic wound incidence 
(Wicke et al., 2009) with approximately two thirds of pressure ulcers occurring in 
people aged 60-80 years old (Leblebici et al., 2007). 
1.2.2.2. Venous leg ulcers 
Leg ulcers commonly occur in patients with venous insufficiency where sustained 
venous hypertension can lead to poor perfusion and damage to the skin 
(Whiddon, 2007). Around 70,000-190,000 individuals are estimated to have a 
venous leg ulcer in the UK at any time with prevalence of 1.2-3.2 per 1000 people 
(Graham et al., 2003). Again, prevalence of venous ulcers correlates with age with 
a study of a local population showing prevalence in individuals over 85 at 
8.29/8.06 (men/women respectively) per 1000 people compared with 0.3/0.5 per 
1000 in younger individuals (Moffatt et al., 2004). 
1.2.2.3. Diabetic foot ulcers 
It is estimated that there are around 64,000 individuals with a foot ulcer at any 
time in the UK (Gordois et al., 2003) and diabetic foot ulcers are estimated to 
occur in 15% of all patients with diabetes (Reiber et al., 1999). Diabetic foot ulcers 
are estimated to precede 84% of all diabetes-related lower-leg amputations 
(Reiber et al., 1995). Furthermore, the rate of amputation of lower-limbs, 
23 
 
adjusted for age, is estimated to be 15 times higher in individuals with diabetes 
than in the general population (Armstrong et al., 1997) with 48.9% of all 
amputations in people with diabetes (Holman et al., 2012). The annual 
expenditure (2010-11) on foot ulcers and amputation is estimated to be up to 
£661m (McInnes, 2012). 
1.2.2.4. Impact on patient quality of life 
In addition to the significant costs associated with chronic wounds, they also have 
a large impact on the quality of life of patients. Physical symptoms from chronic 
wounds, such as leakage, odour and particularly pain, as well as impairments to 
daily living such as difficulties with mobility have been reported to affect patients 
(Franks and Morgan, 2003, Price et al., 2008, Green and Jester, 2010). A vicious 
cycle which contributes to the non-healing nature of chronic wounds also exists in 
that chronic wound development often causes disability and immobility which in 
itself can contribute to impaired healing (Kloth, 2009). Pain was found to be the 
worst impact on patients suffering with an ulcer (Herber et al., 2007). Further 
studies which examine other aspects of the quality of life of patients including 
physical, emotional and social aspects found that patient scores were reduced in 
all categories with the presence of venous ulcers (Dias et al., 2014). Physical 
aspects of quality of life were affected most significantly by ulceration (Dias et al., 
2014, Szewczyk et al., 2015). 
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1.2.3. Wound management 
1.2.3.1. Current strategies 
Due to the complex nature of the tissue repair process and the risk of poor 
healing due to many factors, proper wound management strategies are important 
to provide optimal conditions for wound healing. This is paramount in patients 
who are susceptible to chronic wound development and in patients who are 
already suffering with a chronic wound.  Guidelines on the clinical wound 
management have been described by numerous sources and will be described in 
more detail here with particular reference to chronic wound management 
strategies. 
The initial step in the management of a wound is usually through assessment of 
the aetiology of the wound and also of the patient, as any pre-existing medical 
condition that may affect the progression of wound healing or the development 
of a wound must be considered. If the observed wound is acute in origin and the 
patient does not suffer from any pre-existing condition that will affect the healing 
of the wound then, with appropriate care, the wound should heal successfully. 
Assessment, proper cleaning, appropriate wound closure methods and suitable 
dressing choices with compression or gauze where required are considerations 
when managing the closure of an acute wound (Nicks et al., 2010). 
The wound management process becomes more complex when a chronic wound 
develops or where a patient is predisposed to develop a chronic wound, such as in 
diabetic or elderly individuals. Certain pre-emptive strategies are often in place 
for those who are known to be susceptible to the development of chronic 
wounds. Nursing staff and other healthcare professionals can implement 
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preventative interventions such as providing support surfaces, such as pressure-
relieving mattresses and bedding (McInnes et al., 2008), and turning or 
repositioning individuals in their care who may be at risk of pressure ulcer 
development (Lyder and Ayello, 2008). Diabetes nurses can actively prevent 
diabetic foot ulcers through early detection of changes to sensitivity, foot care, 
dressing applications and education (Aalaa et al., 2012). 
In cases where chronic wounds do develop, standard practise for wound 
management usually involving debridement and dressing changes provided by a 
specialist wound-care nurse or other healthcare professional. 
Debridement is described as the removal of non-viable, infected and 
hyperkeratotic tissue and is a method used to encourage and accelerate the 
wound healing process. During debridement, healthcare professionals aim to 
remove ischaemic and necrotic tissue as they have more potential to acquire 
infection and contamination by foreign bodies and bacteria, which impairs the 
wound healing process. Several techniques for the debridement of wounds exist 
(Steed, 2004). Surgical debridement with a knife or scissors is rapid and the most 
efficient debridement method but is not used in all cases as patients may be at 
medical risk or are not in need of extensive debridement. Mechanical 
debridement through the application and removal of gauze or saline irrigation can 
be carried out. The lavage of wounds with saline or an anti-bacterial/anti-biotic 
solution can also be used to decrease bacterial contamination. Irrigation must be 
appropriate for the wound as it is suggested that low pressure irrigation may not 
reach contamination below the surface whereas the use of high pressure 
irrigation may cause damage to fine tissues although more wound area can be 
accessed and so is only recommended for wounds with severe contamination. 
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Enzymatic and biologic approaches to debridement also exist. In cases of 
widespread infection or where there is difficult access to the whole wound and 
other debridement options aren’t appropriate, an operative approach to remove 
contaminated and necrotic tissue may be employed, or a necrectomy. During an 
operation, a surgeon uses indicators such as capillary refill, muscle fibre 
contraction and colour to determine which tissues need removal. Certain tissues 
such as tendons and fascia are not removed except in cases of severe 
contamination as they promote the progression of healing. In extreme cases of 
infection, amputation may be required. Debridement is used most often in 
chronic wounds to attempt to make the wound behave more like an acute wound 
by removing infection and tissue abnormalities that may delay progression 
through the normal wound healing process. 
Along with debridement and reducing contamination of the wound, dressings are 
one of the most important aspects of wound care. Many wound dressings types 
and materials are available for numerous wound types and so the selection of 
appropriate dressings is important for improving healing. The multiple available 
dressing options are reviewed in detail in numerous publications and new 
dressings are regularly being developed to find novel ways to encourage chronic 
wounds to heal (Dhivya et al., 2015, Sarabahi, 2012, Sood et al., 2014). 
Historically, some of the characteristics of an ideal wound dressing include: 
providing a barrier to external contaminants, high moisture vapour permeability, 
high capacity for absorption and cost effectiveness (Goodman et al., 1956). With 
the advancement of technology, hundreds of products have been developed 
which can formulate dressings and act to encourage wound healing by targeting 
various aspects of the healing process. As such, current additional characteristics 
of an ideal wound dressing include the ability to: enhance epidermal migration, 
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promote angiogenesis and synthesis of connective tissue and provide 
debridement action to name a few (Dhivya et al., 2015). 
Examples of some of the types of dressings used in the current treatment of 
chronic wounds include absorbent dressings, compression bandages, 
antimicrobial dressings, film dressings, foam dressings and hydrogel dressings, 
some of which are described briefly here. Hydrogels are gauze or sheets with a 
high water content which have a gentle debriding effect whilst rehydrating 
necrotic tissue and causing minimal damage to healthy tissue. They require a 
secondary absorbent dressing and are not suitable to heavy exuding wounds (Lay-
Flurrie, 2004). Alginates are another antimicrobial dressing approach and are 
composed of soft fibres which react with a moist wound and can facilitate 
autolytic debridement (Kannon and Garrett, 1995). Silver impregnated dressings 
in the form of alginates, foams and gels utilise the antiseptic properties of silver to 
promotes tissue repair (Demling and Leslie DeSanti, 2002). Regular dressing 
changes are required for the proper management of chronic wounds and 
decisions on the types of dressing and intervals between changes and 
debridement is different depending on the type, size and position of the wound. 
On top of dressings, compression bandages or stockings are often applied for the 
treatment of venous leg ulcers. These are used to narrow veins, reduce 
ambulatory venous pressure and reduce venous reflux and they help decrease 
inflammatory cytokines, lowers capillary fluid leakage so alleviating limb oedema. 
This is all with the goals of reducing pain, prevention of recurrence and healing of 
ulcers (Nair, 2014). 
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1.2.3.2. Recent developments in wound management strategies 
As has been described in earlier sections, the problems associated with the 
incidence of chronic wounds, which cause stress on both patients and healthcare 
systems, are widespread and long-standing. Due to the difficult nature of these 
wounds, many unconventional treatments have been used historically in an 
attempt to treat them, such as the use of wine, honey, egg whites and deliberate 
infection (Shah, 2011). Nowadays, the approaches for the treatment of chronic 
wounds include more established methods which usually include dressing, 
debridement and compression of the wounds. However, the lack of proper 
investigation and classification of chronic wounds has been identified by several 
studies (Drew et al., 2007, Gottrup et al., 2001, Harding et al., 2002) and currently 
healthcare professionals are often limited to the traditional wound care 
approaches that have previously been described to manage wounds. In recent 
years, developments have been made in the surgical, nursing and academic 
arenas in an attempt to provide better standards of care to patients suffering with 
chronic wounds.  
The advancement in dressing types and properties represent a significant step 
forward in wound management techniques in recent years. Better understanding 
of the underlying mechanisms of chronic wound development and requirements 
for effective healing has enabled the design of dressings that can adjust the 
wound environment to accommodate these requirements and actively encourage 
wound healing. For instance, bioactive wound dressings can be derived from 
natural tissues or artificial sources with examples including collagen-, hyaluronic 
acid-, chitosan- and elastin- based dressings (Dhivya et al., 2015). Bioengineered 
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skin substitutes which contain cultured epidermal substitutes have also been 
shown to be effective biological wound dressings (Kuroyanagi et al., 2001). 
Interventions and advice from healthcare professionals based on new findings on 
the prevention and healing of chronic wounds can also help with the burden of 
chronic wounds. This is possible now due to specialised departments and training 
dedicated to the treatment of chronic wounds. For instance, exercise has been 
shown to accelerate wound healing amongst healthy older individuals (Emery et 
al., 2005). Where appropriate, this can be used as a measure to try and encourage 
potentially beneficial lifestyles in susceptible individuals and as a measure to 
encourage wound healing where chronic wounds are present.  
The use of hyperbaric oxygen therapy is being used to treat pressure ulcers where 
devices or chambers maintain increased pressure and oxygen levels on the wound 
areas. This method has been proven to be very successful treatment option for 
chronic wounds in addition to dressings and debridement (Bhutani and 
Vishwanath, 2012). Oxygen therapy with delivery through dressings directly onto 
the wound site is another modern method being developed for the treatment of 
chronic wounds. Biophysical modalities such as electrical stimulation and the use 
of ultrasound for diagnostic and therapy purposes have also been studied as 
modern methods for the treatment of chronic wounds (Frykberg and Banks, 
2015). 
The burden of chronic wounds on healthcare systems and patients, and limited 
treatment options, highlights the need for effective diagnosis and the 
identification of new therapeutic approaches.  The complex and diverse 
underlying genetic and molecular processes involved in the wound healing 
process and chronic wound development make identifying the cause of a 
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particular chronic wound a difficult task. However, these genetic and protein 
expression deficiencies in chronic wounds also represent potential diagnostic and 
therapeutic opportunities. Several studies have explored these molecular changes 
and as a result have highlighted many novel proteins that could potentially be 
used to explain the development of chronic wounds, offer prognoses and even 
influence wound repair through development of new drugs and treatments. For 
example, several studies have examined the expression protein content of chronic 
wound exudates (Fernandez et al., 2008, Huang et al., 2006) and the gene 
transcript expression changes (Jiang and Harding, 2011) to identify potential 
indicators of wound status. Furthermore, our understanding of the molecular 
changes in chronic wounds has led to the studying the effect of applying factors 
which may be able to encourage wound healing. For example, the application of 
cytokines and growth factors, in particular basic-FGF and granulocyte 
macrophage-colony stimulating factor (GM-CSF) has been shown to improve 
pressure ulcer closure (Chen et al., 2008). Moreover, the important role of growth 
factors such as PDGF and EGF in wound healing and the effect of improved wound 
healing following exogenous application has been studied many times. As such, 
PDGF and EGF are approved for human application to encourage wound healing. 
A recent query during the preparation of this thesis for “wound healing” in 
PubMed retrieved 136493 records ranging back from 1989. Almost half of these 
articles were published in the last 10 years demonstrating an upsurge in the 
research into wound healing in recent times. As research continues and 
understanding of the subtleties and underlying mechanisms of wound healing and 
hence chronic wounds improves, new key signalling molecules and their roles are 
being identified, new phases and sub-phases are being delineated and novel 
therapies based on these discoveries are being developed to treat chronic 
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wounds. This study highlights the molecule nWASP as a novel prognostic marker 
and therapeutic target in the context of chronic wounds. 
1.3. nWASP 
nWASP is a well characterised protein belonging to the Wiskott-Aldrich syndrome 
protein/WASP family verprolin-homologous protein (WASP/WAVE) protein family. 
There are several members known members of this family which are divided into 
the WASP subfamily (referred to as WASPs), and WAVE subfamily (referred to as 
WAVEs). 
1.3.1. The WASP/WAVE protein family 
The first member of the WASPs to be identified was WASP itself, mutations in 
which were found to be the cause of Wiskott-Aldrich Syndrome (WAS) (Derry et 
al., 1994). WAS is an X-linked recessive disorder initially described in patients 
suffering with thrombocytopenia, eczema and immunodeficiency (Aldrich et al., 
1954), now commonly labelled the clinical triad of WAS symptoms. Patients 
exhibit varied severity of symptoms with some suffering with the full classic triad 
of clinical manifestations, who often do not survive until adulthood, whereas 
many patients demonstrate a milder phenotype and have an improved survival 
rate (Sullivan et al., 1994). Different mutations of the WASP gene have been 
linked to the varied phenotypes of WAS with evidence that mutations that disrupt 
the activity of the important functional domains lead to more severe phenotypes 
(Orange et al., 2004, Zhu et al., 1997). A molecule identified in the brain, but is 
widely expressed in different tissues, which shares several functional motifs with 
WASP was named neural-WASP (nWASP) and is the second member of the WASP 
subfamily (Miki et al., 1996). In addition to the WASP subfamily, WAVE1, 2 and 3 
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make up the WAVE subfamily. WAVE1 (also referred to as Scar1, suppressor of 
cAR 1) was first identified in 1998 as a regulator of the actin cytoskeleton through 
interactions with the actin-related protein (Arp) 2/3 complex downstream of Rac 
(Miki et al., 1998b, Machesky and Insall, 1998). Following the identification of 
WAVE1, two further WAVE homologues, which were also found to associate with 
the Arp2/3 complex as with WAVE1, were characterised and named WAVE2 and 3 
(Suetsugu et al., 1999). Novel members of the WASP/WAVE family also have 
recently been identified based on the resemblance between characteristic 
domains in their protein structure. These are WASP and SCAR homologue (WASH), 
WASP homologue associated with actin, membranes and microtubules (WHAMM) 
and junction mediating and regulatory protein (JMY) (Linardopoulou et al., 2007, 
Campellone et al., 2008, Zuchero et al., 2009). 
1.3.2. Structure and activation of WASP/WAVE proteins 
nWASP shares several multifunctional domains with WASP including the WASP 
homology (WH1) domain, GTPase-binding domain/Cdc42 and Rac interactive 
binding (GBD/CRIB) domain, a proline-rich region and VCA domain consisting of a 
verprolin-homology (V) region, a cofilin-like (C) region and an acidic (A) region. 
Some of the shared domains between WASP/WAVE proteins and commonly 
studied binding partners of nWASP are shown in Figure 1.5. 
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Figure 1.5: The structure of WASP/WAVE family proteins and binding partners of 
nWASP. The main functional domains of nWASP, WASP and WAVE proteins are 
shown in this simplified diagram. The N-terminal WH1 domain of WASP and 
nWASP mediates protein complex formation with proteins such as WIP. The 
WAVE homology domain is present on the N-termini of WAVE proteins. The basic 
(B) domain binds phosphoinositides which is important for protein localisation. 
Activators such as cdc42 bind to the GTPase-binding domain (GBD) in WASP 
proteins activation allows exposure of the C-terminal VCA domain. Actin 
monomer binding to the V domain combined with the Arp2/3 complex interaction 
at the CA regions leads to actin polymerisation. The proline rich-region binds SH3 
domain-containing proteins which have varied roles in directing the activity of 
WASP/WAVE proteins. Image adapted from (Takenawa and Suetsugu, 2007) and 
(Tyler et al., 2016). 
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The WAVE family consists of WAVE1, 2 and 3, all of which have a WAVE homology 
domain (WHD) but lack the GBD/CRIB domain and, like the WASPs, have a basic 
region, a proline-rich region and a VCA domain (Takenawa and Miki, 2001). The 
shared domains found in WASP and WAVE proteins are shown in Figure 1.5. 
Endogenous WAVEs assemble into a heterologous, multi-molecular complex 
referred to as the WAVE complex. The multi-protein complex associated with 
WAVE1 was first described as comprising several components, namely, p53-
inducible messenger RNA (PIR121, also called Rac2 associated protein/Sra1), Nck-
associated protein (Nap1), haematopoietic stem/progenitor cell protein 300 
(HSPC300) and Abl Interactor 2 (Abi2) (Eden et al., 2002). Complexes consisting of 
the same proteins, or their paralogues, as described in the WAVE1 complex were 
later identified for WAVE2 and 3 as well (Gautreau et al., 2004, Stovold et al., 
2005, Innocenti et al., 2004). 
The WASP/WAVE family regulates actin dynamics through interactions with many 
other factors, in particular the Arp2/3 complex. The Arp2/3 becomes activated 
when bound to the CA region on the C-terminal of WASP/WAVE proteins and 
initiates actin polymerisation when bound in conjunction with an actin monomer 
binding to the V region (Machesky and Insall, 1998, Takenawa and Miki, 2001, 
Rohatgi et al., 1999, Yarar et al., 1999). This interaction is the most important in 
terms of WASP function with many other binding partners regulate WASP and 
WAVE activation. 
1.3.2.1. nWASP activation 
Under resting conditions, nWASP and WASP exist in an auto-inhibited, folded 
conformation where an interaction between the GBD domain in the N-terminal 
region and the C-terminus masks the VCA region, as shown in Figure 1.6A. This 
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interaction inhibits access of the Arp2/3 complex to the CA region and so WASP 
and nWASP remain inactive (Kim et al., 2000, Miki et al., 1998a). The competitive 
binding of ligands such as the Rho GTPase, Cdc42 and phosphatidylinositol 4, 5-
bisphosphate (PIP2) with WASPs can disrupt the interactions between the C- and 
N- termini which mask the VCA region. Cdc42 binds to the GBD and PIP2 can 
interact with the basic region. Either of these interactions can destabilise the 
auto-inhibited conformation of WASPs and enhance the binding of the other 
ligand leading to exposure of the VCA region and the activation of WASP family 
proteins (Prehoda et al., 2000, Rohatgi et al., 2000). When WASP proteins are 
active, Figure 1.6B, the exposed VCA domain is able to bind the Arp2/3 complex, a 
globular actin (G-actin) molecule and an actin filament as substrates leading to the 
polymerisation of a branched actin filament (Le Clainche and Carlier, 2008). 
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Figure 1.6: Activation of nWASP. Under resting conditions (section A), nWASP 
exists in an autoinhibited state where an intramolecular reaction between the 
GTPase-binding domain (GBD) and C region conceal the catalytic VCA region from 
accessing the Arp2/3 complex. Many regulators, such as PIP2 and cdc42 as 
described in Figure 1.5, can interact with nWASP and destabilise the autoinhibited 
state allowing interaction between the VCA regions and the Arp2/3 complex and 
actin (section B). Actin filament nucleation and polymerisation can then take place 
through the activity of the Arp2/3 complex. Image based on (Goley and Welch, 
2006). 
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In addition to the autoinhibitory regulatory mechanism controlling the activation 
of WASP proteins, phosphorylation has been implicated in regulating their 
activity, although the importance of phosphorylation in WASP and nWASP 
regulation is reported to be variable. Common sites of WASP phosphorylation in 
the GBD domain (tyrosine 291) and in the VCA region (serines 483 and 484) have 
been shown to regulate WASP activation, turnover and subcellular localisation 
(Dovas and Cox, 2010). Phosphorylation of nWASP has also shown to infer some 
regulation of activity. One study demonstrated that phosphorylation of nWASP 
can result in its activation or degradation in neurites depending on the 
experimental conditions (Suetsugu et al., 2002), whereas threonine 
phosphorylation of nWASP has been shown to promote the autoinhibitory 
conformation (Park et al., 2012). Furthermore, phosphorylation at tyrosine 256 by 
FAK has been shown to regulate the subcellular localisation to the cytoplasm and 
subsequent stimulation of cell migration (Wu et al., 2004). However, the 
importance of nWASP phosphorylation is not well understood but appears to infer 
some level of regulation on nWASP activity. 
1.3.2.2. nWASP inhibitors 
Small molecule inhibitors of nWASP have been identified, namely 187-1 (Peterson 
et al., 2001) and wiskostatin (Peterson et al., 2004), which bind to nWASP and 
allosterically block its activity by stabilising the closed, auto-inhibited 
conformation of nWASP, depicted in Figure 1.6A.  
In 2001, Peterson et al. carried out a screening to identify inhibitors of compounds 
that could inhibit PIP2-induced actin assembly. 187-1, a 14-amino acid long cyclic 
peptide, was found to successfully block this actin assembly and nWASP was 
found to be the target of the compound. 187-1 was found to bind to nWASP and 
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allosterically stabilise its autoinhibited conformation and so prevented the 
activation of the Arp2/3 complex and downstream actin polymerisation. 187-1 
showed a dose-dependent inhibition of PIP2-stimulated actin assembly (IC50 ~ 
2µM).  
Peterson et al. also carried out a screening to identify molecules that can 
effectively inhibit actin polymerisation in 2004 and identified wiskostatin, a cell-
permeable N-alkylated carbazole that interacts with a cleft in the regulatory GBD 
of nWASP in the solution structure of the complex. Through this interaction, 
wiskostatin acts to bias the allosteric equilibrium towards the inactive 
conformation of nWASP. An EC50 of ~4µM was calculated for wiskostatin to inhibit 
actin assembly in response to PIP2. Examination of the binding of wiskostatin in 
the GBD cleft of nWASP also suggested that the interaction between wiskostatin 
with WASP is likely to be conserved. Furthermore, concentrations over 20µM 
were found to inhibit spontaneous actin polymerisation. This is an important 
consideration as it suggests that wiskostatin may not be specific to nWASP at high 
inhibitor concentrations, as such, some studies have claimed that using 
wiskostatin as a tool for selectively examining nWASP function is inappropriate. 
For instance, one study demonstrated non-specific effects on membrane 
transport and cellular ATP levels at high levels of 25µM wiskostatin and above 
(Guerriero and Weisz, 2007) and another study demonstrated that inhibition of 
cytokinesis by wiskostatin at 10µM levels does not rely on nWASP (Bompard et al., 
2008). However, many other studies have used wiskostatin, often alongside 
nWASP knockdown models, to highlight key roles of nWASP in vitro. For instance, 
wiskostatin has been used to highlight the role of nWASP in cell spread (Zhang et 
al., 2014) and in the regulation of B-cell receptor signalling (Liu et al., 2013).  
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These two non-natural, structurally unrelated molecules, wiskostatin and 187-1, 
both mediate nWASP inhibition through allosteric regulation of the autoinhibitory 
mechanism that controls nWASP activation. Use of nWASP inhibitors have helped 
to elucidate the roles of nWASP in vitro, as discussed further in this chapter, with 
wiskostatin used more extensively in research to examine the role of nWASP. 
1.3.2.3. Activation of WAVE proteins 
The mechanism of activation of WAVEs has been the subject of debate for many 
years. It is now clear that the native form of WAVEs, in a multi-protein complex, is 
inactive with its actin polymerisation ability inhibited (Derivery et al., 2009). This 
has been confirmed by studies examining the reconstitution of the WAVE complex 
and purified native WAVE complexes. These reports also suggest that WAVEs are 
inhibited in a similar fashion to WASPs, through the masking of the VCA region by 
interactions in the WAVE complex (Ismail et al., 2009, Lebensohn and Kirschner, 
2009). Since WAVEs do not possess a GBD like WASPs, they do not directly 
interact with Rho-GTPases, however they do act as downstream effectors of the 
Rho-GTPase Rac, as well as other signals (Miki et al., 1998b). A conformational 
change brought about by Rac binding to the Sra component of the WAVE complex 
seems to release the VCA region (Ismail et al., 2009). Phosphatidylinositol (3,4,5)-
trisphosphate (PIP3) has also been implicated in the mechanism of activation of 
WAVEs. It has been shown that PIP3 recruits the WAVE complex to the plasma 
membrane through binding to the basic domain of WAVE2 and acts in synergy 
with IRSp53 (also called BAIAP2, brain-specific angiogenesis inhibitor 1-associated 
protein 2) to activate WAVE2 through Rac activity (Oikawa et al., 2004, Suetsugu 
et al., 2006). For comprehensive information on the mechanisms of activation of 
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the WASP/WAVE family, several reviews have covered this in more detail 
(Derivery and Gautreau, 2010, Takenawa and Suetsugu, 2007). 
1.3.3. Function of WASP/WAVE family proteins 
1.3.3.1. WASPs, WAVEs and cell motility 
When members of the WASP/WAVE family are active, the VCA region is exposed 
allowing the Arp2/3 complex and an actin monomer to bind to it leading to the 
nucleation of a new actin filament. The activation of the WASP/WAVE family 
members has been implicated in many biological processes where actin 
cytoskeleton reorganisation is required such as vesicle trafficking, pathogen 
infection and cell-substrate adhesion (see reviews (Takenawa and Suetsugu, 2007, 
Takenawa and Miki, 2001)). WASP/WAVE proteins have also been implicated in 
the control of cellular motility, with the focus of many research papers and 
reviews on WASP/WAVE proteins in the control of cancer cell motility and 
behaviour (Frugtniet et al., 2015), some findings which are summarised here. 
The motility of eukaryotic cells, as has briefly been discussed in previous sections 
of this chapter (see Figure 1.3), is accomplished through dynamic remodelling of 
the actin cytoskeleton. Cell motility in two-dimensional (2D) environments, such 
as on culture dishes or over the ECM is driven by lamellipodia and filopodia 
formation at the leading edge. It is traditionally believed that lamellipodia are the 
key structures that provide the main driving force in 2D cell motility. This was first 
demonstrated by a simple experiment where a section excised from a fish 
keratinocyte lamellipodium was seen migrating at a similar speed to an intact cell 
(Euteneuer and Schliwa, 1984). Filopodia, although they are not implicated to be 
the major force behind cell motility, seem to have a role in sensing the 
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environment outside the cell to guide cell migration and in forming adhesions 
with the ECM (Nemethova et al., 2008, Galbraith et al., 2007). The organisation of 
actin filaments is different in the various protrusions that drive cell motility. Actin 
filaments assemble in a branching network in lamellipodia, whereas in filopodia 
they form long parallel bundles (Welch and Mullins, 2002). WASP/WAVE family 
proteins interact with the Arp2/3 complex to induce the formation of branched 
actin networks, where actin filaments are assembled at a 70-degree angle from 
the side of pre-existing filaments, which are the main structures responsible for 
lamellipodia formation (Chhabra and Higgs, 2007). 
Many advances in our understanding of the mechanisms of cell motility and the 
role of WASP/WAVE family proteins have been as a result of studying features of 
cells that move in 2D. Although the mode of migration of many cells, such as 
cancer cells, is better represented as migration through 3D matrices, 2D migration 
is thought to better represent epithelial migration (Rubinstein and Pinto, 2015) 
during processes such as wound healing. As such, findings from studies examining 
the role of WASP/WAVE proteins in features of cells that move in 2D are discussed 
here. 
Initial work investigating the role of WASP/WAVE family proteins in cell motility 
found that Cdc42 signalling requires nWASP activity in order to form the actin 
structures seen in filopodia and WAVE1 activity downstream of Rac is required for 
lamellipodia formation (Miki et al., 1998a, Miki et al., 1998b). However, it is now 
clear that these studies give a limited understanding of the role of the 
WASP/WAVE family as nWASP activity is not essential for the formation of 
filopodia in response to Cdc42 signalling in fibroblasts (Lommel et al., 2001). 
Moreover, many reports have implicated nWASP in the control of the actin 
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dynamics in lamellipodia through demonstrating nWASP activity localised at the 
leading edge of lamellipodia in a variety of cell types (Lorenz et al., 2004, 
Kawamura et al., 2004, Le Clainche et al., 2007). However, several studies have 
also shown that depletion of WASP or nWASP activity does not affect the 
formation of lamellipodia in several cell types including mice fibroblasts, HeLa 
cells and Drosophila S2 cells (Snapper et al., 2001, Innocenti et al., 2005, Rogers et 
al., 2003). Instead, many reports support the idea that members of the WAVE 
subfamily are key in the control of lamellipodia formation in various cell types 
(Rogers et al., 2003, Suetsugu et al., 2003, Krause and Gautreau, 2014). In 
particular, induced WAVE2 deficiency in mouse endothelial, embryonic fibroblast, 
melanoma and macrophage cells resulted in impaired ability of the cells to form 
lamellipodia and a decrease in cell motility (Krause and Gautreau, 2014, Yamazaki 
et al., 2003, Kurisu et al., 2005, Kheir et al., 2005). These findings collectively 
suggest that the WAVE subfamily, particularly WAVE2, has a more important role 
in the formation of lamellipodia protrusions and mesenchymal migration, and 
hence some aspects of cell motility, than the WASP subfamily but that there is 
evidence that the contribution of the WASP/WAVE family members to the control 
of actin dynamics varies in different cell types. Most of these studies analysing the 
generation of filopodia and lamellipodia have used cells cultured on rigid 2D 
substrates which can help us understand the mechanisms involved in cell motility. 
While the formation of these protrusions or cell structures similar to them does 
take place in normal in motile cells in the body, cells in vivo and especially cancer 
cells generally use different methods of migration as they have to invade through 
a 3D matrix (Friedl and Wolf, 2003). Nevertheless, cancer cells do still utilise actin-
based protrusions to allow them to invade through the ECM and migrate during 
the process of metastasis. The WASP/WAVE family proteins have been shown to 
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be important in the formation of these protrusions that are more specific to 
motility in 3 dimensions and in cancer cell migration, as well as in 2D motility. 
Interestingly, a recent report has suggested that the WASP/WAVE family 
members may have different roles depending on the mode of cellular migration 
(Tang et al., 2013). This group targeted the WAVE complex using siRNA silencing 
techniques and found that, although it promotes motility in 2D, disruption of the 
WAVE complex promotes cell invasion and enhances FAK activity and nWASP 
localisation at invasive protrusion sites. They also proposed that the WAVE 
complex and nWASP have opposing roles in 3D epithelial cell invasion and that 
there may be an interplay between the WASP/WAVE family members in the 
control of various modes of cell motility.  
1.3.3.2. nWASP and cancer 
Due to the known role of nWASP, and the WASP/WAVE family, in the control of 
cell motility and migratory behaviours, naturally interest in the potential role of 
nWASP in cancer cells has been of interest. nWASP has been highlighted in 
numerous studies in the context of cancer through the control of cancer cell 
protrusions and as a prognostic indicator (Frugtniet et al., 2015, Kurisu and 
Takenawa, 2010).  
nWASP and the Arp2/3 complex have been implicated in the formation of 
invadopodia. These are specialised membrane surface structures that have a role 
in the migration of invasive cancer cells and the degradation of the ECM. They 
contain a core of actin filaments as well as adhesion proteins, proteinases for ECM 
degradation and many signalling molecules (Linder et al., 2011, Buccione et al., 
2004). Using a biosensor, nWASP has been shown to be active at invadopodia in 
MTLn3 rat mammary adenocarcinoma cells (Lorenz et al., 2004). nWASP staining 
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has also shown clear localisation with invadopodia in these highly metastatic cells, 
and also other cancer cell types. Furthermore, RNA interference techniques have 
been used to show that nWASP and some of its interaction partners, in particular 
the Arp2/3 complex, are crucial for invadopodium formation. These findings, 
agree with other studies, in their conclusion that nWASP in is involved in 
invadopodium formation in various cell types including rat fibroblasts and 
adenocarcinoma cells (Oser et al., 2009, Mizutani et al., 2002, Yu et al., 2012). 
Since invadopodium formation correlates with the invasive capacity of cancer cells 
(Coopman et al., 1998) it is clear that the nWASP pathway could be considered a 
therapeutic target for the inhibition of invasion in various cancers. 
A great deal of work has been carried out examining the role of WASP/WAVE 
family proteins in the context of breast cancer (Frugtniet et al., 2015). nWASP has 
been implicated in the progression of mammary tumours by one group who 
interfered with endogenous nWASP levels in MTLn3 cells using shRNA techniques. 
When these cells were injected into the mammary glands of SCID mice and rats a 
significant reduction in the number of circulating tumour cells and lung 
metastases were observed compared with the controls. Moreover, in vivo time-
lapse images of control and nWASP-deficient GFP-labelled cells in tumours 
demonstrated that there was a dramatic decrease in motile cells and 
invadopodium-like protrusion formation in nWASP deficient tumours compared 
with control tumours. This study demonstrates that nWASP activity is involved in 
proteolytic protrusion formation, and consequently the invasion and metastasis to 
the lungs of MTLn3 cell tumours (Gligorijevic et al., 2012). A further study treated 
MDA-MB-231 breast cancer cells with the nWASP inhibitor wiskostatin (Escudero-
Esparza et al., 2012). A resulting decrease in the motility of the cells treated with 
the inhibitor was detected using electric cell-substrate impedance sensing (ECIS), 
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a method that detects the movement of cells over an electrode in real-time. This 
study suggested that interactions between nWASP and the tight junction 
component Claudin-5, shown through immunoprecipitation and immunoblotting, 
may be involved in motility of these cancer cells. Lastly, a study examining the 3D 
invasion of MDA-MB-231 cells that infiltrate through membrane pores in response 
to PDGF signals in a PI3K-dependent manner, shown by using PI3K inhibitors, 
demonstrated that nWASP was co-localised with intensive F-actin accumulations 
at the site of infiltration. Diminution of nWASP using siRNA techniques also 
demonstrated a significant reduction in the cell invasion and F-actin accumulation 
was also depleted (Takahashi and Suzuki, 2011).  
These studies therefore suggest that nWASP may be related to the behaviour of 
breast cancer cells and progression of tumour formation. The molecular 
mechanisms that are responsible for the changes to breast cancer cell motility, 
invasion and migration related to nWASP activity are still being explored but 
several interaction partners and activators of nWASP have already been 
implicated, such as Cdc42-interacting protein 4 (CIP4) and focal adhesion kinase 
(FAK) (Pichot et al., 2010, Sanchez et al., 2010). 
1.3.3.3. nWASP and endocytosis 
Actin polymerisation has important role in vesicle fission and vesicle trafficking 
and many of the membrane binding proteins that form part of the endocytosis 
machinery in cells are also known to bind to nWASP. Bar (Bin, amphiphysin, 
Rvs167) and EFC (extended Fer-CIP4 homology) domains are both commonly 
found in membrane deforming proteins that are able to manipulate membranes 
into narrow tubule structures. Most of these proteins have SH3 domains that can 
interact with WASP/WAVE proteins and also the GTPase dynamin which is 
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important for endocytotic membrane fission events (Ferguson and De Camilli, 
2012). For instance, the nWASP interactor pacsin (also known as syndapin) 
contains an EFC domain, a SH3 domain and is a dynamin interactor. Through 
pacsin, nWASP has been shown to be involved in endocytosis (Qualmann et al., 
2000, Kessels and Qualmann, 2002). Blocking actin polymerisation has also shown 
that nWASP mediated actin polymerisation is important for fission and 
subsequent movement of vesicles (Tsujita et al., 2006, Itoh et al., 2005). In 
summary, nWASP has been implicated in activities at the membrane beyond the 
formation of actin-rich extensions as it is also involved in endocytosis and 
vesicular trafficking (Takenawa and Suetsugu, 2007) and may have a role in signal 
transduction through receptor trafficking that is yet to be fully explored (Smythe 
and Ayscough, 2006). 
1.4. Parallels between wound healing and cancer 
metastasis 
Wound healing is a controlled series of events during which several cellular 
processes must take place for effective wound closure. Impairments in these 
processes are evident in the chronic wound environment, as has already been 
discussed, and it is interesting to note that many of these processes are common 
in cancer development and metastasis. Notably, Schäfer reviewed cancer as an 
over-healing wound examining common cellular and molecular mechanisms that 
are active in wounds and cancer tissues (Schafer and Werner, 2008). This was not 
the first study to observe the environment and processes in wound healing and 
how similarities with cancer development can be drawn with Haddow and Dvorak 
both drawing comparisons in 1972 and 1986 respectively (Haddow, 1972, Dvorak, 
1986). Cancer cell behaviour is not limited and strictly controlled like wound 
47 
 
healing but numerous processes that are critical to both are shared, such as 
increases in proliferation, the requirement for cell invasion/migration and 
angiogenesis, and as such, some molecular mechanisms are also shared between 
these two processes. Figure 1.7 illustrates some of these key biological events 
underlying the metastatic progression of cancer, many of which are shared with 
the wound healing process, as will be discussed in greater detail throughout this 
chapter. 
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Figure 1.7: The stages of metastasis and similarities with wound healing. The 
initial step in cancer cell metastasis is for cells in the primary tumour site to 
proliferate, induce angiogenesis, reduce adhesion with neighbouring cells and 
degrade and invade through the basement membrane and stroma (A) until they 
can enter the blood stream through intravasation (B). Cancer cells travel in the 
bloodstream to secondary sites (C) which they can attach to through being 
trapped in capillary beds or through receptor interactions and then may exit the 
blood stream (D) and invade into the new environment. To proliferate in this 
colonisation site, cells release pro-inflammatory compounds and proteinases that 
induce growth factor signalling and angiogenesis allowing a secondary tumour to 
form (E). Several steps during metastasis are common to the wound healing 
process and are shown in yellow bubbles. Image adapted from (Schroeder et al., 
2011) and (Jiang et al., 2015). 
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1.4.1. Invasion and migration 
A unifying process that is critical in both wound healing and cancer metastasis is 
that of cellular migration. This is the resulting movement of cells in response to 
chemotactic signals and is required for angiogenesis, reepithelialisation and 
invasion as well as other processes. Cell migration involves regulation of several 
signalling pathways, the adhesive and protrusive behaviour and, critically, the 
actin cytoskeletal arrangements of cells (see Figure 1.3 for visual representation). 
The regulation of migration in a cell can be due to chemotaxis, towards a 
chemoattractive signal gradient, mechanotaxis, which is due to mechanical forces, 
and/or haptotaxis, towards a gradient of immobilised ligands. The coordination of 
protrusion at the cell periphery in the direction of movement, adhesion of the cell 
to the extracellular environment and traction which propels the cell body in the 
direction of motion enables cell movement. 
The initial change in cell behaviour during motility, involves cell polarisation and 
the extension of actin-rich membrane structures in the direction of movement. 
Signal attenuation through the detection and response of receptors to 
extracellular signalling molecules such as growth factors and cytokines are critical 
for directing motion and cell activities in both a wound healing and cancer setting. 
For example, EGFR has been described in previous sections to be important in 
both epithelial proliferation and migration during wound healing and has been 
highlighted as being overexpressed in non-small cell lung cancer (NSCLC) as 
discussed in greater detail in section 1.5. STAT3 is one of the many signalling 
proteins that is activated by EGFR and other cytokine receptors and promotes 
both wound repair and carcinogenesis (Sano et al., 2008).  
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The protrusions that form at the leading edge of a migrating cell can have varied 
structures. Long, thin structures, or filopodia, and broad sheet-like structures, 
called lamellipodia, are commonly seen in migrating cells whereas specialised 
protrusions named invadopodia are found in cancer cells and allow cells to 
degrade and invade into the surrounding environment as has previously been 
described. The formation of these structures, which are crucial for cell motility, is 
controlled by the rearrangement of the actin cytoskeleton (Ridley et al., 2003, 
Linder et al., 2011, Insall and Machesky, 2009, Ridley, 2011, Buccione et al., 2004). 
Cyclic assembly and disassembly of actin at and behind the leading edge 
maintains the protrusive force required for motility in the direction of the signal. 
Actin dynamics, and hence the extension of membrane surface structures and 
changes to morphology involved in cell migration, are coordinated by numerous 
signals and molecules. The Rho GTPase family of proteins, which includes Rac and 
Cdc42, are important signal transduction molecules which interact with 
downstream effectors such as WASP/WAVE family members to regulate actin 
dynamics (Raftopoulou and Hall, 2004). As such, members of these pathways, 
including nWASP has been shown to be important in migration and also has been 
implicated in the control of cancer cell behaviour. 
Adhesion is also an important process in cell migration and allows the actin 
cytoskeleton in the leading edge migrating cells to connect to the ECM or to 
surrounding cells, allowing the cell to gain traction and move. Integrins acts as 
primary receptors for ECM proteins and mediate adhesion along with a number of 
other signalling and structural proteins. As well as being important in the process 
of cell migration, adhesion is particularly important for the progression of a 
tumour to metastatic disease. This is since tumour cells are required to escape 
from the site of adhesion in a primary tumour in order to enter the blood stream 
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and colonise a secondary site, at which the ability of cancer cells to adhere to and 
invade at a new site is critical. 
1.4.2. Inflammation 
Prolonged inflammation and the increased presence of inflammatory cells is a 
hallmark of both chronic wounds and cancer. Although inflammation has a critical 
role in combatting infection the acute healing process, the activity of neutrophils 
may actually impair the progression of the healing process in the absence of 
infection, with chronic wounds exhibiting persistent inflammation and abundant 
neutrophils (Eming et al., 2007). The loss of functional neutrophils and 
macrophages has actually been shown to enhance wound healing in some studies 
(Martin et al., 2003, Dovi et al., 2003). It is thought that neutrophil action and 
prolonged inflammation act to retard the wound healing process through the 
production of toxic molecules, including ROS, which act to fight infection in 
normal wound closure, as previously described, but which might also cause 
damage to other cells at the wound site in chronic wounds so delaying healing 
(Kumin et al., 2007). Inflammation also has an important role in cancer 
progression (Balkwill et al., 2005, de Visser et al., 2006) with the activity of 
macrophages in particular highlighted as key players in tumorigenesis. In tumour 
tissues, cytokines frequently induce macrophage differentiation to the M2 
phenotype which can stimulate ECM breakdown and angiogenesis through 
angiogenic growth factor and MMP production (Allavena et al., 2008). MMP and 
proteinase secretion by macrophages at the invasive front of a tumour therefore 
enhances motility and invasion of cancer cells (Condeelis and Pollard, 2006). The 
tumorigenic influence of inflammatory cells and the role they may have in 
impaired healing in chronic wound environments highlights the inhibition of 
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inflammation as a promising strategy for wound healing and cancer progression. 
The use of anti-inflammatory drugs or other therapies to reduce the effect of 
enhanced inflammation, perhaps through drugs that reduce the effect of ROS in 
tissues, might be employed to control inflammation and hence cancer 
development and inflammation in the wound environment (Albini and Sporn, 
2007, Braun et al., 2002, Yu and Kensler, 2005). 
1.4.3. Angiogenesis 
The formation of new blood vessels is critical for the supply of oxygen and 
nutrients in the wound healing process. Angiogenesis is also required for the 
growth of tumours over 2mm diameter (Ferrara and Kerbel, 2005). In both wound 
and tumour environments, the formation of new blood vessels occurs through 
sprouting from pre-existing vessels. Various growth factors, proteinases and 
matrix molecules have been studied as coordinators of angiogenesis, several 
which are common in wound healing and tumorigenesis. Members of the VEGF 
family are particularly well-characterised for their role in angiogenesis. The 
transcription factor hypoxia-inducible factor-1α (HIF1α) is activated under hypoxia 
and leads to VEGFA upregulation. This is important for cancer growth and VEGFA 
antagonists have been approved for the treatment of numerous cancers (Ferrara, 
2002). Whereas, over expression of VEGFA was found to enhance wound 
angiogenesis in mice (Hong et al., 2004) and deletion of the Vegfa gene in 
keratinocytes in mice delayed wound healing due to impaired angiogenesis 
(Ferrara, 2002). Placental growth factor (PLGF) is another member of the VEGF 
family and has also been shown to have roles in wound healing and cancer. 
Angiogenesis in the wound and tumour setting was impaired in PLGF-deficient 
mice (Carmeliet et al., 2001) whereas overexpression of PLGF in the epidermis of a 
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diabetic mouse model, which exhibit impaired wound healing, accelerated 
angiogenesis and improved the defective wound healing process (Cianfarani et al., 
2006). Furthermore, the growth of mouse melanomas which overexpressed PLGF 
was enhanced compared with the controls (Marcellini et al., 2006). In addition to 
these members of the VEGF family, further regulators of angiogenesis have been 
shown to have a role in both wound healing and tumour settings including FGF2, 
thrombospondin 1 (TSP1), and VEGFC. 
In summary, several processes and molecular mechanisms have been highlighted 
in numerous studies which show shared pathways and functions of cells involved 
in wound healing and in cancer progression. nWASP has been shown to have 
diverse function and is implicated in invasive and migratory phenotypes and 
potentially in the control of signal transduction through its role in endocytosis. 
nWASP is therefore a molecule of interest in the context of both wound healing 
and cancer. This study therefore begins to investigate the role of nWASP in both 
wound healing and in the control of events responsible for cancer progression. 
Owing to the availability of resources and the experience at the host laboratory, 
this work encompasses comparable studies between wound healing and lung 
cancer. 
1.5. Lung Cancer 
1.5.1. Incidence and mortality 
Lung cancer is one of the most commonly diagnosed cancers, particularly in 
males, accounting for 13% of the total cases worldwide (Jemal et al., 2011). The 
incidence of new lung cancer cases in the UK is estimated to be 78/68 
(males/females) per 100,000 population (Cancer Research UK, 2014). It is also one 
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of the leading causes of cancer death globally with survival rates much lower in 
patients diagnosed with distal metastases (Siegel et al., 2015, Edwards et al., 
2014).  
Lung cancer morphology can be classified as small-cell lung cancer (SCLC), which 
makes up 10-15% of lung cancer cases, or as non-small cell lung cancer (NSCLC) 
which make up the majority of cases in the UK [National Lung Cancer Audit annual 
report 2015 (for the audit period 2014), Royal College of Physicians]. SCLC is an 
aggressive subtype of cancer that is closely linked to smoking of cigarettes and has 
often metastasised beyond the lung at the time of diagnosis. Smoking is well-
known to be a significant risk factor associated with lung cancer incidence with 
86% of lung cancer cases linked to smoking [Cancer Research UK, 2014]. Non-
small cell lung cancer cases can be divided into further histological categories, the 
two predominant subtypes are adenocarcinomas (estimated to account for 50% 
of NSCLC cases) and squamous cell carcinomas (~40%) (Chen et al., 2014). 
Squamous carcinomas tend to arise in more proximal airways and are associated 
with smoking and chronic inflammation more so than adenocarcinomas, which 
arise in more distal airways. As with SCLC, prognosis is poorer for NSCLC patients 
with metastatic disease, i.e. later stage cancer, with approximately 1% 5-year 
survival rate for stage IV NSCLC compared with ~45-49% for stage 1. This 
highlights the importance of understanding the mechanisms involved in lung 
cancer metastasis and considering how molecular pathways involved in this 
process could form novel potential therapeutic targets. 
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1.5.2. Lung cancer progression 
Lung cancer progression is staged according to the TNM grading system which 
encompasses information regarding tumour size (T), spread to the lymph nodes 
(N) and status of metastasis (M). Table 1.1 gives a basic description of the ways 
lung cancer is classified within each category. Representations of what may be 
encountered in lung cancer at stage 1 and 4 are shown in Figure 1.8. 
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Table 1.1: Lung cancer staging according to TNM classification. The size of a 
tumour (T), lymph node involvement (N) and status of metastasis (M) can be used 
to grade lung cancer. This table describes a very basic breakdown of the expected 
tumour status at each stage. However, many more considerations, such as the 
tissues into which the cancer has spread, and the location of the tumour within 
the lung tissues, may influence how a tumour is graded. Table based on 
information from Cancer Research UK. 
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Figure 1.8: Representation of lung cancer progression. Lung cancer at stages 1A 
or B (A) exhibits small (<3cm or <5cm respectively), contained tumours. Cancer at 
stage 1B may have spread into nearby structures such as the pleura or bronchus. 
At stage 4 (B), the tumour has metastasised significantly either to both lungs, to 
elsewhere in the body such as the liver or bones or is exhibiting pleural effusion. 
Images from Cancer Research UK. 
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Cancer invasion and metastasis must occur for the progression of lung cancer 
from stage I, where a tumour is contained in its point of origin, to the later stage 
III-IV cancers, where prognosis and survival rates are relatively poor. The 
metastatic cascade of events, whereby lung cancer cells travel to and colonise 
distal sites, involves many cellular processes and interactions and requires the 
contribution of numerous molecular pathways. The detachment and invasion into 
the surrounding tissues of tumour cells, requiring the degradation of the ECM and 
changes to the adhesive and migratory properties of the invading cells, are the 
critical initial steps in cancer cell metastasis. Following this, intravasation into 
blood or lymphatic vessels then adhesion, extravasation and colonisation at distal 
sites, leading to a secondary tumour formation, occurs (Steeg, 2006). The critical 
stages of lung cancer metastasis can be found in Figures 1.6 and 1.7 and have 
been discussed previously. 
1.5.3. Risk factors, current therapies and research 
Several strategies are currently in place with the goal of preventing lung cancer 
development. The most well-known strategy for the prevention of lung cancer 
that is encouraged nationwide is to reduce smoking which has been linked to the 
development of lung cancer for many years (Freedman et al., 2008). Individuals 
who do not smoke cigarettes, and even those who quit smoking, reduce the risk 
of developing lung cancer in later life (Peto et al., 2000, Ebbert et al., 2003). In 
addition to advice to stop smoking, recreational physical activity has also been 
shown to reduce the risk of developing lung cancer by 20-30% in women and 20-
50% in men (Emaus and Thune, 2011). Diet, air pollution and occupational 
exposure are also factors that can increase the risk of developing lung cancer and 
are considerations for its prevention (Molina et al., 2008). 
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Current standard therapies for patients with lung cancer vary according to the 
subtype of cancer. SCLC is mostly treated with chemotherapy due to the increased 
likelihood that the cancer has metastasised at the time of diagnosis. NSCLC can be 
treated with surgery, chemotherapy and/or radiotherapy depending on the 
tumour grade (Molina et al., 2008). Surgery for tumours that are completely 
resectable and where the patient can tolerate this intervention is the most 
successful and consistent option for curing lung cancer. Accurate staging is critical 
to decide the most appropriate treatment, especially where surgical resection is 
used, to ensure complete removal of the tumour in the hope of achieving a cure 
(Little, 2006). In cases where tumours are unresectable, i.e. in ~70% of patients 
(Molina et al., 2008), where lung cancer presents with locally spread or metastatic 
disease at diagnosis, chemotherapy is used. Several studies have found adjuvant 
chemotherapy to be beneficial to patient survival (Arriagada et al., 2004, Winton 
et al., 2005, Douillard et al., 2005). Various chemotherapeutic regimens are also 
recommended for the treatment of metastatic lung cancer (Molina et al., 2008). 
In addition to the use of surgical and chemotherapeutic approaches, large areas of 
study have been devoted towards developing therapies in recent years to target 
signalling pathways that may be responsible for the regulation and progression of 
lung cancer. Receptor tyrosine kinases, particularly EGFR, angiogenesis pathways 
and cell cycle control are amongst the potential therapeutic targets that have 
been studied. 
EGFR is overexpressed in 40-80% of NSCLC patients and this correlates with poor 
prognosis (Mendelsohn and Baselga, 2003). Gefitinib, an EGFR inhibitor, is the first 
targeted therapy to be registered with the FDA for use in lung cancer (Kris et al., 
2003). Gefitinib failed to show improved survival versus the placebo in phase-3 
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randomised trials though (Thatcher et al., 2005). A second EGFR inhibitor, 
Erlotinib, was found to significantly improve survival times in a phase 3 study and 
was hence approved by the FDA for use in NSCLC patients with local advanced of 
metastatic disease who showed no response to previous therapy options 
(Shepherd et al., 2005). In addition to a large amount of research into EGFR in 
lung cancer, VEGFR has also been studied as a target for the treatment of lung 
cancer. VEGFR signalling has a critical role in angiogenesis amongst other cell 
functions which are required for cancer cell function and progression. 
Bevacizumab, a monoclonal antibody which targets VEGF, has been trialled in the 
treatment of non-squamous NSCLC and was found to improve survival times and 
so now has FDA approval in combination with chemotherapy for lung cancer 
(Sandler et al., 2006). 
The identification of biomarkers which can affect the response to targeted 
therapies has been studied with the goal of predicting patient response to drugs 
and clinical outcome. For instance, mutations of EGFR in NSCLC can correlate with 
a patient’s response to EFGR inhibitor treatments (Janne et al., 2005) and so 
research into the underlying tumour molecular markers is a current area of 
research interest. Furthermore, oncogenic driver mutations are also known to be 
present in up to 60% of adenocarcinomas and up to 50-85% of squamous cell 
carcinomas (Alamgeer et al., 2013, Savas et al., 2013). These are often found in 
protein kinases or receptors which can stimulate cross-signalling pathways such as 
the Ras-Raf-Mek-Erk, MAPK, Akt-mTOR and/or Jak-STAT pathways (Chan and 
Hughes, 2015) which when dysregulated can lead to uncontrolled growth, and 
survival. These findings have encouraged the development of therapies that can 
inhibit these pathways in cases where they are upregulated.  
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Gaining a better understanding of the molecular and signalling changes that take 
place during lung cancer progression is critical in order to discover new potential 
biomarkers for prognosis and novel therapeutic targets, through which it may be 
possible to treat lung cancer from a new angle. 
1.6. Hypothesis and Aims 
nWASP and the other WASP/WAVE proteins mediate the signals between Rho 
GTPase family members and machinery that play a key role in controlling actin 
dynamics. Through this actin polymerisation activity and the interaction with 
numerous interaction partners, they have been shown to coordinate many 
cellular functions such as membrane protrusion, endocytosis and vesicle 
trafficking. These functions are all critical for the processes of cell migration and 
motility through the attenuation of extracellular signals and extension of 
membrane protrusions to achieve movement. As such nWASP is a molecule of 
interest in several contexts where these cell behaviours are paramount. In 
particular, in the control of cancer, where nWASP has been shown to affect 
invasive phenotypes and its activity correlates with cancer phenotypes in 
numerous studies. As discussed in the previous section, many parallels can be 
drawn between the processes of cancer progression and wound healing and as 
such this study highlights nWASP as a potential molecule of interest in wound 
healing and also explores nWASP in a lung cancer context.  
The main hypothesis of this study is that nWASP will provide an effective potential 
target in the treatment of non-healing chronic wounds and that it may also have a 
role in the progression of lung cancer. To do this the following aims will be 
addressed: 
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 To explore the expression of nWASP in the wound environment, 
particularly in chronic wounds which represent a significant problem for 
thousands of patients in the UK every year.  
 To explore the role of nWASP in the control of skin cell function through 
the use of nWASP inhibitors to examine the effect on adhesive and 
migratory behaviours of skin cell models.   
 To evaluate the use of nWASP inhibitors as a viable treatment option by 
using an animal chronic wound model. 
 To investigate the potential effects of these nWASP inhibitor treatments 
on downstream signalling changes in skin cells.  
 Alongside this, the role of nWASP in a lung cancer setting will also be 
studied. 
These aims will be addressed throughout the following chapters with the overall 
focus towards evaluating whether nWASP inhibition may be a viable therapeutic 
option for the treatment of chronic, non-healing human wounds. 
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Chapter 2: Materials 
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2.1 Materials 
2.1.1 Cell lines 
The current study uses the HaCaT immortalised keratinocyte cells line (Boukamp 
et al., 1988), HECV vascular endothelial cell line and TE-354-T fibroblast cell line 
with the main focus of the study on HaCaT and HECV cells. Also used in this study 
are the SK-MES-1 and A-549 human lung cancer cell lines. Details of these cell 
lines are presented in Table 2.1. HaCaT cells were obtained from the German 
Cancer Institute/Cell Service, (Heidelberg, Germany). HECV cells obtained from 
Interlab (Genova, Italy). TE-354-T, SK-MES-1 and A-549 cell lines were obtained 
from America Type Culture Collection (ATCC, VA, USA). All cell lines described 
were routinely cultured in normal culture medium described in section 2.4.1 and 
were incubated at 37°C, 5% CO2 and 95% humidity. 
STR profiles used to validate the HaCaT, SK-MES-1 and A-549 cell lines used in this 
study are given in Table 2.2 and were obtained from 
http://web.expasy.org/cellosaurus/. 
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Table 2.1: Human cell lines used in this study. Information regarding the 
morphology, origin and passage numbers of the cell lines that have been used in 
this study are detailed below.  
Cell line Morphology Ethnicity Gender Sources Passage 
number 
used 
HaCaT Epithelial, 
keratinocyte 
Caucasian Male Normal skin 2-23 
HECV Endothelial, 
vascular 
Caucasian Female Umbilical cord 3-23 
TE-354-
T 
Fibroblast Unknown Female Basal cell 
carcinoma 
3-5 
SK-
MES-1 
Epithelial Caucasian Male Lung cancer, 
squamous 
carcinoma 
1-18 
A-549 Epithelial Caucasian Male Lung cancer, 
adenocarcinoma 
4-19 
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Table 2.2: STR profiles of HaCaT, SK-MES-1 and A-549 cell lines. STR profiles 
obtained from http://web.expasy.org/cellosaurus/ for HaCaT, SK-MES-1 and A-
549 cell lines are presented. The expected product size in base pairs (bp), which 
corresponds with each STR profile when using the primer sets described in section 
2.1.2, are also given. 
STR HaCaT A-549 SK-MES-1 
Allele Size (bp) Allele Size (bp) Allele Size (bp) 
AM X 212 X, Y 212, 218 X, Y 212, 218 
CSF1PO 9, 11 303, 311 10, 12 307, 315 12 315 
D13S317 10, 12 177, 185 11 181 11 181 
D16S539 9, 12 149, 161 11, 12 157, 161 13 165 
D5S818 11, 12 149, 153 11 149 11 149 
D7S820 9, 11 210, 218 8, 11 206, 218 8 206 
TH01 9.3 198 8, 9.3 191, 198 6, 9.3 183, 198 
TPOX 11, 12 244, 248 8, 11 232, 244 8 232 
vWA 16, 17 146, 150 14 138 14 138 
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2.1.2 Primers 
All the primers used in the present study were designed with the use of the 
Primer-BLAST programme available from NCBI. Reverse primers designed for use 
in quantitative polymerase chain reaction (qPCR) were designed with an 
additional z-sequence present on the 5’ end of the primer. All primers were 
synthesized by Sigma-Aldrich (Dorset, UK) and diluted in PCR water (dH2O which 
has been UV treated) according to the provided data sheet to 100µM and stored 
at -20°C. Primers were diluted again in PCR water at 1:10 from the master stock 
for use in conventional polymerase chain reaction (PCR) and the forward and 
reverse primers were diluted 1:10 and 1:100 respectively for use in qPCR. Full 
sequences and details of primers used for PCR and qPCR in this study are given in 
Table 2.3 and Table 2.4 respectively.  
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Table 2.3: Primer sequences used for conventional PCR. The target genes and 
sequences of the primer pairs used for conventional PCR are detailed in the 
following table. 
Target gene Forward (F) and reverse (R) primer sets and sequences (5’>3’) 
AMEL_XY 
F: ACCTCATCCTGGGCACCCTGG 
R: AGGCTTGAGGCCAACCATCAG 
BDNF 
F8: TTCATACTTTGGTTGCATGA 
R8: TTCAGTTGGCCTTTTGATAC 
CSF1PO_12 
F1: AACCTGAGTCTGCCAAGGACTAGC 
R1: TTCCACACACCACTGGCCATCTTC 
D13S17_11 
F2: ACAGAAGTCTGGGATGTGGA 
R2: GCCCAAAAAGACAGACAGAA 
D16S539_13 
F2: GATCCCAAGCTCTTCCTCTT 
R2: ACGTTTGTGTGTGCATCTGT 
D5S818_11 
F2: GGGTGATTTTCCTCTTTGGT 
R2: TGATTCCAATCATAGCCACA 
D7S820_8 
F3: TGTCATAGTTTAGAACGAACTAACG 
R3: CTGAGGTATCAAAAACTCAGAGG 
GAPDH 
F8: GGCTGCTTTTAACTCTGGTA 
R8: GACTGTGGTCATGAGTCCTT 
nWASP 
F8: AGTCCCTCTTCACTTTCCTC 
R8: GCTTTTCCCTTCTTCTTTTC 
TH01_6, 9.3 
F1: GTGGGCTGAAAAGCTCCCGATTAT 
R1: ATTCAAAGGGTATCTGGGCTCTGG 
TPOX_8 
F1: ACTGGCACAGAACAGGCACTTAGG 
R1: GGAGGAACTGGGAACCACACAGGT 
TrkB 
F2a: CCCACTCACATGAACAATGG 
R2a: TCAGTGACGTCTGTGGAAGG 
vWA_14 
F1: CCCTAGTGGATAAGAATAATC 
R1: GGACAGATGATAAATACATAGGATGGATGG 
VE Cadherin 
F11: GTGTGCAAGTGCAACGAG 
zR11: ACTGAACCTGACCGTACATCACTGTGATGGTGAGGAT 
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Table 2.4: Primer sequences used for qPCR. The additional z-sequence present on 
the 5’ end of reverse primers used for qPCR primers are written in bold. 
Target gene Forward (F) and reverse (R) primer sets and sequences (5’>3’) 
Actin 
F8: GGACCTGACTGACTACCTCA 
zR8: ACTGAACCTGACCGTACAAGCTTCTCCTTAATGTCACG 
BDNF 
F8: TTCATACTTTGGTTGCATGA 
Rz8: ACTGAACCTGACCGTACACTCTTGAACCTGCCTTGG 
GAPDH 
F: CTAGTACGTCGTGGAGTC 
zR: ACTGAACCTGACCGTACACAGAGATGATGATGACCCTTTTG 
PDPL 
F: GAATCATCGTTGTGGTTATG  
zR: ACTGAACCTGACCGTACACTTTCATTTGCCTATCACAT 
nWASP 
F8: AGTCCCTCTTCACTTTCCTC 
zR8a: ACTGAACCTGACCGTACAAGATCTCTGTGGATTGTCCT 
TrkB 
F2a: CCCACTCACATGAACAATGG 
Rz2a: ACTGAACCTGACCGTACATCAGGATAATTTGGGTTTGC 
 
.
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2.1.3  siRNA 
nWASP siRNA (sc36006) was obtained from Santa Cruz Biotechnology Inc. (USA) 
and non-targeting siRNA (NT) was obtained from Dharmacon (D001810; 
Layfayette, CO, USA). The nWASP siRNA pellet from the manufacturer was 
resuspended in 330µl of RNAse-free water to produce a 10µM stock. This was 
aliquoted and stored at -20°C. The NT siRNA pellet from the manufacturer was 
diluted to 20µM stock and stored in the same way. 
2.1.4  Antibodies 
2.1.4.1 Primary antibodies 
Details of the primary antibodies used in Western blotting (labelled WB), 
immunofluorescence (labelled IF) or immunohistochemistry (labelled IHC) studies 
throughout this study are given in Table 2.5. The supplier and manufacturer’s 
code, species produced in and the dilution used in each assay are given. 
2.1.4.2 Secondary antibodies 
Details of the secondary antibodies used in Western blotting (labelled WB) and/or 
immunofluorescence studies (labelled IF) in this study are given in Table 2.6. Also 
given are the details of DAPI (stored at 1mg/ml) used in immunofluorescence 
experiments. 
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Table 2.5: Primary antibodies used in this study 
Antibody Code Supplier Species 
produced in 
Dilution (use) 
actin sc1615 Santa-Cruz Goat 1:200 (WB) 
Erk1/2 v114A Promega Goat 1:5000 (WB) 
FAK BD610058 BD Biosciences Mouse 1:1000 (WB) 
1:100 (IF) 
GAPDH sc32233 Santa-Cruz Mouse 1:1000 (WB) 
paxillin BD650052 BD Biosciences Mouse 1:5000 (WB) 
1:100 (IF) 
p-FAK sc11766 Santa-Cruz Goat 1:200 (WB) 
1:100 (IF) 
PLCγ1 sc81 Santa-Cruz Rabbit 1:200 (WB) 
p-PLCγ1 sc22141 Santa-Cruz Rabbit 1:200 
nWASP NBP1-82512 Novus Biologicals Rabbit 1:200(WB) 
1:100 (IF) 
TrkB Y816 ABN1381 EMD-Millipore Rabbit 1:500 (WB) 
1:20 (IF) 
TrkB pan 07-225 EMD-Millipore Rabbit 1:200 (WB) 
TrkB pan sc136990 Santa-Cruz Mouse 1:20 (IHC) 
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Table 2.6: Secondary antibodies used in this study 
Antibody Code Supplier Species 
produced in 
Dilution (use) 
Anti-mouse 
IgG 
A4416 Sigma-Aldrich Goat 1:1000 (WB) 
Anti-rabbit 
IgG 
A6154 Sigma-Aldrich Goat 1:1000 (WB) 
Anti-goat IgG A5420 Sigma-Aldrich Rabbit 1:1000 (WB) 
DAPI D1306 Life 
Technologies 
N/A 1:1000 (IF) 
AlexaFluor 
488 
Anti-rabbit: 
A21206 
Life 
Technologies 
Donkey 1:500 (IF) 
Anti-mouse: 
A21202 
AlexaFluor 
594 
Anti-rabbit: 
A21207 
Life 
Technologies 
Donkey 1:500 (IF) 
Anti-mouse: 
21203 
Anti-goat: 
A11058 
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2.1.5  Inhibitors 
nWASP inhibitors, wiskostatin and 187-1 were from Enzo Life Sciences (NY, USA) 
and TOCRIS (Bristol, UK), respectively. For in vitro studies, wiskostatin was 
dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich) initially to avoid 
precipitation and then in normal culture medium to a stock concentration of 
300µM in 30% v/v DMSO in normal culture medium (see section 2.4.1). 187-1 was 
dissolved in PBS to a stock concentration of 500µM. Both inhibitor solutions were 
aliquoted and stored at -20°C. For the in vivo studies, the nWASP inhibitor 
compounds were formulated for systemic and topical application as described in 
sections 2.8.2 and 2.8.3. SOS1 (BML P3050001; Enzo Life Sciences, NY, USA), a 
competitive inhibitor of Grb2 activity, was diluted in sterile PBS to achieve 500µM 
stock solution which was aliquoted and stored at -20°C.  
2.1.6 Plastic- and culture-ware 
All plastic culture-ware including flasks (T25 and T75) and plates (6-,24- and 96- 
well) are from Greiner Bio-One Ltd. (Gloucestershire, UK) unless otherwise stated. 
All microfuge tubes were also obtained from Greiner Bio-One Ltd. 
2.2 Reagents and solutions 
2.2.1 Solutions for molecular biology 
2.2.1.1 Diethylpyrocarbonate (DEPC) water 
500µl of DEPC (Sigma-Aldrich) was added to 500ml of deionised H2O then left 
overnight and then autoclaved before use. 
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2.2.1.2 Tris-Boric-Acid-EDTA (TBE) 
10x TBE buffer (T4415; Sigma-Aldrich) was diluted with dH2O to achieve a 1x 
solution and stored at room temperature for further use. 
2.2.2 Solutions for use in tissue culture 
2.2.2.1 Ethylenediaminetriacetic acid (EDTA)-Trypsin solution 
10x Trypsin-EDTA solution (T4174; Sigma-Aldrich) was diluted using dH2O to 
achieve a 1x solution which was then divided into 25ml aliquots and stored at -
20°C until further use. When an aliquot was in use during routine tissue culture, 
trypsin-EDTA (referred to as ‘trypsin’ hereafter) was stored at 4°C. 
2.2.2.2 Phosphate buffered saline (PBS) 
10x PBS (P5493; Sigma-Aldrich) was diluted using dH2O to achieve a 1x solution 
which was then divided into 25ml aliquots and stored at room temperature until 
further use. 
2.2.3 Solutions used for Western blotting 
2.2.3.1 Lysis buffer 
8.76g of NaCl (150mM), 6.05g of Tris (50mM), 200mg Sodium azide (0.02%, w/v), 
15ml Triton X-100 (1.5%, v/v) and 5g sodium deoxycholate (0.5%, w/v) was 
dissolved in/added to 1L dH2O to make a 1L stock of protein lysis buffer. 50ml of 
the lysis buffer was then used to dissolve one of the cOmplete™, EDTA-free 
protease inhibitor cocktail tablet (Roche Diagnostics, Mannheim, Germany). This 
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complete lysis buffer (referred to as ‘lysis buffer’ hereafter) was then aliquoted 
into 1ml microfuge tubes and stored at -20°C for further use. 
2.2.3.2 10% w/v ammonium persulfate (APS) 
1g APS (Melford Laboratories Ltd., Suffolk, UK) was dissolved in 10ml dH2O and 
then stored at 4°C. 
2.2.3.3 10% w/v sodium dodecyl sulphate (SDS) 
50g sodium dodecyl sulphate (Melford Laboratories Ltd., Suffolk, UK) was 
dissolved in 500ml dH2O and stored at room temperature. 
2.2.3.4 Tris Buffered Saline (TBS) and 0.1% v/v TBS/Tween (TBST) 
1L 10x Tris Buffered Saline (T5912; Sigma-Aldrich), was diluted in 9L dH2O to make 
1x TBS and stored at room temperature. To make 0.1% TBST, 500µl Tween 20 
(Sigma-Aldrich) was added to 0.5L 1x TBS and stored at room temperature. 
2.2.3.5 Running Buffer 
1L of 10x Tris-Glycine-SDS buffer (T7777; Sigma-Aldrich) was diluted in 9L dH2O to 
produce 1x running buffer and stored at room temperature. 
2.2.3.6 Transfer Buffer 
1L of 10x Tris-Glycine buffer (T4904; Sigma-Aldrich) was added to 7L dH2O and 2L 
methanol (Fisher Scientific UK, Loughborough, UK) to produce 1x transfer buffer 
and stored at room temperature. 
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2.2.3.7 Ponceau S stain 
0.1% Ponceau S (P3504; Sigma-Aldrich) was dissolved in 5% acetic acid (w/v) to 
produce Ponceau S staining buffer and was stored at room temperature. 
2.2.4 Lysis buffer solution for KinexusTM antibody array 
preparation 
100mM Tris buffer was made using 6g Tris powder (Sigma-Aldrich) in 1.5L dH2O. A 
cOmpleteTM, EDTA-free protease inhibitor cocktail tablet (Roche Diagnostics, 
Mannheim, Germany), 5ml 2-mercaptoethanol (10% v/v), nonidet P-40 (1% v/v) 
and 5ml of 500mM NaFL (50mM) were added to 50ml of the Tris buffer. The 
solution was mixed and aliquoted into 1ml aliquots and stored at -20°C.  
2.2.5 Avidin-biotin complex (ABC) 
The ABC complex for use in immunohistochemical staining was prepared using a 
VECTASTAIN® Elite ABC HRP Kit (PK-6200; Vector Laboratories Inc, CA, USA). Four 
drops each of reagent A and reagent B were added to 20ml of was buffer. The 
solution was mixed and left a 4°C for at least 30 minutes before use. 
2.2.6 Solutions for functional assays 
2.2.6.1 Thiazolyl blue tetrazolium bromide (MTT) 
5mg/ml MTT solution was made up using 200mg of MTT powder (Sigma-Aldrich) 
to 40ml PBS. This was kept in the dark through wrapping container with foil and 
placed on roller (Stuart, Wolf Laboratories, York, UK) until dissolved. The solution 
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was then filtered through a 0.2µm minisart filter (Sartorius, Epsom, UK) into 
another foil wrapped UC and stored at 4°C. 
2.2.6.2 Acidified isopropanol 
50ml 2M HCl was added to 2.5L isopropanol (Sigma-Aldrich) and left for at least a 
month at room temperature before use in MTT assays.  
2.3 Tissue collection and processing 
2.3.1 Collection of human chronic wound tissues 
Two cohorts of patient chronic wound samples were used in this study. The first 
tissue cohort used for transcript analysis in this study, hereafter described as 
‘cohort 1’, consisted of 69 chronic venous leg ulcer wound edge biopsies. Samples 
were collected between 1990 and 1995 from the University Hospital of Wales 
wound healing clinic as part of a prospective study to investigate potential 
diagnostic/prognostic indicators of chronic wound healing (Ref CT1010). Patients 
were treated for 12 weeks with best practise medical treatments which included 
compression at 40mmHg using 3 layers of TubigripTM bandages (Mölnlycke Health 
Care, Dunstable, UK), regular wound care and appropriate dressings. Wounds 
were assessed 12 weeks following biopsy collection and classified as ‘healing’ 
(n=20) if a decrease in size or complete wound closure was seen. Biopsies from 
wounds that had shown an increase or no change in size in the 12-week follow-up 
period were termed ‘non-healing’ (n=49). 
A second cohort was also used in this study for qPCR analysis and also 
immunohistochemical staining, hereafter described as ‘cohort 2’. This cohort 
consisted of 109 venous leg ulcer wound edge biopsies and was collected in the 
78 
 
same wound clinic as cohort 1 between 2010 and 2013 according to local research 
ethics committee approval and following collection of written informed patient 
consent. These tissues were collected as part of a study that aimed to develop a 
diagnostic platform and novel therapies for non-healing chronic wounds based on 
impaired keratinocyte reepithelialisation (Ref 09/wse02/51). Again, wound 
healing was assessed in the 12 weeks following tissue collection and samples were 
classified as ‘healing’ (n=77) or ‘non-healing’ (n=32) in the same way as cohort 1. 
Patients were included in both studies described above on the basis that no 
evidence of infection was found, as judged by the leading clinical physician. 
Where required, swabs were taken to confirm this. Venous disease was diagnosed 
by Duplex ultrasonography and further inclusion criteria were that there was no 
evidence of other diagnosis and that the ulcers had been present for at least 3 
months prior to biopsy collection.  
Collection, storage and processing of tissue samples in both cohort 1 and 2 were 
done using the same methodology as described here. Samples were aseptically 
collected from the wound edge using a 6mm hole punch biopsy method under 
local anaesthetic (1% Lidocaine). This allowed incorporation of both epidermis 
and dermis at the wound edge and the adjacent distal tissues. Sample biopsies 
were frozen immediately to prevent morphological distortions and damage. The 
tissue was orientated onto a cork board by rotating the biopsy 90o in order to 
obtain a full section of both epidermis and dermis at the wound edge and distal to 
the wound edge, and then OCT medium (Optimal Cutting Temperature 
compound) was applied. The sample biopsy was then snap frozen in iso-pentane 
that had been pre-cooled and floated on liquid nitrogen, in order to prevent ice 
crystal formation that would damage the architecture of the tissue. Biopsies were 
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stored at -80°C and then in liquid nitrogen for long-term storage. Samples were 
sectioned on a cryostat (Leica, Microsystems Ltd., Milton Keynes, UK) at 20µm 
thickness for processing for RNA extraction or at 7µm thickness for 
immunohistochemical staining. 60 sections (20µm thickness) from the same 
patient sample biopsy were pooled and homogenised in ice cold TRI reagent 
(Sigma-Aldrich, Poole, UK) using a hand-held homogeniser (Cole Palmer, London, 
UK) in preparation for RNA extraction. For immunohistochemical staining, 10 
biopsies from each group (healing/non-healing) were chosen from Cohort 2 based 
on the quality of the tissue as determined by H & E staining and also the 
completeness of clinical information.  
2.3.2 Collection of human lung cancer tissues 
Lung carcinoma tissues at TNM stages of 1 to 3, with matched normal tissues, 
were obtained from 150 patients who received curative resection in Peking 
University Cancer Hospital from January 2001 to December 2006, as a part of an 
institution research collaborative between Cardiff University and Peking 
University. Ethical approval was provided by the Ethics Committee at Peking 
University Cancer hospital (approval number 20060918). Tissues were collected 
immediately after surgical resection and stored at -80°C in the Tissue Bank of 
Peking University Oncology School until use. Clinicopathological factors, including 
age, sex, histological types of tumours, TNM stage, lymph node metastasis and 
survival were recorded and stored in the patient database. Frozen tissue samples 
were sectioned on a cryostat (Leica, Microsystems Ltd., Milton Keynes, UK) at 
20µm thickness. 30 sections from the same patient sample biopsy were pooled 
and homogenised in ice cold TRI reagent (Sigma-Aldrich, Poole, UK) using a hand-
held homogeniser (Cole Palmer, London, UK) in preparation for RNA extraction. 
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2.4 Tissue culture methods 
2.4.1 Routine cell culture 
Cells were cultured in medium made up using Dulbecco’s Modified Eagle’s 
Medium Nutrient Mixture F-12 Ham with 15mM HEPES, NaHCO3, pyridoxine and 
L-Glutamine medium (DMEM; Sigma-Aldrich, Dorset, UK). This medium is also 
referred to as ‘serum-free medium’ (SFM) before the addition of any antibiotics or 
FBS supplements. A 5ml aliquot of 100x antibiotic antimycotic solution (A5955; 
Sigma-Aldrich) was added to 500ml DMEM to achieve 1x dilution and it was also 
supplemented with 50ml foetal bovine serum (FBS; Sigma-Aldrich, Dorset, UK) to 
achieve 10% v/v FBS. This antibiotic and serum supplemented DMEM constitutes 
‘normal culture medium’. All culture mediums were stored at 4°C and used at 
room temperature. Cell lines were cultured in 25cm2 (T25) or 75cm2 (T75) culture 
flasks (Greiner Bio-One Ltd., Gloucestershire, UK) in incubator at 37°C, 5% CO2 and 
95% humidity with caps loosely fastened. Cells cultured in T25 flasks were 
generally incubated with 4-5ml normal culture medium, T75 flasks were 
incubated with 10-15ml normal culture medium. Medium was periodically 
changed when appropriate depending on the cell type used - approximately every 
3 days. All cell work was carried out aseptically, using a Class II Laminar Flow 
Cabinet with sterile and autoclaved equipment and consumables. 
2.4.2 Trypsinisation 
When appropriate, usually when cells reach ~90% confluency for routine 
maintenance and sub-culture but also when required for functional assays, cells 
were trypsinised to detach cells adherent to the flasks. Medium was aspirated and 
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cells were washed with 1/3ml sterile PBS (for T25/T75 flasks respectively) for 30 
seconds in order to remove excess FBS which could reduce the efficacy of the 
trypsin. PBS was then aspirated and 1/3ml sterile trypsin (for T25/T75 flasks 
respectively) added and the flasks were incubated at 37°C, 5% CO2 and 95% 
humidity with caps loosely fastened for approximately 15 minutes until 
detachment of the cells could be seen. An equal volume of normal culture 
medium was added to the cell suspension and this was transferred to a universal 
container (UC; Greiner Bio-One Ltd., Gloucestershire UK) and centrifuged at 1,700 
rpm for 4 minutes. The resulting supernatant was aspirated and the remaining cell 
pellet was resuspended in normal culture medium (or SFM where stated). The cell 
number in this cell solution was then counted and cells were transferred to 
further flasks for re-culturing and cell maintenance or to plates/other culture 
ware for experiments as described in the following sections. 
The in vitro assays employed throughout this study involve the use of a variety of 
types and sizes of culture-ware. Although the seeding density of cells varies with 
each experiment the volumes applied to each well are standard, unless otherwise 
stated: 300µl per well on a 96-well plate, 500µl per well for a 24-well plate, 1ml 
per well for a 6-well plate. 
2.4.3 Cell counting 
25µl of single cell solution was pipetted into a Tali™ Cellular Analysis slide and 
then placed in the Invitrogen™ Tali™ Image-based Cytometer (ThermoFisher). The 
focus was adjusted for optimum counting settings according to manufacturer’s 
instructions and then the cell number, average cell size and cell concentration was 
measured based on calculations from 9 fields of view. Cells were then diluted and 
seeded at appropriate concentrations for experimental requirements. 
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2.4.4 Cell storage 
Cells were trypsinised as described in section 2.4.2 and the cell pellet was 
resuspended appropriate volumes of 10% v/v DMSO in normal culture medium. 
The cell suspension was quickly divided into 900µl aliquots in 1ml CRYO.STM tubes 
(Greiner Bio-One Ltd., Gloucestershire, UK) and stored at -80°C for short periods 
of time. Cells were transferred to liquid nitrogen tanks at a later date for long-
term storage of low-passage cell stocks. 
2.4.5 Cell revival 
Frozen cell stocks were revived by rapidly thawing cells in CRYO.STM tubes using 
pre-warmed culture medium and transferring cell solution to a UC. Normal culture 
medium was added to make a total volume of 4ml and then solution was 
centrifuged at 1,700rpm for 5 minutes to obtain a cell pellet. The supernatant 
containing DMSO was removed, the pellet was resuspended in 5ml normal culture 
medium and transferred to a T25 flask which was then incubated under normal 
culture conditions overnight. After 24 hours, the revived cells were examined 
under the microscope (an Olympus CKX31 microscope, Olympus corporation, 
Tokyo, Japan) to visually assess the viability of the adherent cells. The medium 
was aspirated and replaced with fresh normal culture medium. The flask was 
returned to the incubator and the previously described normal cell culture 
protocols were then employed. 
2.4.6 Mycoplasma testing 
Mycoplasma contamination was tested for using an EZ-PCR Mycoplasma Test Kit 
(Biological Industries, Israel) upon revival of cell stocks and before storage or 
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discarding of cells. Medium was taken from cells that had been cultured for at 
least 24 hours from seeding and used for mycoplasma testing according to the kit 
instructions. PCR and gel electrophoresis techniques were used as directed by the 
kit instructions, see sections 2.5.5 and 2.5.7 respectively. Cells were discarded on 
discovery of any mycoplasma infection. 
2.4.7 siRNA transfection 
The pellet resulting from trypsinised cells (see section 2.4.2) was resuspended in 
SFM containing no antibiotics and plated in 500µl in 24-well plates (Greiner Bio-
One) at 1.5 x 105 cells/well for the HaCaT cell line and 2 x 105 cells/well for lung 
cancer cell lines. Cells were allowed to adhere overnight at 37°C. Cells were 
transfected with nWASP siRNA (sc360006; Santa Cruz Biotechnology Inc., USA) at 
varying concentrations, or NT control siRNA at the same concentration, as 
described. siRNA, diluted according to the desired end concentration in SFM, was 
combined with equal volumes of Lipofectamine 3000 reagent (ThermoFisher 
Scientific, MA, USA), also diluted in SFM for 1-1.5µl per well at end delivery. This 
siRNA/Lipofectamine 3000 mix in SFM (with no antibiotics) was allowed to stand 
at room temperature for 30-40minutes. Antibiotic-free DMEM supplemented with 
5% FBS was then added to the siRNA/Lipofectamine 3000 solution to achieve the 
desired end concentration of reagents and make up the required volume for 
application to cells then 330µl of the final solution was gently applied to each 
well. Cells were incubated under normal culture conditions and normal culture 
medium was used 24 hours after transfection for any further culturing or assays, 
unless stated otherwise. 
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2.5 Methods for gene expression detection 
2.5.1 RNA isolation 
RNA isolation was carried out using TRI-reagent (Sigma-Aldrich) according to the 
manufacturer’s instructions for both clinical tissue samples collected from 
patients and cultured cells. Medium from cells culture in a monolayer in flasks or 
plates was aspirated and TRI-reagent (1ml per flask or per well of 6-well plate, 
500µl per well of 24-well plate) was added. 28cm length Cell Scrapers (Greiner 
Bio-One) were used to maximise the harvest of the cell lysate from flasks. The cell 
lysate was passed several times through a pipette tip to produce a homogenate 
lysate and transferred to a 1.5ml Eppendorf. For RNA extraction from patient 
samples, multiple frozen tissue sections from the same patient biopsy were 
combine and homogenised in 1ml of ice-cold TRI-reagent as described in section 
2.3. Lysates were stored at -20°C for short term (up to a week), or at -80°C for 
longer time periods, or immediately used for RNA extraction. 
The same procedure for extraction of RNA from cell lysates in TRI-reagent was 
undertaken for both clinical samples and cultured cells. The lysate was allowed to 
incubate at room temperature for 5 minutes. 0.1ml 1-bromo-3-chloropane 
(Sigma-Aldrich) was added and samples were vigorously shaken for 15 seconds 
then allowed to stand at room temperature for 15 minutes. The Eppendorf was 
then centrifuged at 12,000g for 15 minutes at 4°C. As a result, the homogenate 
separates into three phases: a red organic phase (protein), a white interphase 
(DNA) and a colourless upper phase containing the RNA. The upper, clear, 
aqueous phase, containing around 40-50% of the volume, was carefully 
transferred to a fresh Eppendorf and 0.5ml of 2-propanol (Fisher Scientific UK) 
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was added to it. The Eppendorf was shaken thoroughly and allowed to stand at 
room temperature for 10 minutes. Samples were then centrifuged at 12,000g for 
10 minutes at 4°C and the RNA precipitate forms as a white pellet. The 
supernatant was discarded and the RNA pellet was washed by vortexing with 1ml 
of 75% ethanol (made using 3:1 v/v of pure ethanol (Fisher Scientific UK) and 
DEPC water). Samples were then centrifuged at 7,500g for 5 minutes at 4°C and 
the pellet was washed and centrifuged again in the same way. After the second 
wash, as much of the ethanol as possible was removed and the RNA pellet was 
then dissolved in DEPC water (8-50µl depending on pellet size) by repeated 
pipetting. The RNA concentration was then measured as described in section 2.5.3 
and then frozen at -20°C for short term storage (up to a month) or at -80°C for 
longer periods. 
2.5.2 Genomic DNA (gDNA) isolation 
Genomic DNA isolation from cultured cells was carried out using TRI-reagent 
(Sigma-Aldrich) according to the manufacturer’s instructions. Cells were lysed 
from flasks at ~80-90% confluency and separated into three phases through 
centrifugation as explained in section 2.5.1. The aqueous upper phase overlaying 
the DNA interphase was removed as best possible and used for RNA isolation or 
discarded. The DNA was precipitated by adding 0.3ml of 100% ethanol per 1ml of 
TRI-reagent used and mixing by inversion. The sample was allowed to stand for 2-
3 minutes at room temperature before being centrifuged at 2,000g for 5 minutes 
at 4°C. The supernatant was removed and discarded and the DNA pellet was 
washed twice in 1 ml of 0.1 M trisodium citrate in 10% ethanol solution for every 
1 ml of TRI-reagent used, to remove phenol from the DNA. The trisodium citrate 
was made using 0.294g trisodium citrate powder, 1ml pure ethanol and 9ml dH2O. 
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The Eppendorfs were centrifuged at 2,000g for 5 minutes at 4°C between washes. 
The DNA pellet was allowed to stand at room temperature for at least 30 minutes, 
with occasional mixing, during each wash. The sample was centrifuged again at 
2,000g for 5 minutes at 4°C and the DNA pellet was resuspended in 1.5 ml of 75% 
ethanol in DEPC water per 1 ml of TRI-reagent and left to stand for 20 minutes at 
room temperature. The DNA was centrifuged again and then the pellet was air-
dried for 5-10 minutes and dissolved by repeatedly pipetting in an appropriate 
volume of 8mM NaOH, usually 100µl for samples from a T25. This repeated 
pipetting assures complete dissolution of the DNA pellet over approximately 10 
minutes. To remove any insoluble material, the sample was centrifuged again and 
the supernatant was transferred to a fresh Eppendorf tube. Appropriate amounts 
of 0.1 M HEPES (~5.9µl for samples from T25) were added to adjust DNA to pH 8.4 
for use in PCR. DNA concentration was measured (see section 2.5.3) and diluted 
to achieve 0.1-1µg per PCR reaction mix.  
2.5.3 RNA and gDNA quantification 
Concentration and purity of RNA and gDNA extracts were measured using a 
NanoPhotometer™ (Implen GmbH, Schatzbogen, Germany). 2µl of DEPC water, to 
blank, and then 2µl of RNA/gDNA were loaded and measured at 260nm 
wavelength. The purity was also estimated using the A260/A280nm ratio. 
2.5.4 Reverse transcription (RT) 
Reverse transcription was carried out using the GoScript™ Reverse Transcription 
System (Promega, Madison, USA). According the measured concentration, RNA 
was diluted in DEPC water to achieve 1µg in 4µl in thin-walled 200µl PCR tubes. 
1µl of Primer Oligo(dT)15 reagent was added to each RNA reaction mix and 
87 
 
samples were heated to 70°C for 5 minutes then immediately chilled on ice for 5 
minutes. 15µl of RT mix (pre-prepared, consisting of 4µl GoScript™ 5x Reaction 
Mix, 1.2µl MgCl2, 1µl PCR Nucleotide Mix, 0.5µl Recombinant RNasin® 
Ribonuclease Inhibitor, 1µl GoScript™ Reverse Transcriptase and 7.2µl DEPC 
water) was then added to the RNA reaction mix and the samples were placed in a 
thermocycler (SimpliAmp Thermal Cycler; ThermoFisher) for the following 
conditions: 25°C for 5 minutes, 42°C for 1 hour, 70°C for 15 minutes, 4°C until 
samples were collected. The resulting cDNA was diluted 1:4 by adding 60µl of PCR 
water to and then stored at -20°C. 
2.5.5 Conventional PCR 
Conventional PCR (also referred to as PCR) was carried out using GoTaq Green 
master mix (Promega, Madison, USA) with specific primers detailed in section 
2.1.2. A 1x PCR reaction mix typically consisted of the ingredients shown in Table 
2.7. 
Table 2.7: Ingredients in typical conventional PCR reaction mix 
Component Volume (µl) 
2x GoTaq Green Master Mix 8 
Forward primer (10pmol) 1 
Reverse primer (10pmol) 1 
PCR water 5 
cDNA/gDNA (or PCR water for negative control) 1 
 
If the volume of components of the reaction mix are altered, for instance in the 
dilution of gDNA to achieve the desired amount, then the volume of PCR water is 
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altered accordingly to maintain the total reaction volume at 16µl. A positive 
control, usually for the housekeeping gene GAPDH, was also run for each sample. 
The reaction mix was formulated in thin-walled 200µl PCR tubes or a 96-well PCR 
plate and briefly centrifuged then placed in thermocycler (SimpliAmp Thermal 
Cycler, ThermoFisher) for the following conditions:  
 Initial denaturation at 94°C for 5 minutes 
 Followed by 28-34 cycles of 94°C for 30 seconds (denaturation), 54°C for 
40 seconds (annealing) and 72°C for 1 minute (elongation) 
 Final elongation at 72°C for 10 minutes 
 Hold stage at 4°C until collection 
PCR products were then visualised using gel electrophoresis. 
2.5.6 Quantitative PCR (qPCR) 
qPCR was performed using Precision FAST 2x qPCR Master Mix (Primer Design, 
Southampton, UK) and Amplifluor ™ Uniprimer™ Universal system (Intergen 
Company®, NY, USA). A 1x qPCR reaction mix consisted the ingredients detailed in 
Table 2.8. 
Table 2.8: Ingredients in typical qPCR reaction mix 
Component Volume (µl) 
Precision FAST 2x qPCR Master Mix 5 
Forward primer (10pmol) 0.3 
Reverse primer (z-primer) (1pmol) 0.3 
Amplifluor ™ Uniprimer™ probe (10pmol) 0.3 
cDNA 4 
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The Amplifluor™ Uniprimer™ probe consists of a 3’ region, which pairs with the z-
sequence (ACTGAACCTGACCGTACA) present on the target-specific primers, and a 
5’ hairpin structure labelled with a fluorophore (FAM). When the hairpin structure 
is intact, and the fluorescent reporter and a quencher (DABSYL) attached to the 5’ 
and 3’ ends of the stem respectively are in close proximity, the fluorescent signal 
is quenched. During the first amplification cycle, the z-primer hybridises to the 
template and is extended. During the second amplification cycle, the other target-
specific DNA primer hybridises to the product of the first and serves as a template 
for the synthesis of a new target strand that contains a sequence complementary 
to the z-sequence. The product from the second amplification cycle can then 
serve as the template for the UniPrimer. In the third amplification cycle, the 
extended UniPrimer serves as a template for the next amplification cycle. In the 
fourth cycle, extension of the template through the UniPrimer causes the hairpin 
to open and adopt a linear configuration. The reporter and quencher are thus 
separated and fluorescence is emitted and detected by the thermocycler. 
Exponential amplification using the second target-specific DNA primer and the 
UniPrimer occurs in subsequent PCR cycles. The resulting fluorescence signal 
detected is proportional to the amount of amplified product in the sample. A 
summary of the qPCR method is shown in Figure 2.1. 
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Figure 2.1: The principle of the Amplifluor™ Uniprimer™ Universal qPCR 
detection system. The method of activation of the Amplifluor™ Uniprimer™ probe 
is described which leads to a fluorescent signal which can be detected and 
measured in accordance to DNA replication. Image from bio-rad.com. 
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The reaction mixes were formulated in a MicroAmp® Optical 96-well reaction 
plate (Applied Biosystems, ThermoFisher, UK) that was compatible with the qPCR 
machine with 4 replicates of each sample and then covered with an optically clear 
MicroAmp® Optical Adhesive film (Applied Biosystems). Quantitative PCR 
amplification was performed using a StepOne plus Real-Time PCR System (Applied 
Biosystems) with the following conditions: 
 Initial denaturation at 94°C for 10 minutes 
 Followed by 100 cycles of 94°C for 10 seconds (denaturation), 55°C for 30 
seconds (annealing) and 72°C for 10 minute (elongation) 
The fluorescent signal detected according to the exponential replication of the 
DNA template and the point at which this reaches a particular threshold, the 
threshold cycle (CT value), can be used to calculate the transcript copy number 
(Figure 2.2). Results were analysed using ΔΔCT normalisation to a housekeeping 
gene, such as GAPDH or actin.  
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Figure 2.2: Sample qPCR amplification plot. The fluorescence detected during the 
qPCR amplification increases according to the amount of product produced. 
Initially, fluorescence is not detectable (cycles 1-19 in example) but as product 
accumulates through several cycles a fluorescent signal is detected. The cycle 
number at which this signal reaches a detectable level is defined at the threshold 
cycle, or CT. This value can be used to calculate the amount of template initially 
present in the reaction. Image from bio-rad.com. 
93 
 
For qPCR experiments for human tissue samples, the expression of the target 
sequence was detected and the number of transcripts was calculated based on an 
internal Podoplanin (PDPL) standard run in the experimental plate. The standard 
samples were prepared containing a known dilution series of PDPL transcripts/ml 
(108, 107, 106, 105, 104, 103, 102, 101) and run alongside the experimental samples 
under the same conditions. The standard curve generated from this reaction 
allowed calculation of the transcript number in the unknown samples which were 
also then normalised against a housekeeping gene, actin or GAPDH. 
2.5.7 Gel electrophoresis 
DNA fragments were separated according to size using agarose gel 
electrophoresis. Samples were loaded onto 0.5-2% agarose gels depending on the 
predicted size of the DNA products and requirements for resolution. Agarose gel 
was made by adding an appropriate amount of agarose (Melford Chemicals, 
Suffolk, UK) into 50 or 150ml 1x TBE buffer, depending on the size of the gel tank 
used, and then heating using a microwave to fully dissolve the powder and leave a 
transparent solution. This was allowed to cool until ~70°C and 5 or 10µl of SYBR 
safe (Abnova, Taiwan) was added to the agarose solution according to the gel 
volume. The gel was poured into prepared casting trays with assembled plastic 
combs (SCIE-PLAS, Cambridge, UK) which create wells as the gel polymerises at 
room temperature over approximately 30 minutes. Once set and cooled, the gel 
was submerged in 1x TBE and the combs were removed. 5µl of PCR Ranger 100bp 
DNA ladder (Geneflow, Staffordshire, UK) and 8µl of PCR products was loaded into 
wells. Electrophoresis conditions of 90V-110V, 150mA and 50W were then applied 
to the gel using an EV243 power consort (Topac Inc., Cohasset, USA) over 25 
minutes – 3 hours to separate the PCR products according to length in base-pairs. 
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Following electrophoresis, the PCR products were visualised and images captured 
using a U: Genius 3 Gel Doc system (Syngene, Cambridge, UK)  
2.6 Methods for protein detection 
2.6.1 Western blotting 
2.6.1.1 Protein extraction, quantification and processing 
Lysis buffer was applied to cultured cells, 20-50µl per well of a 6-well plate, and 
cell lysates were scraped into Eppendorf tubes using 28cm length Cell Scrapers 
(Greiner Bio-One). Alternatively, cells were trypsinised and centrifuged as 
described in section 2.4.2 and lysis buffer was added directly to the cell pellet and 
then transferred to an Eppendorf. Cell lysates were placed on a Labinoco rotating 
wheel (Wold Laboratories, York, UK) for approximately 30 minutes at 25rpm, 4°C. 
Lysates were then centrifuged at 14,000rpm for 4 minutes and the supernatant 
(protein lysate) was transferred into a fresh 1.5ml Eppendorf tube. Samples were 
then used for further processing or stored at -20°C for future use. 
Protein samples were quantified according to the Bio-Rad DC™ protein assay kit 
(Bio-Rad Laboratories, Hemel-Hempstead, UK). Standard BSA protein samples at 
10mg/ml were made by dissolving bovine serum albumin (BSA) powder (Sigma-
Aldrich) in lysis buffer. Eight 5µl volumes of serially diluted BSA standard samples 
in lysis buffer, from 10mg/ml diluted 1:2, were plated in a 96-well plate in 
triplicate. 5µl of protein samples in triplicate were also plated. Sufficient volumes 
of reagent A’ was made through combining 1 part reagent S with 50 parts reagent 
A. 25µl of reagent A’ was added to the 5µl protein/BSA standard samples already 
plated. 200µl of reagent B was then added and the plate was transferred to a 
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shaker for 30minutes at room temperature to allow the colorimetric reaction to 
take place. The absorbance was then detected at 630nm using an ELx800 plate 
reading spectrophotometer (Bio-Tek, Wolf Laboratories, York, UK). A standard 
curve was generated from the absorbances of the BSA standards and this was 
used to calculate the unknown protein sample concentrations. 
Protein samples were diluted 1:1 with 2x Laemmli Buffer (Sigma-Aldrich) and then 
boiled at 100°C for 10 minutes to denature the proteins. These samples were then 
stored on ice temporarily or at -20°C until use in SDS-PAGE. 
2.6.1.2 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE was undertaken using an OmniPAGE VS10DYS vertical electrophoresis 
system (OmniPAGE, Cleaver Scientific Ltd., Rugby, UK). The vertical 
electrophoresis system was properly assembled according to the manufacturer’s 
guidelines. 10% resolving and stacking gels were prepared in 15ml and 5ml 
aliquots respectively for an experiment using two gels. These solutions 
constituted the ingredients detailed in Table 2.9. 
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Table 2.9: The components of a 10% resolving and stacking gel solution 
Component Volume (ml) in 15ml of 
Resolving Gel 
Volume (ml) in 5ml of 
Stacking Gel 
dH2O 5.9 3.4 
30% Acrylamide mix 
(Sigma-Aldrich) 
5 0.83 
1.5M Tris-HCl buffer pH8.8 
(Bio-Rad Laboratories) 
3.8  
0.5M Tris-HCl buffer pH6.8 
(Bio-Rad Laboratories) 
 0.63 
10% SDS 0.15 0.05 
10% APS 0.15 0.05 
TEMED (Sigma-Aldrich) 0.006 0.005 
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Resolving gel was loaded immediately after preparation between glass plates 
assembled in the loading cassette to a level approximately 2cm below the top and 
then 2-propanol (Fisher Scientific UK) was applied over the top whilst the gel 
polymerised at room temperature for around 30 minutes. When fully set, the 2-
propanol was poured away and the stacking gel was loaded to the top of the glass 
plates and then a well-forming Teflon comb was inserted. Once the gel had 
polymerised, the loading cassette was transferred to an electrophoresis tank, the 
central reservoir was filled with running buffer and the area surrounding the gel 
cassette was half filled with running buffer. The combs were removed and 8µl of 
BLUeye Prestained Protein Ladder (Geneflow Ltd., Staffordshire, UK) and 20-30µl 
of pre-prepared protein sample was loaded into the wells. Electrophoresis was 
carried out using an EV243 power consort (Topac Inc., MA, USA) using the 
conditions: 110V, 150mA, 50W for 2 hours and 30 minutes.  
2.6.1.3 Western blot transfer of proteins to polyvinylidene fluoride 
(PVDF) membrane 
Immobilon-P PVDF transfer membrane (EMD Millipore Corporation, MA, USA) was 
cut into 7.5cm x 7.5cm pieces (one piece per gel) and prepared by soaking in 100% 
methanol (Fisher Scientific UK) for at least 30 seconds, submersion in dH2O for at 
least 30 seconds and then submersion in transfer buffer for at least 5 minutes. 
Filter paper (six sheets per gel; Sigma-Aldrich) were also prepared by cutting into 
7.5cm x 7.5cm pieces and immersed in transfer buffer with sponges (two per gel). 
On completion of SDS-PAGE the glass plates were separated and the stacking gel 
discarded. The resolving gel was placed on top of one sponge and 3 pieces of filter 
paper and the PVDF membrane was then placed on top of the gel followed by 3 
more pieces of filter paper and a sponge. This ‘sandwich’ was placed in a transfer 
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cassette and positioned in a wet transfer tank, a Mini Trans-Blot cell (Bio-Rad, 
Laboratories, Hamel-Hempstead, UK), in the correct orientation for effective 
protein transfer from the gel to the membrane. The arrangement and equipment 
used in this stage are shown in Figure 2.3. The tank was filled with transfer buffer 
and either kept cool in the cold room at 4°C overnight or through the addition of 
an ice pack to the transfer tank for same-day transfer. The tank lid was assembled 
and transfer was carried out using an EV202 power consort (Topac Inc., MA, USA) 
with the conditions 100V, 280mA, 50W for 1h for same-day transfer or 30V for an 
overnight transfer. 
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Figure 2.3: Equipment and arrangement used in Western blot transfer. Mini 
Trans-Blot equipment was used for the transfer stage of the Western blot 
protocol (A). The acrylamide gel and membrane were assembled in a ‘sandwich’ in 
the transfer cassette as shown (B). Image (A) from www.protocol-online.org.
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2.6.1.4 Membrane processing and immunoprobing 
On completion of the transfer process, verification of successful protein transfer 
was carried out using Ponceau S staining to the membrane. Washing with dH2O 
removed the Ponceau S stain revealing protein presence as pink bands. If 
required, the membrane was cut using a scalpel at this stage. The membrane was 
left in blocking buffer (5% w/v milk in 0.1% TBST, made using Marvel skimmed 
milk powder dissolved in 0.1% TBST) for 1 hour at room temperature on a rocker. 
Following blocking, membranes were transferred to bijous tubes, UCs or falcon 
tubes (depending on the size of the membrane) with the protein-containing side 
facing towards the middle of the tube. Primary antibodies delivered in blocking 
buffer were added to the tubes in 1ml or 4ml volumes depending on the size of 
the container at the dilutions specified in Table 2.5. The membranes were left on 
a roller (Stuart, Wolf Laboratories, York, UK) at room temperature for 1 hour or 
overnight in the cold room at 4°C. Following incubation in primary antibodies, 
membranes were washed three times in appropriate volumes of 0.1% TBST for 5 
minutes per wash. HRP-conjugated secondary antibodies (Sigma-Aldrich) 
appropriate for the primary antibody used were then added to the tubes in 1ml or 
4ml volumes again. Secondary antibodies were diluted 1:1000 in blocking buffer 
and are detailed in Table 2.6. Membranes were incubated at room temperature 
for 1 hour in secondary antibodies on a roller and then washed three times in 
0.1% TBST as previously described. 
2.6.1.5 Protein detection 
Membranes were treated with EZ-ECL Chemiluminescent Detection Kit (Biological 
Industries, Israel) for visualisation. Equal parts of EZ-ECL solution A and B were 
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mixed and left in the dark at room temperature for at least 5 minutes. EZ-ECL was 
applied to completely cover the membrane and left in the dark for approximately 
1 minute. Excess EZ-ECL was drained from the membrane and the 
chemiluminescent signal was detected using a G:BOX Chemi RxQ imaging system 
(Syngene, Cambridge, UK). ImageJ (National Institutes of Health, NY, USA) was 
used to carry out semi-quantitative analysis of Western blot results using the 
integrated density to assess protein expression in the samples normalised by a 
housekeeping gene. 
2.6.1.6 Protein extraction and processing for KinexusTM Antibody 
Microarray 
Cells were cultured and treated in T75 flasks in preparation for a Kinexus Antibody 
Microarray study. When ready for protein extraction, cells were washed twice in 
PBS and then scraped from the flask using a 28cm length Cell Scraper (Greiner Bio-
One) in lysis buffer prepared specifically for the array study (section 2.2.4). The 
cell lysate was placed on a Labinoco rotating wheel for 40 minutes and then 
samples were centrifuged at 14,000rpm for 4 minutes and the supernatant 
transferred to a fresh Eppendorf as described in section 2.6.1.1. 
Fluorescamine reagent (F9015, Sigma-Aldrich) was used to quantify total protein 
in preparation for this antibody array assay. Fluorescamine was dissolved in 
absolute acetone (Fisher Scientific UK) to achieve 3mg/ml concentration in a glass 
vial. BSA standard samples were serially diluted over 8 wells of a 96-well plate in 
triplicate as described in section 2.6.1.1. The protein samples were diluted to 1 in 
10 in PBS and also aliquoted in triplicate to get a final volume of 150µl 
protein/BSA standard per well. 50µl of fluorescamine/acetone was then added to 
each well and shaken for 1 minute. The fluorescence signal was detected using a 
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GloMax®-Multi Microplate Multimode Reader (Promega Biosystems Inc., CA, USA) 
with a 365nm excitation and 410-460nm emission filter. The concentration of the 
protein samples was calculated based on the standard curve generated by the 
BSA standards. The protein samples were then diluted to 4mg/ml using lysis 
buffer to make 300µl stock. These samples were stored at -20°C and then 
dispatched to Kinexus Bioinformatics, Vancouver, Canada to undergo Kinexus™ 
Antibody Microarray analysis. 
2.6.1.7 KinexusTM Antibody Microarray 
This study utilised the KinexusTM KAM880 protein array service provided by 
Kinexus Bioinformatics Ltd. (Vancouver, Canada) which uses array slides, each 
containing two sets of 877 antibody spots allowing for simultaneous testing of 
two samples per slide. Antibodies are covalently immobilised the array slides 
under conditions which ensure high binding efficiency and specificity. Each 
microarray has antibody and loading controls to ensure consistent protein loading 
in all fields. The binding of dye-labelled proteins to each pan- or phospho-specific 
antibody spot is measured according to fluorescence in duplicate to provide semi-
quantitative analysis of the expression and phosphorylation of hundreds of 
proteins. The methodology behind the KinexusTM KAM880 Antibody Microarray 
system is illustrated in Figure 2.4A-C, highlighting how the problems of false 
negatives and positives can occur. An example image of the fluorescence that 
would be detectable on the array slide during the process is also shown in Figure 
2.4D. 
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Figure 2.4: KinexusTM protein microarray procedure. The KinexusTM protein microarray system involves labelling of the protein samples (A) with a dye (B) 
and then applying the samples to the microarray slide where proteins bind to the appropriate antibody (Ab) spot (C). Issues with false positive and negative 
results are highlighted. An example output from the array analysis can be seen (D) where signal intensity of each antibody spot corresponds with colour 
(red, orange, yellow, green, blue in order of highest intensity). Images adapted from www.kinexus.ca. 
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Signal quantification is performed with ImaGene 8.0 by Kinexus Bioinformatics 
Ltd. which has predetermined settings for spot segmentation and background 
correction. The background corrected raw intensity data is then globally 
normalised by summing the intensities of all the net signal median values for a 
sample to get the globally normalised signal intensities for each protein. These 
values along with some further parameter were then returned in spreadsheet 
format for further data analysis and investigation. The % change of the treated 
samples from the control was calculated based on the globally normalised 
intensity for each protein using the following calculation: %CFC = (Globally 
normalized treated – Globally normalized control) /Globally normalized control) x 
100. The % Error Range was also calculated to examine how tightly the globally 
normalised net signal intensity varies for duplicate spots of the same protein in 
the sample. Z-scores were also calculated by subtracting the overall average 
intensity of all replicate spots from the raw intensity for each spot and then 
dividing it by the standard deviation of all the measured intensities within each 
sample. The z-ratio was calculated by dividing the differences between the 
observed z-scores by the standard deviation of all the differences for that 
comparison. Several factors were used to determine the most important changes 
in protein expression and phosphorylation including %CFC, error ranges, value for 
the globally normalised intensity of one of the samples of >1500 and significance 
based on z-ratios of <-1.96 or >1.96. 
2.6.2 Immunofluorescence staining 
Cells were cultured in Millicell EZ 8-well chamber slides (Merck Millipore, 
Watford, UK) in 300µl of treatment/culture medium at an appropriate seeding 
density. To fix the cells, culture medium was removed, cells were washed with 
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PBS using a disposable pastette and then fixed in 100% ice cold ethanol (500µl per 
well). Cells were left for at least 20 minutes at -20°C and up to 2 weeks in pure 
ethanol. To proceed with immunofluorescence staining, cells were washed 3 
times in PBS for 5 minutes per wash and then permeabilised by adding 500µl of 
0.1% Triton X-100 (Sigma-Aldrich) in PBS for 5 minutes at room temperature. 
Wells were then washed for 3 x 5 minutes with PBS and 500µl of blocking buffer 
(7.5% donkey serum (D9663, Sigma-Aldrich, UK) in PBS) was added to each well. 
The slide was left for 3 hours at room temperature in blocking buffer. Primary 
antibodies were prepared (1:100 in blocking buffer, see Table 2.5) and 250µl was 
added to the appropriate wells. The chamber slide was incubated with primary 
antibodies for an hour on the bench, or at 4°C overnight, and then washed 3 times 
with PBS for 5 minutes per wash again. Secondary antibodies were made up at the 
appropriate dilutions (1:500 for Alexa secondary antibodies and 1:1000 for DAPI, 
see Table 2.6) using blocking buffer and 250µl was added to the appropriate well. 
Slides were allowed to incubate in the dark for 1 hour on the bench. Slides were 
then washed 3 more times with PBS and mounted. To do this the chambers were 
removed, FluorSave™ (Calbiochem, Nottingham, UK) was applied to the slide and 
a cover slip was applied. The slides were left in the dark at 4°C for at least 2 hours 
whilst the FluorSave set and then visualised using an Olympus BX51 microscope 
with a Hamamatsu Orca ER digital camera at x 40. Images were analysed using 
ImageJ. 
2.6.3 Immunohistochemistry (IHC) 
Immunohistological analysis using an avidin-biotin peroxidase technique was 
performed on human tissue samples collected from cohort 2, as detailed in 
section 2.3.1. The frozen sections were fixed in dried acetone (10162180, Fisher 
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Scientific UK) for 15 minutes, air dried for 15 minutes and washed in TBS for 5 
minutes three times. Sections were then incubated in 0.1% BSA/ 10% horse serum 
in TBS (referred to as blocking solution) in a humidified box at room temperature 
for 1 hour. Excess blocking solution was removed and the sections were incubated 
in primary antibody solutions (diluted in blocking buffer to final concentration of 
2µg/ml), or just blocking buffer for negative control samples, for 1 hour. Sections 
were washed with TBS and then biotinylated horse anti-mouse/rabbit IgG 
secondary antibody (Vector Laboratories, UK) was applied for 30 minutes 
followed by 30 minutes in ABC reagent, both which were provided in the 
VECTASTAIN® Elite ABC Kit (Vector Laboratories). 3’3 diaminobensidine (DAB) 
substrate (5mg/ml) was used to develop the final reaction product and the 
sections were rinsed in tap water and counterstained with Gill’s haematoxylin 
(Vector Laboratories). Sections were then dehydrated through a series of graded 
alcohol solutions, cleared in xylene (Fisher) and mounted in Distyrene Plasticizer 
Xylene (DPX, Merck Pharmaceuticals, UK). 
Staining was visualised using a Leica DM1000LED microscope with a MC120 HD 
camera and Leica Application Suite (version 3.0.0) software (Leica Microsystems, 
UK). The localisation and intensity of staining was judged blindly by two people 
independently. Positive staining was seen as a brown/black deposit, whilst 
negatively stained cells could be clearly distinguished by a blue nucleated stain. 
2.7 In vitro assays 
2.7.1 Crystal violet staining and counting of stained cells 
Following in vitro functional assays, cells were often quantified using the following 
crystal violet staining method. Cells cultured in plastic tissue culture plates 
107 
 
(usually 96-well plates) were washed gently with PBS and then fixed using 4% 
formalin (Sigma-Aldrich, Dorset, UK) for 10 minutes at room temperature. The 
formalin was then discarded and cells were stained with 1% crystal violet (Sigma-
Aldrich, Dorset, UK) for 10 minutes at room temperature. Excess crystal violet was 
gently washed away and the plate could then be dried and the stained cells could 
be imaged at x5 magnification using a Leica DMi1 microscope equipped with a 
MC120 HD camera and Leica Application Suite version 3.0.0 software (Leica 
Microsystems, Milton Keynes, UK).  
Images were analysed using ImageJ (National Institutes of Health, NY, USA). 
Images were imported in a sequence and converted to 8-bit images (greyscale). 
The background from the images was subtracted and then the threshold was 
adjusted to a level where cells were adjusted to be black and the background was 
adjusted to be white (Figure 2.5B). The ‘watershed’ process was then applied to 
the images which separated groups of cells into individual units. The number of 
particles in the image, within a defined size range to exclude small debris and 
background particles, was then counted (Figure 2.5C) and the properties of these 
particles, which represent individual cells, were measured. The cell number 
and/or cell coverage in the image could then be calculated. The measurements 
produced using this method are accurate representations of cell number, Figure 
2.6. Crystal violet could be extracted from cells on the dried plate using 10% acetic 
acid (Sigma-Aldrich, Dorset, UK) in dH2O (v/v) and absorbance determined at 
540nm wavelength on an absorbance plate reader (Biotek ELx800). Absorbance 
measured following crystal violet staining has been shown to be a sensitive 
method to measure cell number as shown by Figure 2.7. 
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Figure 2.5: Cell counting using ImageJ. Images adjusted using ImageJ as described in section 2.7.1 in order to count cells by measuring particle size or total 
area covered by cells. A549 cells are used in these example images. The original image taken at x5 zoom (A) is adjusted using ImageJ to show cells in black 
and the background in white (B). This image can be used to measure cell coverage or a watershed can be applied and the particles numbered and counted 
(C) to get a cell count. 
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Figure 2.6: Cell count and coverage as a measure of cell number. Graphs 
demonstrates a linear relationship (R2 = 0.9972 and R2 = 0.997 respectively) 
between cell count (A) or cell coverage (B) and the number of cells seeded, 
following crystal violet staining. A-549 cells were used in this instance and were 
allowed to settle for 3 hours in a 96-well plate, following seeding in a serial 
dilution, before fixing, staining and counting as described in section 2.7.1. 
 
Figure 2.7: Absorbance as a measure of cell number. This graph demonstrates a 
linear relationship (R2 = 0.9976) between cell number and the absorbance 
measured at 540nm following crystal violet staining. A-549 cells were used in this 
instance and were allowed to settle for 3 hours in a 96-well plate, following 
seeding in a serial dilution, before fixing and staining as described in section 2.7.1. 
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2.7.2 Growth assay 
Cells were seeded into a 96-well plate with appropriate treatments at a density of 
3,000 cells in each well. Within each experiment 10-replicates were set up. After 
1, 2, and 3/4-day incubation periods, cells were washed, fixed, stained and 
counted as described in section 2.7.1. Cell growth was presented as an increase in 
cell number which was measured according to absorbance.  
2.7.3 MTT assay 
Cells were seeded in a 96-well plate at a density of 1,500 cells per well and left 
overnight to adhere to the plate. The following day, cells were treated with 
nWASP inhibitors (wiskostatin or 187-1) at a range of concentrations, with 
appropriate vehicle controls, in triplicate and the plate was incubated for 72-
96hours. Wells containing no cells were also treated with treatments and vehicle 
controls. After the incubation period 1:10 volume of 5mg/ml MTT solution was 
added to each well and plates were incubated for a further 4 hours. The liquid was 
then removed from the plates and 100μl of acidified isopropanol was added to 
the wells and the plates were shaken for 30 minutes to dissolve the formazan 
crystals. Optical density (OD) was determined using an absorbance reader (Biotek 
ELx800) at 540nm wavelength and used to calculate the relative cell viability. This 
was calculated at each treatment concentration by: (average ODtreated wells, cells – 
average ODtreated wells, no cells) / (average ODcontrol well, cells – average ODcontrol wells, no cells). 
Negative values resulting from this calculation were set to 0 for analysis. 
Sigmoidal dose-response curves were produced using GraphPad Prism 6 for each 
experiment and used to calculate the IC50, the concentration of each inhibitor that 
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is required to achieve 50% growth inhibition compare with the growth of the 
untreated cells. 
2.7.4 Electric cell-substrate impedance sensing (ECIS) 
Z-theta models of the ECIS (electric cell substrate impedance sensing) instruments 
(Applied Biophysics Inc., NJ, USA) were used to electrically monitor the behaviour 
of a monolayer of cells, following seeding and after wounding events, by 
measuring the impedance of cells attached to gold electrodes on the base of a 
96W1E+ array (Applied Biosystems Inc.), as shown in Figure 2.8. This technique 
monitors the resistance and capacitance parameters of the impedance at multiple 
frequencies at numerous time-points which enables the measurement of different 
functional and structural properties of cells cultured in the ECIS array. Resistance, 
when measured at relatively low frequencies of 4,000Hz or below, is considered 
to represent the properties of the cell barrier with the surrounding cells and 
environment. Capacitance, especially at higher frequencies of 32kHz and above is 
considered to measure the coverage of the electrode surface (Wegener et al., 
2000). During this study, the resistance and capacitance are monitored over time 
at a range of frequencies to allow measurements of the attachment and spreading 
and monolayer formation following seeding and also the migration/invasion of 
cells following electrical wounding. 
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Figure 2.8: ECIS culture ware. ECIS assays have been carried out in 96W1E+ arrays 
(A, image from biophysics.com) which consist of a 96-well plate with each well 
containing two gold electrodes, each with an area of 0.256mm2, at the base. Cells 
can be cultured over these electrodes (B) allowing cell behaviour to be electrically 
monitored. Shown are A-549 cells being cultured in an ECIS array, scale bar 
represents 2mm. 
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To set up an ECIS assay, 200μl of normal cell culture medium was added to each 
well of the 96W1E+ array and it was placed in the ECIS station and stabilised. 
Following this, 4 or 8 x 104 cells were seeded into each well in 100μl of culture 
medium and appropriate treatments were added in 200μl. An electrode check 
was run to assess the integrity of the array and connections between the 
electrodes and plate and then ECIS monitoring was initiated. After monitoring the 
resistance of the cells in culture for 24-35 hours the monolayer of cells was 
electrically wounded for 20 or 30 seconds with wound current at 2400 or 3000μA 
and frequency of 60,000Hz, depending on the cell type used. Resistance and 
capacitance of the cell monolayer as it healed was then monitored for a further 35 
hours. The ECIS station is stored in an incubator which allows normal culture 
conditions of 37°C, 5% CO2 and 95% humidity to be maintained for the duration of 
the experiment. Each sample was plated in at least triplicate in the plate. 
On completion of the ECIS assay, data was exported and analysed. The resistance 
or capacitance values at the desired frequencies were collected and normalised 
according to the first time point following set-up or wounding.  
2.7.5  Adhesion assay 
Wells on 96-well plates were pre-coated with Matrigel basement membrane 
matrix (BD Biosciences) dissolved at 50μg/ml in SFM and air dried. The Matrigel 
was then rehydrated with 100μl SFM for 40 minutes. 8 x 105 cells were then 
seeded into each well onto the Matrigel matrix in 200μl of normal medium 
containing treatments and incubated for 25 minutes. Loosely attached or non-
adherent cells were washed off using PBS. Adherent cells were fixed, stained and 
counted as described in section 2.7.1. Adherent cells were visualised under the 
microscope at x5 magnification. 
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2.7.6 Transwell invasion assay 
Cell culture inserts (0.8μm pore ThinCert™ 24-well plate inserts, Greiner Bio-One 
GmbH, Austria) were placed into a 24-well plate and loaded with Matrigel 
basement membrane matrix (BD Biosciences) at 50μg/ml in normal culture 
medium then air dried. The Matrigel was then rehydrated with 100μl of normal 
culture medium for 1 hour. Cells were seeded into inserts at a density of 3 x 104 
cells per well in 200μl containing appropriate treatments or controls. 1ml of 
treatment or control medium at the appropriate concentration was also added 
beneath the inserts. A typical set-up of the transwell invasion culture ware is 
depicted in Figure 2.9. The plates were incubated for 3 days in normal culture 
conditions. After this period, the Matrigel layer and non-invasive cells present 
inside the inserts were cleaned away with a cotton bud. Cells which had invaded 
through the Matrigel and migrated through the pores on the inserts were fixed 
and stained as described in section 2.7.1. Once washed, the inserts were 
examined under the microscope to ensure that non-invasive cells had effectively 
been removed. Crystal violet was then extracted using 10% acetic acid (Sigma-
Aldrich, Dorset, UK) in distilled water (v/v). Absorbance was determined at 540nm 
wavelength on a plate reader (Biotek ELx800). There were 4 replicates of each 
treatment and control in each experiment. 
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Figure 2.9: Schematic diagram of the set-up for a transwell invasion assay. A 
Matrigel layer is added to the base of a 0.8µm pore ThinCert™ insert. Cells are 
seeded in this insert which is placed in a 24-well plate. Invasive cells move 
through the Matrigel and pores to the base of the insert. 
116 
 
2.7.7 Scratch migration assay 
7 x 105 cells were seeded in appropriate treatments into each well on a 24-well 
plate. Upon reaching confluence the monolayer was scraped with a pipette tip to 
create a linear wound. Cell debris was removed by gentle PBS washing and 
treatments/control culture medium was added gently to cells. The plate was 
placed in an EVOS® FL Auto Imaging System (Life Technologies, Paisley, UK) which 
maintained the plate in normal culture conditions throughout the experiment. 
Images at x10 or x20 magnification, to account for the size of the scratch, were 
captured of the wound every 30 minutes for up to 24 hours. Closure of the wound 
was observed and the rate of wound closure was measured through examining 
the width of the wound in the images taken at different time points with ImageJ. 
For each treatment/control concentration at least 6 replicate fields of view were 
examined in every experiment. 
2.7.8 Cytodex-2 bead motility assay 
Cell motility, or ability to migrate, was assessed using a cytodex-2 bead motility 
assay. Cells were incubated at a density of 7 x 105 cells/ml in normal culture 
medium, containing 100μl of cytodex-2 beads (Sigma-Aldrich, Dorset, UK at 
20mg/ml in BSS), for 4 hours with regular agitation to allow the cells to adhere to 
the beads. Following a visual check to ensure beads were adhered evenly and 
effectively on the surface of the beads, as shown in Figure 2.10, the beads were 
washed 5 times in normal culture medium to ensure maximal removal of non-
adherent cells. Following the washes, beads were resuspended in 2ml of normal 
culture medium. 100μl of the cell/bead suspension was added to wells on a 96-
well plate which already contained 200μl of appropriate treatments. The plates 
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were incubated for 18 hours. Following incubation, the medium and beads were 
removed and wells were washed gently with PBS. Any cells which had migrated 
from the beads to the plate were fixed, stained and counted as described in 
section 2.7.1. One image was captured in the centre of each well at x5 zoom and 
the absorbance at 540nm was also examined to allow cell density to be measured. 
There were 6 replicate wells for each treatment/control concentration in each 
experiment. 
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Figure 2.10: Representative images of cell-covered cytodex-2 beads. The image 
demonstrates cytodex-2 beads used in cell motility assays. Adhered to the beads 
are HaCaT cells in this example image. Scale bar represents 200µm. 
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2.7.9 Tubule formation assay 
40μl of neat Matrigel matrix (10mg/ml) was gently pipetted into the bottom of 
each well in 96-well plate. The plate was placed at 37°C for 40 minutes whilst the 
Matrigel polymerised. 4 x 104 cells in 200µl in normal medium (and 
treatments/control reagents where appropriate) were plated on top of the 
Matrigel in each well in replicates of 3 and incubated at 37°C, 5% CO2 and 95% 
humidity. Images of each well were captured at x5 magnification at intervals 
ranging from 30 to 1170 minutes using a Leica DMi1 microscope equipped with a 
MC120 HD camera and Leica Application Suite version 3.0.0 software (Leica 
Microsystems, Milton Keynes, UK). Analysis of the images was carried out using 
ImageJ where the length of cell structures that form part of a tubule structure was 
measured to track the progress of tubule formation. 
2.8 In vivo assays 
2.8.1 Animals 
CD-1 athymic mice (Charles River Laboratories) were used in in vivo tolerance 
assays owing to their slow and steady rate of growth and hairlessness which 
allows for easier observation of changes to the skin. Diabetic db/db (also called 
Leprdb/db) strain mice (Harlan Laboratories, Cambridgeshire; now called Envigo), 
which exhibit impaired wound healing abilities, were also used in in vivo tolerance 
tests but also in in vivo efficacy tests. This in vivo study was carried out under the 
Home Office project license number PPL/2591. Both CD-1 and db/db mice were 
used between 4-6 weeks of age when body weight reached 20g. Mice were 
housed in groups of three in filter topped cages. Procedures were carried out in 
class-II safety cabinets for the athymic mice. 
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2.8.2 Tolerance assay 
After CD-1 and db/db mice were settled for 1 week in the laboratories, 187-1 and 
wiskostatin were injected via the intraperitoneal route on a daily basis. 1µM and 
10µM dosages in 100µl volumes for each compound were administered, 
equivalent to 1.8g/kg/day and 17.8g/kg/day for 187-1 and 0.43g/kg/day and 
4.3g/kg/day for wiskostatin. The mice were observed daily and weighed twice 
weekly. Any severe side effects (agitation, dehydration, skin lesions) or significant 
weight loss (>20% of body weight) would lead to the termination of the study. 
2.8.3 Wound healing assay 
Db/db mice were used in in vivo wound healing assays. Creation of a wound was 
by using an ear punch method (Cho et al., 2006). Briefly, after being housed for a 
week, the db/db mice were first ear-pieced using an ear puncher in order to 
create a wound (hole) of 1mm in diameter in the pinna. The following day the 
mice were weighed and the wound photographed using a digital camera (Nikon) 
at a distance from the ear of approximately 12 cm. Treatment was given 
systemically (as described in section 2.8.2) or topically.  
For topical application, two carrier gels that are currently used in standard wound 
care therapy were purchased from the Pharmacy at the University Hospital of 
Wales. Aquaform Hydrogel Wound Dressing (Aspen Medical Europe Ltd., 
Leicestershire) and Bactroban mupirocin ointment (GSK, Middlesex) were the 
carrier gels used and hereafter are referred to as Topical gels A and B respectively 
following the addition of nWASP inhibitors. The inhibitors were diluted from the 
master stock in the gels by low speed homogenisation using a hand-held 
homogeniser for 2 minutes. The newly formulated gels, which showed no signs of 
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change to consistency, were stored at 4°C until use. Treatments were applied 
topically in 150µl amounts by gently rubbing onto the wounded area using 
fingers. For systemic application, 187-1 was applied at 0.5 and 5µM (equivalent to 
0.89g/kg/day and 8.9g/kg/day) and wiskostatin was applied at 1 and 10µM 
(equivalent to 0.43g/kg/day and 4.3g/kg/day).  
Both systemic and topical treatments were given every other day (Monday, 
Wednesday and Friday) and images were obtained on days 1, 7, 15, 21 and 24 
following wounding. Each sample group consisted of 3 mice each with a hole 
punch wound given to both ears giving a sample size of 6 wounds per treatment. 
Due to considerations of the 3R’s in animal use, only one control group was used 
which received hole-punch wounds but no systemic or topical treatments. 
The size of the wounds was determined using image analysis software (ImageJ). 
Data are presented as the area of the wounds in pixels, where t-tests were used 
for statistical analysis. Data were then normalised by subtraction to the average 
wound size (in pixels) at Day 1 using and the percentage change in wound size 
from Day 1 was calculated for each wound measurement. The formula used to do 
this was: (wound size at a given point – average wound size at Day 1 
point)/(average wound size at Day 1) x 100. The mean and standard deviation for 
each percentage change in wound size from Day 1 was then calculated and 
plotted. 
2.9 Statistical analysis 
Statistical analysis was carried out using Sigma Plot (Systat Software Inc.) for 
patient clinical sample data and GraphPad Prism (version 6, GraphPad Software 
Inc., CA, USA) for other analyses. The Mann-Whitney test was used to analyse 
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qPCR data from patient clinical samples. Other data are presented as mean ± or + 
SD and unpaired t-tests and 2-way ANOVA tests were used to statistically analyse 
data. Each experiment was conducted at least 3 times, unless otherwise stated. 
Either representative examples of each experiment or the change from the 
control, calculated using the mean of all repeats of the experiment normalised by 
division to the control group, are shown. A p-value < 0.05 over at least 3 
independent repeats of an experiment was considered statistically significant. 
Asterisks (*) are used to indicate significant findings with * = p<0.05, ** = p<0.01, 
*** = p<0.001 and **** = p<0.0001 or ‘ns’ to label not-significant results. 
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3.1. Introduction 
nWASP belongs to a group of molecules called the WASP/WAVE (WASP family 
verprolin-homologous protein) family. This 65kDa protein was named neural 
WASP due to its shared homology with WASP, the first identified member of the 
WASP/WAVE family, and abundance in the brain. However, it is also widely 
expressed in different tissues throughout the body, including the heart, lung and 
colon (Miki et al., 1996). nWASP is a cytoplasmic protein which responds to 
several cellular signalling molecules to mediate actin polymerisation through 
interactions with the Actin-related protein 2/3 (Arp2/3) complex (Prehoda et al., 
2000). Through this role, as a reorganiser of the actin cytoskeleton, nWASP has 
been implicated in the control of many cellular processes such as vesicle 
trafficking, pathogen infection and neurite extension to name a few. In addition to 
this, nWASP has been shown to be involved in changes in cell morphology, such as 
membrane protrusion formation, growth and cell movement and hence has been 
the focus of many studies into its activity in a cancer progression context 
(Takenawa and Suetsugu, 2007, Takenawa and Miki, 2001, Kurisu and Takenawa, 
2010). 
Wound healing consists of a complex series of events orchestrated by several cell 
types and multiple signalling pathways (Barrientos et al., 2008, Shaw and Martin, 
2009). Delays in or impairments to this process can lead to chronic wound 
development which pose a significant problem to patients and healthcare systems 
worldwide as they are difficult to manage and treat (Clark, 2002). Since nWASP 
has been implicated in the control of a variety of cell behaviours, in particular cell 
motility, the question of whether nWASP activity could be important in the 
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control of cell behaviour during the complex process of wound healing has been 
considered in this study.  
Studies of the expression and role of nWASP in the skin are limited but, despite 
this, nWASP has been shown to have a role in this skin as a regulator of hair-
follicle cycling (Lefever et al., 2010). However, the role of nWASP in skin cell 
behaviour and wound healing remains largely unexplored. Therefore, this chapter 
examines the expression profile of nWASP in skin cells and wound tissues in order 
to evaluate the potential role of nWASP in skin cells and the wound healing 
process. Furthermore, an in vitro cell model is established which will be used in 
subsequent chapters to further explore the effect of nWASP on the functions of 
skin cell models. 
3.2. Materials and Methods 
3.2.1. Wound tissue collection and processing 
Cohort 1 and 2 consist of 69 and 109 chronic venous leg ulcer wound edge 
biopsies respectively. Samples were collected on the basis that no evidence of 
infection was found and that the ulcers had been present for at least 3 months. 
Patients were treated for 12 weeks with standard treatments. Wounds were 
assessed at the end of the 12-week period and classified as ‘healing’ (n=20/77, 
cohort 1/2 respectively) if a decrease in size or complete wound closure was seen. 
Biopsies from wounds that had shown an increase or no change in size were 
termed ‘non-healing’ (n=49/32, cohort 1/2 respectively).  
Collection, storage and processing of tissue samples in both cohort 1 and 2 were 
done using the same methodology. Samples were collected from the wound edge 
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using a 6mm hole punch biopsy method under local anaesthetic. Biopsies were 
stored at -80°C prior to being sectioned on a cryostat (Leica, Microsystems Ltd., 
Milton Keynes, UK) at 20µm thickness. 60 sections from the same patient sample 
biopsy were pooled and homogenised in ice cold TRI reagent in preparation for 
RNA extraction. 
3.2.2. Antibody and primers 
Polyclonal rabbit anti-nWASP antibody (NBP1-82512) was obtained from Novus 
Biologicals (Abingdon, UK). Polyclonal mouse anti-GAPDH antibody (sc-32233) was 
obtained from Santa Cruz Biotechnology (Santa Cruz, California, USA). All 
antibodies used in this study are listed in Tables 2.5 and 2.6. Primers used for PCR 
were synthesised by Invitrogen (Paisley, UK). Primer sequences are shown in 
Tables 2.3 and 2.4. 
3.2.3. Cell lines and culture conditions 
HaCaT, HECV and TE-354-T cells were routinely cultured in DMEM as described in 
section 2.4 
3.2.4. Knockdown of nWASP using siRNA 
HaCaT cells were seeded in a 24-well plate in serum-free DMEM (no antibiotics) at 
1.5 x 105 cells/well. After 24 hours, cells were transfected with 0.5 or 1µg/ml 
(0.17µg or 0.34µg per well) nWASP siRNA (sc36006; Santa Cruz Biotechnology Inc., 
USA), or non-targeting siRNA (NT) at the same concentration, delivered in 
antibiotic free DMEM supplemented with 5% FBS with 1µl Lipofectamine 3000 
reagent (ThermoFisher Scientific, MA, USA) per well. After a further 24 hours, cells 
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were then used for RNA/protein extraction or functional assays using normal 
culture medium for further culturing where necessary. 
3.2.5. Genomic DNA extraction, RNA isolation and cDNA 
synthesis 
GDNA and RNA isolation from tissue samples and cell lines was carried out using 
Tri reagent (Sigma-Aldrich, Dorset, UK) according to the manufacturer’s 
instructions. The final RNA or gDNA samples were quantified using a 
spectrophotometer (WPA UV 1101, Biotech, Cambridge, UK) and then 
standardised. Reverse transcription of RNA was carried out to produce cDNA 
using GoScript™ Reverse Transcription kit (Promega, Madison, USA) for RNA 
extracted from cell lines and using a Bio-Rad RT Kit (Bio-Rad, Hemel Hempstead, 
UK) for patient tissue samples. 
3.2.6. PCR and Gel Electrophoresis  
CDNA or gDNA was used in PCR using the following cycling conditions: 94°C for 5 
minutes, then 34 cycles (unless stated otherwise) of 94°C for 30s, 55°C for 40s, 
72°C for 60s with a final extension of 10 minutes at 72°C. The products were run 
on a 2% agarose gel and visualised using SYBR safe. 
3.2.7. QPCR 
This study adopted Amplifluor quantitation technology in which one set of gene 
specific primers (designed using Primer blast) and Uniprimer probes (Intergen Inc., 
New York, USA) were used, in combination with a qPCR master mix. The reaction 
was carried out using the ICycleIQ (Bio-Rad). Real-time qPCR conditions were 95°C 
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for 15 minutes, followed by 60 cycles of 95°C for 20 s, 55°C for 30 s and 72°C for 
20 s. In all the assays, GAPDH or actin was also amplified and used as the house 
keeping control gene. An internal standard was also employed, for quantitation 
purposes, in qPCR analysis of the wound tissues. Primers are detailed in Table 2.4. 
3.2.8. Protein extraction, SDS-PAGE and Western blot analysis 
Briefly, lysis buffer was used to extract protein from pre-confluent HaCaT and 
HECV cells which was then used for SDS-PAGE. Proteins were transferred onto 
Immobilon® PVDF membranes (Merck Millipore, Watford, UK) which were 
blocked and probed with anti-nWASP (1:200) and anti-GAPDH (1:1000) antibodies 
and then incubated with the corresponding peroxidase conjugated secondary 
antibodies (1:1000). Proteins were visualised using EZ-ECL Kit (Biological 
Industries, Israel). Details of antibodies used in this study are detailed in Tables 
2.4 and 2.5. 
3.2.9. Immunofluorescence staining 
Pre-confluent HaCaT and HECV cells were fixed using 100% ethanol and 
immunofluorescence staining of nWASP was carried out using anti-nWASP 
primary antibody (1:100) followed by Alexa-594 secondary antibody (1:500). Cells 
were also stained with DAPI. Images captured using an Olympus BX51 microscope 
with a Hamamatsu Orca ER digital camera at x 40 zoom. 
3.2.10. Statistical analysis 
Analysis of qPCR results using patient samples was carried out using a Mann-
Whitney U test where the median and interquartile range for the transcript 
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expression normalised to housekeeping gene expression are presented. T-tests 
are used to analyse other results. A p-value of <0.05 is considered statistically 
significant. 
3.3. Results 
3.3.1. nWASP expression in human chronic wound tissues 
QPCR analysis of human chronic wound tissues demonstrated that nWASP 
transcript expression is significantly increased non-healing chronic wounds 
compared with wounds which reduced in size or healing in the 12 weeks following 
biopsy collection. In cohort 1, nWASP expression normalised with actin in 
healing/healed wounds (n=20) is lower than in non-healing wounds (n=49) with 
p=0.0028, Figure 3.1A. Likewise, cohort 2 shows a similar trend where nWASP 
transcript levels are significantly lower (p=0.0001) in healing chronic wounds 
(n=77) than in non-healing wounds (n=32), Figure 3.1B. 
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Figure 3.1: nWASP transcript expression in healing/non-healing chronic wounds. 
qPCR analysis of wound tissues from cohort 1 (A) and cohort 2 (B) shows that 
nWASP transcript expression is significantly higher in non-healing chronic wounds 
(p=0.0028 and p=0.0001 respectively) than in wounds that reduced in size or 
healed over a 12-week period following biopsy collection. Shown are median and 
the interquartile range of the transcript level. 
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3.3.2. Characterisation of HaCaT and HECV cell types 
HaCaT and HECV cell lines were selected as models of human keratinocytes and 
vascular endothelial cells for use in further experiments throughout this study. To 
confirm the identity of these cells, validation experiments were carried out using 
genomic DNA and through examination the expression of particular genetic 
markers in HaCaT and HECV cell lines. 
An STR profile is available for HaCaT cells on the Cell Line Data Base (Romano et 
al., 2009) and so PCR using STR profiling primers allowed validation by comparison 
to the known DNA fingerprint. The results of this PCR, Figure 3.2, demonstrate the 
pattern of expression that is expected for this cell type. The full details of the STR 
profile for the HaCaT cell line can be found in Table 2.2. 
Validation of HECV cells was also desirable but a known STR profile could not be 
found in the literature. As a result, confirmation that these cells were of 
endothelial origin was carried out by examining expression of VE Cadherin. 
Through RT-PCR, VE-Cadherin was found to be expressed at transcript level in 
these cells, Figure 3.3, hence confirming their endothelial origin. 
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Figure 3.2: STR profiling of HaCaT cell lines. PCR using primers for specific sites to 
examine the STR profile of the HaCaT cell line. 
 
Figure 3.3: Endothelial origin of HECV cell line. The expression of VE cadherin 
transcript in HECV cells. 
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Following the validation of the HaCaT and HECV cell lines, further experimentation 
could be carried out with confidence that the intended cell lines will have been 
used. 
3.3.3. nWASP is expressed in cell types pertaining to the skin 
nWASP transcript expression was examined in three human cell lines, 
representative of typical skin cells, HaCaT keratinocyte cells, HECV vascular 
endothelial cells and TE-354-T fibroblasts. Figure 3.4 demonstrates that nWASP 
transcript is consistently expressed in all cell lines examined. In addition, nWASP is 
expressed at a protein level in both HECV and HaCaT cells as shown through 
Western Blot analysis in figure 3.5. nWASP protein expression is also shown in 
HaCaT and HECV cells through immunofluorescence staining, shown in Figure 3.6. 
Arrows in Figure 3.6 indicate areas of nWASP expression in the cytoplasm in 
HaCaT and HECV cells and also at areas on the cell peripheries in HaCaT cells in 
particular. These results collectively show nWASP expression at both a transcript 
and protein level in cell types pertaining to the skin. 
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Figure 3.4: Screening cell lines for nWASP mRNA expression. Keratinocyte 
(HaCaT), vascular endothelial (HECV) and fibroblast (TE 354 T) cell lines were 
screened for mRNA expression of nWASP using conventional PCR. 
 
 
 
 
Figure 3.5: Screening cell lines for nWASP protein expression. Keratinocyte 
(HaCaT) and vascular endothelial (HECV) cell line protein extracts were screened 
for nWASP expression using SDS-PAGE and Western blot. 
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Figure 3.6: Immunofluorescence staining for nWASP in keratinocyte and 
endothelial cell lines. Keratinocyte (HaCaT) and endothelial (HECV) cell lines were 
screened for nWASP protein expression (red) using immunofluorescence staining. 
DAPI (blue) used to stain nuclei. Scale bar represents 200µm. 
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3.3.4. Knockdown of nWASP in HaCaT cells 
Using nWASP siRNA at two different concentrations (0.5 and 1µg/ml), nWASP 
expression was successfully knocked down in HaCaT cells at both RNA transcript 
and protein levels from 24 hours following treatment when compared with cells 
treated with the non-targeting control siRNA (NT). QPCR showed significant 
knockdown of nWASP transcript expression at both levels of siRNA treatment (p < 
0.0001 in both cases) with 1µg/ml treatment causing a greater reduction in 
nWASP transcript expression than with the lower level of treatment at 0.5µg/ml, 
as expected, Figure 3.7A. PCR and western blot analysis also show successful 
knockdown at 24 hours following siRNA treatment, Figure 3.7B, C respectively. 
nWASP protein knockdown was measured and found to be present at timepoints 
up to 96 hours following 1µg/ml siRNA treatment enabling these knockdown cells 
to be used for the duration of ECIS wounding assays (see figure 4.4).  
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Figure 3.7: nWASP knockdown in HaCaT cells. HaCaT cells were treated with 
nWASP siRNA/non-targeting siRNA (NT) at 0.5 and 1µg/ml and then analysed for 
nWASP expression after 24 hours. QPCR analysis of nWASP transcript expression 
demonstrates a significant decrease in nWASP expression in siRNA treated cells at 
both levels of treatment, n=4 replicates (A). PCR also demonstrates a decrease in 
nWASP expression following siRNA treatment (B). Representative Western blot 
demonstrating knockdown of nWASP at protein level in siRNA treated cells at 24 
hours (C). 
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3.4. Discussion 
This study has initiated a field of study focussing on nWASP in the context of 
human skin, chronic wounds and wound healing. nWASP activity has previously 
been implicated in the control of a variety of cell behaviours which are important 
for the wound healing process, such as cellular motility, and hence has been 
studied to explore its role in cancer which shares these functional traits. This 
raises the question of whether nWASP activity could have comparable roles in the 
skin and cells involved in the wound healing process, a context in which nWASP 
activity has not previously been extensively studied. This chapter therefore hoped 
to begin to explore the role of nWASP in the context of the skin, and wound 
healing, with particular focus on examining its expression in chronic wounds. 
From RT-PCR, immunofluorescence and Western blot analysis, it has been shown 
that nWASP is expressed at a transcript and protein level in various cell types 
pertaining to the skin including keratinocytes, vascular endothelial cells and 
fibroblasts. These cell lines were selected as models of cells-types involved in the 
proliferation and reepithelialisation stage of wound healing which is the stage 
which does not advance as expected in the context of chronic wounds. Knowing 
that nWASP is expressed in several skin cell models, this chapter then examined 
the expression of nWASP in human wound tissues in order to gain an insight into 
its potential function in human wound healing. QPCR screening of patient chronic 
wound tissues from two cohorts demonstrated that nWASP was significantly 
elevated in wound tissues which did not go on to heal or reduce in size in the 
following 12-week period from sample collection. This finding was significant in 
both cohorts and suggests that high levels of nWASP expression may be indicative 
of how likely a chronic wound is to exhibit healing behaviour. This also highlights 
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nWASP as a potential therapeutic target in order to encourage healing in difficult 
chronic wounds. 
Chronic wounds and the issues associated with them have highlighted a need to 
identify molecules that could be used as a therapeutic target to encourage wound 
healing. Here, nWASP has been identified as a marker which is indicative of 
wound prognosis and as a molecule which could even be responsible for the 
prolonged non-healing behaviour of chronic wounds. This study therefore 
proposes that targeting nWASP through inhibitors in a clinical setting may provide 
a means to encourage healing behaviour in chronic wounds.  
This study is focussed towards elucidating the role of nWASP in cell types involved 
in the proliferation and reepithelialisation stage of wound healing because of the 
impairment to this stage in chronic wounds and due to the expertise available in 
the host laboratory. However, it is noteworthy that the study of nWASP 
expression in the two clinical cohorts described here was entirely based on gene 
transcript analyses. Although protein analysis of nWASP in the wound tissue 
samples was desirable, due to unavailability of suitable antibodies and a lack of 
abundance in tissues samples available for further staining, this was not possible 
during this study. Protein analysis of nWASP expression in chronic wound tissues 
is desirable for the improvement of this investigation in the future but in its 
absence, the contribution of the different cell types within the wound towards the 
overall change in nWASP expression between healing and non-healing chronic 
wounds is exhibited is unclear. nWASP is ubiquitously expressed throughout the 
body and as such numerous studies using several cell types have highlighted a role 
for nWASP in many contexts including hair follicle cycling (Lefever et al., 2010), 
macrophage chemotaxis and membrane extension (Isaac et al., 2010) and 
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fibroblast adhesion and spreading (Misra et al., 2007). In particular, a recent study 
has shown that nWASP knockdown in fibroblasts in vivo enhanced wound closure 
and mice exhibited keratinocyte hyperproliferation (Jain et al., 2016).  These 
studies highlight that nWASP may have a critical role in the function of many 
individual cell types in the wound healing process and that interplay between 
these cell types as a direct response of altered nWASP activity may also affect 
wound healing, as has been shown by Jain et al. This study aims to improve the 
understanding of the role of nWASP with a focus towards keratinocyte and 
vascular endothelial cells but realises that understanding how global nWASP 
expression levels in the wound site may contribute to chronic wound healing is a 
difficult task without examining nWASP activity and the resulting effects in all the 
cell types present in a chronic wound. 
In order to further evaluate nWASP as a potential therapeutic target in chronic, 
non-healing human wounds, a novel nWASP knockdown cell line was produced, 
based on the HaCaT keratinocyte cell line, using siRNA treatment. The siRNA 
reagent used in this assay contains a pool of 3 target-specific siRNAs (sc36006A, B 
and C). Future work to examine the effects of each individually applied siRNA 
should be carried out owing to the known possibility of observing off-target 
effects using pooled siRNAs (Mooren et al., 2015). However, due to time 
constraints this was not possible as part of this study. The novel cell line produced 
using the pooled siRNA exhibited reduced nWASP transcript expression and is 
used in subsequent chapters, along with nWASP inhibitors, to examine the role of 
nWASP on HaCaT cell behaviour. 
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4.1. Introduction 
Wound healing is an extremely complex process consisting of several overlapping 
phases including inflammation, haemostasis, proliferation and remodelling 
(Velnar et al., 2009, Bryant and Nix, 2012). During this cascade of events several 
cell types, including fibroblasts, keratinocytes, endothelial cells and immune 
response cells, must undergo changes to their function, behaviour and 
morphology in order for the wound healing response to take place timely and 
effectively. Furthermore, the coordination of a variety of signalling pathways is 
critical in the control of these cell behaviours during the wound healing process. 
Several key pathways and signalling molecules that are involved in human wound 
healing have been previously recognised, such as the PDGF and VEGF receptor 
signalling pathways which have been extensively studied. However, nWASP has 
not previously been considered in the context of human wound healing. As shown 
in Chapter 3, this study has identified that nWASP may have a role in the human 
wound healing process and in prolonged poor healing of chronic wounds. The 
current chapter therefore hopes to explore the role of nWASP in the control of 
cell behaviour in HaCaT keratinocyte cell models and also in HECV vascular 
endothelial cells. An nWASP knockdown cell model based on the HaCaT 
keratinocyte cell line has been generated using siRNA as described in Chapter 3 
and will be used to examine the role of nWASP on cellular functions. In addition, 
the use of nWASP inhibitors, 187-1 and wiskostatin, was employed to further 
examine the effect of altered nWASP activity on cell function. This section of the 
study will be particularly important given that nWASP has been identified as a 
potential therapeutic target in human chronic wounds and will help to evaluate 
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not only the role of nWASP in cell behaviours but also the potential use of nWASP 
inhibitors as a therapy to encourage healing. 
4.2. Materials and Methods 
4.2.1. Cell lines 
HaCaT keratinocyte and HECV vascular endothelial cell lines were used in this 
study. Cells were continuously maintained in DMEM supplemented with 10% FBS 
and antibiotics as described in section 2.4. HaCaT nWASP knockdown cells, 
generated using siRNA as described in chapter 3, were also used in this study. 
Normal culture medium and conditions were used for these nWASP knockdown 
cells as with wild-type cell lines. 
4.2.2. Reagents and treatments 
nWASP inhibitors, wiskostatin (Enzo Life Sciences, NY, USA) and 187-1 (TOCRIS, 
Bristol, UK) were used in this study. Wiskostatin was dissolved in DMSO and then 
diluted in normal cell culture medium to a stock concentration of 300µM in 30% 
DMSO. 187-1 was diluted in PBS to a sock concentration of 500µM. Inhibitors 
were diluted to the desired concentrations using normal culture medium for 
experiments. Control reactions received appropriate DMSO treatments equivalent 
to the level of DMSO in the wiskostatin treatments. Likewise, where 187-1 was 
used, PBS vehicle controls were used. 
4.2.3. In vitro cell viability test 
Cells were seeded at a seeding density of 1,500 cells per well in a 96-well plate. 
After adhering to the plate overnight, cells were treated with nWASP inhibitors, or 
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vehicle controls, at a range of concentrations and cultured under normal culture 
conditions for 92hours (where HaCaT cells were used) or 44 hours for experiments 
using HECV cells. After a further 4hour incubation in 1:10 MTT solution (5mg/ml in 
PBS), acidified isopropanol was applied and optical density (OD) was determined 
using an absorbance reader (Biotek ELx800) at 540nm and used to calculate 
relative cell viability at each treatment concentration. A sigmoidal dose response 
curve was used to calculate the IC50 where appropriate.  
4.2.4. In vitro cell growth assay 
Cells were seeded into a 96-well plate in 100µl volumes with 3 x 104 cells per well 
containing 100µl of appropriate treatments. 5 replicate wells per treatment were 
used. Cells were incubated under normal culture conditions and fixed after 1/2/4-
day incubation periods. Absorbance following crystal violet staining was used to 
analyse growth. 
4.2.5. In vitro cell adhesion assay 
Wells were pre-coated with Matrigel basement membrane matrix (BD 
Biosciences) at 50μg/ml in serum-free medium. The Matrigel was then rehydrated 
using serum-free medium and 8 x 105 cells per well were seeded onto the Matrigel 
membrane in treatments and incubated for 25 minutes. Adherent cells were 
fixed, stained and quantified as described in section 2.7.1. 
4.2.6. In vitro cell motility assay 
Cells in solution were incubated at a density of 7 x 105 cells/ml in normal culture 
medium, containing 100μl of cytodex-2 beads (Sigma-Aldrich at 20mg/ml in BSS), 
for 4 hours with occasional agitation to allow the cells to adhere to the beads. 
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Following washes, 100μl of the cell-bead suspension was added to a 96-well plate 
and incubated for 18 hours in treatments with 6 replicates per treatment. The 
medium and beads were discarded and cells which had migrated from the beads 
to the plate were fixed, stained and counted according to absorbance. 
4.2.7. In vitro scratch migration assay 
Cells were seeded into a 24-well plate with 7 x 105 cells seeded per well. Upon 
reaching confluence the monolayer was scratched to create a linear wound and 
treatments or appropriate vehicle controls were added to the plate. The plate was 
placed in an EVOS® FL Auto Imaging System (Life Technologies, Paisley, UK) and 
images were captured of the wound every 30 minutes for up to 24 hours.  
4.2.8. ECIS 
In this study, Z-theta ECIS instruments (Applied Biophysics Inc., NJ, USA) were 
used to electrically monitor coverage of gold electrodes on the base of 96W1E+ 
arrays by measuring the resistance and capacitance at range of frequencies 
between 1-64kHz. ECIS assays enable the electrical sensing of cells through 
measurement of the components of impedance, namely resistance and 
capacitance, over a range of different frequencies. Measuring these different 
elements over time can allow the interpretation of several different behaviours of 
the cells. As described by Wegner et al. (Wegener et al., 2000), measuring the 
capacitive portion of the impedance at high frequencies (i.e. 32,000Hz and 
above), essentially reports only the fraction of the electrode covered with cells. As 
such, analysis at this level can allow interpretation of the attachment and spread 
of cells on the electrode but does not consider more subtle changes to cell 
behaviour such at the barrier function and level of adhesion to the electrode and 
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between the cells. Measuring the resistance at intermediate ECIS frequencies 
depends not only on the coverage of cells on the electrode but also the spaces 
between the electrode and the basal cell membrane and so accounts partially for 
the attachment properties of the cells. For functional assays, resistance at 4kHz 
and capacitance at 32kHz were used to analyse cell behaviour. These frequencies 
were selected for both HaCaT and HECV cell lines following frequency selection 
analysis. 4 x 105 cells/well were seeded in normal culture medium containing 
treatments or vehicle controls. At least 3 replicates per treatment/control were 
used. Wound settings were 30 seconds, current of 2400μA and frequency of 
60,000Hz and wounding was initiated after 20 hours unless otherwise stated. The 
resistance/capacitance data was normalised to the first time point after seeding 
or wounding through division, or subtraction where stated, and analysed for 
statistical significance between the groups using 2-way ANOVA analysis using 
GraphPad Prism. For experiments using wiskostatin the statistical data has been 
included on graphs whereas separate tables or graphs have been presented 
alongside data from experiments using 187-1 to avoid confusion. 
4.2.9. In vitro cell spreading assay 
Cells were seeded at 1 x 104 cells/well in a 24-well plate in treatments/vehicle 
controls in normal culture medium and placed in an EVOS® FL Auto Imaging 
System (Life Technologies, Paisley, UK). After approximately 6 hours, cells were 
imaged at 4 randomly selected fields of view at x20 zoom. The perimeter of 
randomly selected individual cells (10 per treatment/control) was calculated using 
ImageJ and analysed using GraphPad Prism software. 
147 
 
4.2.10. In vitro microtubule formation assay 
Matrigel (10mg/ml) was slowly defrosted and 40µl was pipetted into wells on a 
96-well plate, carefully so as to avoid bubbles. Matrigel was allowed to polymerise 
at 37°C for approximately 30-45 minutes whilst cells were prepared. Cells were 
seeded in 10µM wiskostatin (or DMSO control) in normal culture medium in 200µl 
volumes on top of the polymerised Matrigel at 4 x 104 cells/ml seeding density. 
The plate was maintained under normal culture conditions for up to 1170 minutes 
with images at x5 magnification in the centre of each well taken at several 
intervals up to this point. Images were analysed using ImageJ to measure the 
length of structures which form part of microtubules as they form. Data was 
normalised over 3 independent repeats. 
4.2.11. Statistical Analysis 
Statistical analysis was carried out using GraphPad Prism software using t-tests or 
2-way ANOVA where appropriate. Each experiment was performed at least three 
times and data is generally presented as the mean of repeats normalised to the 
control, unless stated otherwise. Results from ECIS assays are presented as 
representative data and any trends and findings are reported if found to be 
statistically significant over three independent repeats. Error bars show standard 
deviation. A p-value of <0.05 is considered statistically significant. 
4.3. Results 
4.3.1. The role of nWASP in HaCaT cell behaviour 
In order to examine the effect of nWASP inhibitor treatment and knockdown on 
HaCaT cell function, a series of functional assays were carried out. Initially ECIS 
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assays were used to determine the effect of a range of inhibitor concentrations 
and nWASP knockdown because this assay is able to detect changes in numerous 
cell functions including attachment, adhesion, spreading and migration. MTT 
assays to determine the effect of the inhibitor treatments on growth were also 
carried out. Inhibitor concentrations were selected based on the outcome from 
these experiments and further functional assays to examine what effect on more 
specific cell behaviours, including adhesion, migration and motility, were carried 
out. 
4.3.1.1. The effect of nWASP inhibition and knockdown on 
HaCaT cell attachment and spreading according to ECIS 
To begin to examine the role of nWASP in the behaviour of keratinocytes, a series 
of ECIS assays were carried out using nWASP inhibitor treatments and also using 
nWASP knockdown HaCaT cells. ECIS allows various aspects of cell functionality to 
be examined in real-time as described in section 4.2.8 and so is a useful tool 
through which the effect of nWASP inhibitors and knockdown on cell behaviour 
can begin to be explored. In order to determine the most appropriate frequencies 
at which to measure the resistance and capacitance for this study, initial 
frequency scanning was carried out as follows. 
4.3.1.1.1. Frequency selection for ECIS assays 
Initial ECIS experiments were carried out to analyse the resistance and 
capacitance over a range of frequencies, from 1 to 64kHz, following the seeding of 
HaCaT wild type cells to identify the most relevant and sensitive frequencies. 4 x 
105 cells were seeded in solution in each well of a 96W1E+ ECIS array and 
monitored over a 20-hour period whilst a confluent monolayer formed over the 
149 
 
electrodes. The attachment of cells to the electrode can be interpreted as an 
increase in the resistance or as a decrease in the capacitance to the point where 
these measurements reach a plateau. The measurements of the resistance (Figure 
4.1A) at high frequencies (at >32kHz) is not as sensitive to the increase in 
resistance as the cells adhere to the electrode as intermediate and low 
frequencies. Low frequencies (of <2kHz) show high initial measurements which 
persist throughout the experiment due to the high resistance of the 
electrode/electrolyte interface which is being detected at these frequencies. As 
such for the most sensitive reading which reflects the attachment and formation 
of a stable monolayer most effectively, resistance at a frequency of 4kHz will be 
used in further experiments. This will allow analysis of both the coverage of cells 
on the electrode itself but also the more subtle changes in cell-cell and cell-
electrode contacts (Wegener et al., 2000). Similarly, capacitance was analysed at a 
range of frequencies between 1 and 64kHz as HaCaT cells adhered to the base of 
an ECIS array, Figure 4.1B. At low frequencies (<4kHz) the capacitance is fairly 
invariable throughout the entire 20-hour period. At higher frequencies, the 
measurements are increasingly more sensitive to the changes at the electrode 
surface as cells attach and spread. Capacitance at these high frequencies are less 
affected by the formation of intercellular junctions than resistance and are more 
representative of cell coverage. Based on this analysis measurements at the 
frequency 32kHz or more will be used for ECIS analysis of the capacitance. 
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Figure 4.1: Frequency scanning for ECIS. Three-dimensional representation of the 
changes in resistance (A) and capacitance (B) as a function of frequency and time 
during the attachment and spreading of HaCaT wild-type cells. Cells were seeded 
at 4 x 104 cells/well onto a 96W1E+ ECIS array were monitored over a variety of 
frequencies for 20 hours. 
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4.3.1.1.2. ECIS analysis following wiskostatin treatment 
A series of ECIS assays were carried out to analyse the effect of the nWASP 
inhibitor wiskostatin on HaCaT cell attachment and spreading behaviour following 
seeding. A range of inhibitor levels were tested from 0.01µM to 10µM levels, each 
with appropriate vehicle controls. At very low wiskostatin concentrations of 
0.01µM (Figure 4.2A), no significant difference between the resistance of the 
control and treated cells was observed indicating no difference in the attachment 
and spreading behaviour between the groups. At 0.1µM levels however, 
significantly higher resistances were consistently detected in wiskostatin treated 
cells compared with the controls at various time points following seeding (Figure 
4.2B). This suggests that wiskostatin treatment at 0.1µM levels may cause an 
increase in the attachment and spreading properties of HaCaT cells compared 
with the controls, especially since the observed difference occurs in the plateau 
section of the ECIS curve where the cell monolayer is assumed to be maturing. 
This increase in resistance in wiskostatin treated cells does not continue with 
increased inhibitor treatments (Figure 4.2C, D). In fact, at high levels of 
wiskostatin treatment of 10µM, the opposite effect is found with a significant 
decrease in the resistance following inhibitor treatment, n=2. This suggests that at 
this inhibitor level the formation of a cell monolayer is impaired perhaps due to 
an impairment on the attachment and spreading behaviour of the cells and/or 
proliferation due to the consistent difference in resistance from inoculation. 
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Figure 4.2: The effect of wiskostatin on HaCaT attachment and spreading 
measured using ECIS. HaCaT cells seeded at 4 x 105 cells per well in a 96W1E+ 
ECIS array were electrically monitored using the measurement of resistance at 
4kHz. Cells were treated with wiskostatin, or appropriate vehicle controls, at 0.01, 
0.1, 1 and 10µM concentrations (A-D respectively) and monitored for 15 hours 
following seeding. Significant differences in the resistance of the control and 
wiskostatin treated wells, analysed using 2-way ANOVA tests, and are 
demonstrated by * = p<0.05, etc. over the appropriate time point. Mean 
normalised resistance ±SD is plotted, at least n=3 replicates used, representative 
data shown. 
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4.3.1.1.3. ECIS analysis following 187-1 treatment 
ECIS analysis of HaCaT cells treated with a range of concentrations of 187-1 
demonstrated that the resistance at 4kHz was significantly increased in wells 
treated with the inhibitor between the concentrations 0.01-10µM 187-1 over 
several time points following seeding, Figure 4.3A. The increase in resistance was 
most consistently significantly increased in 10µM 187-1 treated wells overall 
repeats of the experiment. The increase in resistance compared with the control 
in the 15 hours following seeding is not found in wells treated with higher levels 
of 187-1 at 25µM, Figure 4.3B, n=1. Results from the statistical analysis of these 
experiments are presented in Table 4.1.  
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Figure 4.3: The effect of 187-1 treatment on HaCaT attachment and spreading 
measured using ECIS. HaCaT cells seeded at 4 x 105 cells per well in a 96W1E+ 
ECIS array were electrically monitored using the measurement of resistance at 
4kHz. Cells were treated with 187-1 at 0.01, 0.1, 1, 10 (A) and 25µM (B) 
concentrations and monitored for 15 hours following seeding. Significant 
differences in the resistance of the control and 187-1 treated wells were analysed 
using 2-way ANOVA tests. P-values from this analysis relating to these figures are 
shown in Table 4.1. Mean normalised resistance ±SD is plotted, at least n=3 
replicates per treatment used, representative data shown. 
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Table 4.1: P-values for ECIS analysis of 187-1 treated HaCaT cells. Statistical 
significance between the resistance (4kHz) of 187-1 treated wells and the controls 
were analysed using 2-way ANOVA. This table presents the resulting p-values 
from this analysis with bold values reaching statistical significance. 
187-1 (µM) p-value for control versus 187-1 at time following seeding (hours) 
3 6 9 12 15 
25 >0.9999 0.9567 0.8051 0.9195 0.8954 
10 0.0168 0.0006 0.0001 0.0001 0.0001 
1 0.0058 0.0001 0.0001 0.0001 0.0001 
0.1 0.3142 0.0901 0.0258 0.003 0.0018 
0.01 0.2079 0.0717 0.0327 0.0026 0.0018 
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4.3.1.1.4. ECIS analysis of nWASP knockdown HaCaT cells 
HaCaT cells treated with nWASP siRNA to produce transient knockdown of nWASP 
were seeded into a 96W1E+ ECIS array and the resistance (4kHz) and capacitance 
(64kHz) were measured, n=1. No significant difference in the resistance or 
capacitance in cells treated with the lower concentration of siRNA (0.5µg/ml) 
compared with the NT control cells was observed over the time points following 
seeding (Figure 4.4A, C respectively). A significant difference in the resistance and 
capacitance is found between the cells treated with 0.1µg/ml siRNA and the NT 
cells from the point where the measurements reach a plateau, at approximately 
30 hours from seeding, and the cells are assumed to have reached confluency 
(Figure 4.4B, D). This difference is particularly prevalent where the resistance at 
4kHz is measured. 
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Figure 4.4: ECIS analysis of nWASP knockdown HaCaT cells. HaCaT cells treated 
with nWASP siRNA (at 0.5, A and C, or 1µg/ml, B and D) or appropriate non-
targeting (NT) control siRNA were seeded at 4 x 105 cells per well 48 hours after 
treatment in a 96W1E+ ECIS array. Cells were electrically monitored using the 
measurement of resistance at 4kHz (A and B) and capacitance at 32kHz (C and D) 
for 45 hours following seeding. Significant differences in the resistance and 
capacitance of siRNA and NT treated wells were analysed using 2-way ANOVA 
tests with significant differences represented by * = p<0.05, etc. over the 
appropriate time points. Mean normalised resistance/capacitance ±SD is plotted, 
at least n=3 replicates per treatment used, n=1. 
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4.3.1.2. Inhibition of growth following nWASP inhibitor 
treatment 
In order to determine whether an effect on proliferation was responsible for the 
functional changes in response to nWASP inhibitor treatment that were observed 
in ECIS experiments and further functional assays described later in this chapter 
were, growth and MTT assays were carried out. The effect of both wiskostatin and 
187-1 nWASP inhibitors on the inhibition of growth of HaCaT cells was analysed 
using MTT assays. Cells were treated for 92 hours with wiskostatin concentrations 
ranging from 0-10µM and then analysed using a sigmoidal dose response curve to 
calculate the IC50. The proportion of viable cells after the treatment period was 
found to decrease sharply between 1 and 10µM wiskostatin treatment and the 
IC50 was calculated to be 1.949, Figure 4.5A. Similarly, HaCaT cells were treated 
with 187-1 at concentrations ranging from 0-15µM and the proportion of viable 
cells after 92 hours was calculated. No significant inhibition in growth was found 
following treatment with the full range of 187-1 tested and hence no IC50 value 
was calculated. 
159 
 
 
 
 
Figure 4.5: Inhibition of growth of HaCaT cells following nWASP inhibitor 
treatment. The proportion of viable cells following 92 hours of treatment with 
wiskostatin (at 0, 0.01, 0.1, 1, 10µM) and 187-1 (0, 1, 5, 10, 15µM) is shown (A and 
B respectively). The sigmoidal dose response curve plotted to calculate the IC50 at 
1.949 is also shown for wiskostatin treated cells (A). Mean proportion of viable 
cells ± SD from 3 independent repeats is plotted, n=3 replicates per treatment in 
each experiment. 
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4.3.1.3. The effect of nWASP inhibitors on growth 
nWASP inhibitor concentrations 0.1µM for wiskostatin and 10µM for 187-1 were 
selected for further investigation into the behaviour of HaCaT cells following the 
results from the ECIS analysis described previously. To further investigate the 
effect of these inhibitors on the growth of HaCaT cells, particularly at these 
selected concentrations, growth assays were carried out. This was to determine 
whether any of the functional changes observed previously or in further 
experiments could be attributed to changes in cell proliferation in response to the 
inhibitors. Over 4 days from seeding, no significant different in the control and 
inhibitor treated cells was detected at 0.1µM wiskostatin and 10µM 187-1, Figure 
4.6 A and B respectively. Sample images at x5 zoom of 187-1 treated and control 
cells over 1, 2 and 4 days following fixing and staining with crystal violet are also 
presented in Figure 4.6C. 
These data indicate that the effect of both wiskostatin and 187-1 on cell function 
described later in this chapter and in sections 4.3.1.1.2 and 4.3.1.1.3 is 
independent of the effect on cell growth. 
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Figure 4.6: The effect of nWASP inhibition on HaCaT growth. Cell number 
according to absorbance at 540nm is shown for HaCaT cells treated with 0.1µM 
wiskostatin (A) or 10µM 187-1 (B) over 4 days from seeding. No significant 
difference found following statistical analysis using t-tests. Average absorbance ± 
SD is presented, representative data shown, n=5 replicates in each independent 
repeat. Representative images of crystal violet stained cells treated with 10µM 
187-1 or control medium over 1, 2 and 4-day time points are shown (C). Images 
taken at x5 zoom. 
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4.3.1.4. The effect of nWASP inhibition on cell migration 
according to ECIS 
The healing of an electrical wound to a monolayer of HaCaT cells following nWASP 
inhibition was monitored using ECIS. To attempt to eliminate contributions from 
cell attachment and spreading behaviour in the measurements, cells were 
monitored and analysed using the capacitance at 32kHz. No consistent significant 
difference in the normalised capacitance, monitored at 32kHz, was observed 
between 0.1µM wiskostatin treated cells (Figure 4.7A), nor 10µM 187-1 treated 
cells (Figure 4.7B), compared with the controls cells. Although some time points in 
two of the independent repeats of this experiment demonstrated a slight 
significant decrease in the capacitance of the 187-1 treated cells compared with 
the control, these time points were once the capacitance values had reached a 
plateau and so weren’t considered to relate to cell migration. 
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Figure 4.7: The effect of nWASP inhibitor treatment on the healing of an 
electrical wound. HaCaT cells seeded at 4 x 105 cells per well in a 96W1E+ ECIS 
array were electrically monitored following an electrical wounding using the 
measurement of capacitance at 32kHz. Cells were treated with 0.1µM wiskostatin 
(A) or 10µM 187-1 (B), or appropriate vehicle controls and monitored for up to 21 
hours following seeding. Significant differences in the normalised capacitance of 
the control and treated wells were analysed using 2-way ANOVA tests. Mean 
normalised capacitance ± SD is plotted, at least n=3 replicate wells per treatment 
were used, representative data shown. 
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4.3.1.5. The effect of nWASP inhibition on scratch wound 
closure 
The effect of nWASP inhibitor treatments on the healing of a scratch wound in 
HaCaT cells was examined. The rate of wound closure (units/minute), measured 
as the decrease in wound width over time, of the cells as the scratch wound 
healed was consistently decreased in nWASP inhibitor treated cells over all 
repeats. This finding was not consistently significant in each individual experiment 
however. Where HaCaT cells were treated with 0.1µM wiskostatin, the rate of 
migration was again consistently reduced compared with the controls however 
this only reached significance in one independent repeat (of three). When results 
from the repeats were combined the rate of migration was found to be on 
average 90% of the control when treated with wiskostatin but this did not reach 
significance (p=0.0572), Figure 4.8A. In 187-1 treated cells, the rate of migration 
was significantly reduced in two independent repeats, out of a total of four. When 
results were analysed as a change from the control over these 4 repeats the rate 
of migration in cells treated with 10µM 187-1 was found to be significantly 
decreased (p=0.0234) at 85% of the control migration rate, Figure 4.8B. 
Representative images of the healing of the scratch wounds are shown in Figure 
4.8C. 
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Figure 4.8: nWASP inhibition and scratch wound closure. The effect of 
wiskostatin and 187-1 on the rate of wound closure of HaCaT cells during the 
closure of a scratch wound is shown as a change from the control over 3 and 4 
independent repeats for 0.1µM wiskostatin (A) and 10µM 187-1 (B) treated cells 
respectively. Normalised rate of wound closure + SD presented. Significance is 
calculated using t-test and represented by ** (p=0.0234) or ns (not significant, 
p=0.0572). Representative images of the scratch wound at 0 and 6 hours taken at 
x10 zoom in 0.1µM wiskostatin/10µM 187-1 treated wells (or the respective 
control wells) are also shown (C).  
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4.3.1.6. The effect of nWASP inhibition on motility 
Cells which actively migrate from cytodex-2 beads onto the surface of a plate, or 
the number of motile cells, was also examined. This complements the previous 
wound healing assays, where the rate of closure of a wound made to a confluent 
cell monolayer was calculated, as the movement of individual cells is being 
measured in this instance. No effect of nWASP inhibitor treatment on HaCaT cell 
motility according to cytodex-2 bead motility assays was detected. No significant 
effect on the number of cells which migrated from the cytodex-2 beads to the 
plate according to the absorbance at 540nm following treatment with 0.1µM 
wiskostatin nor 10µM 187-1 (Figure 4.9A and B respectively) was found in each of 
the three independent repeats of the experiment. 
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Figure 4.9: Motility of HaCaT cells in response to nWASP inhibition. The effect on 
the motility of HaCaT cells in cytodex-2 motility assays according to the 
absorbance at 540nm following 0.1µM wiskostatin (A) and 10µM 187-1 (B) 
treatments is shown. The change from the control is presented with mean + SD 
shown. Significance was analysed using t-tests and non-significant findings are 
labelled with ‘ns’. 
168 
 
4.3.1.7. The effect of nWASP inhibition on HaCaT adhesion and 
spreading 
The effect on the ability of HaCaT cells to initially adhere to a Matrigel matrix in 
response to nWASP inhibitor treatment was examined. No significant difference in 
the number of cells adhered to the matrix according to the absorbance after 25 
minutes was found following neither 0.1µM wiskostatin treatment nor 10µM 187-
1 treatment (Figure 4.10A and B respectively). A consistent decrease in the 
number of adhered cells following wiskostatin treatment was observed over all 4 
independent repeats of the experiment but the results of only one of these 
experiments was found to be significant. 
An alternative measure of cell adhesion through measuring the spread of HaCaT 
cells several hours after seeding in nWASP inhibitor treatments was also 
examined. The spread according to the perimeter of cells 6 hours after seeding 
was found to be significantly increased in cells treated with 0.1µM wiskostatin 
compared with the controls (p = 0.0137, Figure 4.10C) over all 3 independent 
repeats of the experiment. The cell perimeter was also found to be increased in 
cells treated with 10µM 187-1 compared with the controls but this increase was 
very small and although it reached significance when the mean of both repeats of 
the experiment was analysed (p = 0.0119, n=2) the individual experiments did not 
show a significant difference. 
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Figure 4.10: HaCaT cell adhesion and spread in response to nWASP inhibition. 
The effect of nWASP inhibitors wiskostatin at 0.1µM (A) and 187-1 at 10µM (B) on 
initial adhesion of cells to a Matrigel matrix over 25 minutes is shown. The effect 
of 0.1µM wiskostatin (C) and 10µM 187-1 (D) on the spread of HaCaT cells 6 hours 
after seeding is also shown. The change from the control is presented with mean 
+ SD shown. Significance was analysed using t-tests and is signified by ‘ns’ where 
no significance was found and * where p<0.05. 
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4.3.2. The effect of nWASP inhibition on HECV cell behaviour 
A similar approach was used to examine the effect of nWASP inhibition on HECV 
cells that was employed with the HaCaT cell model, beginning with examining the 
effect of nWASP inhibition according to ECIS. nWASP inhibitors wiskostatin and 
187-1 were applied to HECV cells during ECIS and the cell behaviour during 
spreading and attachment following seeding and then the migratory behaviour 
following and electrical wounding was monitored. A range of nWASP inhibitor 
concentrations were applied to assess the levels of treatment at which changes in 
cell behaviour could be detected. 
4.3.2.1. The effect of nWASP inhibition on HECV cell attachment 
and spreading according to ECIS 
The effect of wiskostatin and 187-1 treatments on the attachment and spreading 
properties of HECV cells following seeding were examined by monitoring the 
resistance at a frequency of 4kHz. The cells settled and formed a confluent 
monolayer after approximately 3-4 hours following seeding based on the time at 
which the resistance reaches a plateau (shown in Figures 4.11 and 4.12). No 
consistent significant effect on the change in resistance monitored at 4kHz was 
detected in HECV cells treated with wiskostatin levels at 0.01, 0.1 and 1µM levels 
compared with the controls, Figure 4.11A, B and C respectively. Although some 
slight significant changes were observed at certain time points throughout the 
experiments, these findings were not consistent over all repeats. 10µM 
wiskostatin treatments consistently significantly delayed the formation of a HECV 
monolayer as shown by the decrease in the resistance in 10µM wiskostatin 
treated cells, Figure 4.11D. 
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Figure 4.11: The effect of wiskostatin on HECV attachment and spreading 
measured using ECIS. HECV cells seeded at 4 x 105 cells per well in a 96W1E+ ECIS 
array were electrically monitored using the measurement of resistance at 4kHz. 
Cells were treated with wiskostatin, or appropriate vehicle controls, at 0.01, 0.1, 1 
and 10µM concentrations (A-D respectively) and monitored for 6 hours following 
seeding. Significant differences in the resistance of the control and wiskostatin 
treated wells, analysed using 2-way ANOVA tests, are demonstrated by * = 
p<0.05, etc. at the appropriate time points. Mean normalised resistance ± SD is 
plotted, data normalised by subtraction to initial time point, at least n=3 
replicates used, representative data shown. 
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The effect of 187-1 at concentrations of 0.01, 0.1, 1 and 10µM on the attachment 
and spreading behaviour of HECV cells was also observed using ECIS analysis of 
the resistance at 4kHz. 187-1 caused a significant reduction in the resistance of 
HECV cells compared with the control during the initial attachment and spreading 
phase following seeding as the resistance increases prior to reaching a plateau. 
This significant reduction in the resistance compared with the control was also 
found in HECV cells treated with higher levels of the inhibitor (1 and 10µM 187-1) 
in the time points following the resistance reaching a plateau. Throughout repeats 
of this assay, some small increases in the resistance were observed in HECV cells 
treated with low levels of 187-1 (0.1µM) at various time points throughout the 
experiments however these findings were not found to be consistently significant. 
Representative data is presented in Figure 4.12 and statistical information from 
the analysis of this experiment is presented in Table 4.2. 
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Figure 4.12: The effect of 187-1 on HECV attachment and spreading measured 
using ECIS. HECV cells seeded at 4 x 105 cells per well in a 96W1E+ ECIS array were 
electrically monitored using the measurement of resistance at 4kHz. Cells were 
treated with 187-1 at 0, 0.01, 0.1, 1 and 10µM concentrations and monitored for 
6 hours following seeding. Significant differences in the resistance of the control 
and 187-1 treated wells were analysed using 2-way ANOVA tests and the resulting 
p-values are shown in Table 4.2. Mean normalised resistance ± SD is plotted, data 
is normalised through subtraction to the initial time point, at least n=3 replicates 
per treatment used, representative data shown. 
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Table 4.2: P-values for ECIS analysis of 187-1 treated HECV cells. Statistical 
significance between the resistance (4kHz) of 187-1 treated wells and the controls 
were analysed using 2-way ANOVA. This table presents the resulting p-values 
from the analysis of the data presented in Figure 4.12 with bold values reaching 
statistical significance. 
187-1 (µM) p-value for control versus 187-1 at time following seeding (hours) 
1 2 3 4 5 6 
10 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 
1 0.0001 0.0001 0.0001 0.0003 0.0090 0.0919 
0.1 0.0004 0.0047 0.145 0.2533 0.7958 0.9639 
0.01 0.9946 0.5251 0.0844 0.2284 0.3052 0.9956 
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4.3.2.2. The effect of nWASP inhibition on the healing of an 
electrical wound in HECV cells 
HECV cells which had been cultured in a 96W1E+ ECIS array until the formation of 
a stable monolayer were electrically wounded. The decrease in capacitance as 
healthy cells migrate over the electrode to reform the cell monolayer was 
monitored at 32kHz. A stable monolayer is reformed and the electrical wound is 
assumed to be fully healing when the capacitance reaches a plateau and occurs 
after approximately 4 hours under these experimental conditions when using 
HECV cells as shown in Figures 4.13 and 4.14.  
The effect of wiskostatin at 0.01, 0.1, 1 and 10µM concentrations on the healing 
of an electrical wound was observed in HECV cells. Low levels of the inhibitor, i.e. 
0.01-1µM concentrations, did not seem to have a significant effect on the healing 
of the electrical wound with no significant differences between the capacitance of 
the 0.01, 0.1 nor 1µM wiskostatin treated cells and the appropriate controls 
detected, Figure 4.13A, B and C respectively. At 10µM levels of wiskostatin 
treatment however the capacitance is consistently significantly increased at 
several time points following the electrical wounding compared with the controls 
suggesting, Figure 4.13D, suggesting a delay in the healing of the electrical wound 
inhibitor treated cells at this level. 
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Figure 4.13: The effect of wiskostatin on the healing of HECV cells following an 
electrical wounding. HECV cells seeded at 4 x 105 cells per well in a 96W1E+ ECIS 
array were electrically monitored using the measurement of capacitance at 32kHz 
following an electrical wounding. Cells were treated with wiskostatin, or 
appropriate vehicle controls, at 0.01, 0.1, 1 and 10µM concentrations (A-D 
respectively) and monitored for 6 hours following wounding event. Significant 
differences in the resistance of the control and wiskostatin treated wells, analysed 
using 2-way ANOVA tests, are demonstrated by * = p<0.05, etc. at the appropriate 
time points. Mean normalised resistance ±SD is plotted, data normalised by 
subtraction to initial time point after wounding, at least n=3 replicates used, 
representative data shown. 
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ECIS analysis of HECV cells after an electrical wounding following 187-1 treatment 
demonstrated contrasting results. 187-1 treatment at 0.1, 1 and 10µM 
concentrations caused the capacitance at 32kHz to consistently decrease when 
compared with the cells not treated with the inhibitor in the time periods before 
the capacitance reaches a plateau, i.e. whilst the healing of the wound is taking 
place, Figure 4.14. 
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Figure 4.14: The effect of 187-1 on the healing of HECV cells following an 
electrical wounding. HECV cells seeded at 4 x 105 cells per well in a 96W1E+ ECIS 
array were electrically monitored using the measurement of capacitance at 32kHz 
following an electrical wounding. Cells were treated 187-1 at 0, 0.1, 1 and 10µM 
concentrations and monitored for 6 hours following an electrical wounding event 
(A). Mean normalised resistance ±SD is plotted, data normalised by subtraction to 
initial time point after wounding, at least n=3 replicates used, representative data 
shown. The mean change in capacity in the 187-1 treated wells from the control 
over three independent repeats of the experiment during time points 1, 2 and 3 
hours following the wounding (whilst the wound is healing) are also shown (B). 
Significant differences in the capacitance of the control and 187-1 treated wells 
were analysed using 2-way ANOVA tests and are represented by * = p<0.05, etc.  
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4.3.2.3. Inhibition of growth in HECV cells following nWASP 
inhibitor treatment 
To ascertain whether the effects observed in other functional assays using HECV 
cells attributed to nWASP inhibitor treatment was a result in growth or other 
functional changes, the effect of nWASP inhibitors on the inhibition of growth of 
HECV cells over a 48-hour period was examined. A change in the proportion of 
viable cells was observed at some levels of inhibitors but the inhibitors did not 
appear to have a large effect on the inhibition of growth of HECV cells as no 
decrease in inhibition of more than 12% was observed even at high inhibitor 
concentrations, Figure 4.15. As such a sigmoidal dose response curve was not 
produced and an IC50 value was not calculated. 
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Figure 4.15: Inhibition of growth of HECV cells following nWASP inhibitor 
treatment. The proportion of viable cells following 48 hours of treatment with 
wiskostatin and 187-1 (at 0, 1, 5, 10, 15µM) is shown (A and B respectively). Mean 
proportion of viable cells ± SD from 3 independent repeats is plotted, n=3 
replicates per treatment in each experiment. 
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4.3.2.4. The effect of wiskostatin on the angiogenic behaviour 
of HECV cells 
Tubule formation assays were used to examine the effect of 10µM wiskostatin 
treatments on the angiogenic behaviour of HECV cells. The length of cell 
structures which form part of microtubules was measured following seeding and 
the mean total length for each image was calculated, representative data is 
shown in Figure 4.16A. Wiskostatin treatment significantly inhibited the formation 
of tubule structures immediately following seeding but did not prevent the 
formation of tubule structures which typically developed after about 8h 30 
minutes both with and without wiskostatin treatment. Following the maturity of 
these tubule formations, HECV cells treated with the control medium began to 
cluster and tubule formations were lost. However, in wiskostatin treated cells, 
although the tubules became thicker and some clustering was also evident, tubule 
formation was still evident after 20 hours. To demonstrate this consistent pattern 
in tubule formation between 10µM wiskostatin treated and control cells, the 
mean length of the tubule structures was normalised to the control group and 
then the mean over three independent repeats of the experiment was calculated 
and plotted, Figure 4.16B. This analysis clearly shows a consistent significant 
decrease in tubule structures in wiskostatin treated cells following seeding. 
Following this there is then a significant increase in tubule structures after 8h 30 
minutes where the tubule structures are maintained in wiskostatin treated cells 
and lost in the control cells as the HECV cells form clusters. This difference is 
shown in Figure 4.16C with representative images from control and 10µM 
wiskostatin treated cells taken after 19 hours and 30 minutes. 
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Figure 4.16: The effect of wiskostatin on tubule formation. Mean length of 
tubule structures over 3 replicate wells in representative experiment shows the 
trend in tubule formation between 10µM wiskostatin treated and control HECV 
cells (A). Tubule structure length from 3 replicate experiments normalised to the 
control values at time points of 150, 270, 510 and 1170 minutes following seeding 
are plotted (B). Representative images from control and 10µM wiskostatin treated 
cells at the 1170-minute time point are shown (C). Arrows indicate tubule 
structures, of which the length was measured for analysis. Data analysed by t-test 
and significant differences between treated and control samples are represented 
by * = p<0.05, etc. Mean + SD presented. 
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4.4. Discussion 
Wound healing, as has been described in great depth in earlier sections, requires 
numerous signalling pathways to control the recruitment and correct activation of 
a wide variety of cell types in order to be effective and timely. In the previous 
chapter nWASP was identified as a potential therapeutic target for the treatment 
of chronic wounds as it was found to be overexpressed at the transcript level in 
non-healing chronic wound samples. It was therefore hypothesised that through 
targeting nWASP with inhibitors such as 187-1 and wiskostatin, it may be possible 
to encourage the closure of non-healing chronic wounds. 
Having identified nWASP as a potential target for the treatment of chronic and 
non-healing chronic human wounds this study then hoped to elucidate the effect 
of the nWASP inhibitors 187-1 and wiskostatin, and also the effect of nWASP 
knockdown, on the behaviour of cell lines that are representative of cell types 
that have a key role in the wound healing process.  
Chronic wounds are often considered to be maintained in a continuous state of 
inflammation (Eming et al., 2007) and do not effectively pass into the proliferation 
and reepithelialisation stage of wound healing where the physical wound closure 
step occurs. nWASP has been found to have significantly higher expression in 
patient tissue samples from non-healing chronic wounds compared with wounds 
that are healed or healing, i.e. wounds have entered the reepithelialisation stage 
of wound healing and have closed or reduced in size in the 12 weeks following 
tissue collection. As such, this study has focussed on elucidating the role of 
nWASP and the effect of nWASP inhibition in models of cell types that are 
involved in this critical proliferation and reepithelialisation stage of wound 
healing. In order to fully understand the role of nWASP in the human wound 
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healing process and whether the use of nWASP inhibitors may be able to 
encourage chronic wound healing, further work will need to be carried out using 
other cell lines and models representative of different settings within the wound. 
In particular, investigation into the importance of nWASP on the activity of cells 
critical to the inflammation stage of wound healing, such as macrophages and 
neutrophils, will be critical to understand if nWASP inhibition is a viable treatment 
method for patients suffering with a chronic wound. However, due to the complex 
nature and multiple cell types known to be important in human wound healing, 
this study has focussed on two cell models of cells types which have a key role in 
the proliferation and reepithelialisation phase of wound healing. Firstly, HaCaT 
cells, a well-established keratinocyte cell model and are frequently used in wound 
healing studies to examine the activity of epithelial cells and such have been the 
main focus of this study. Secondly HECV cells were also chosen to investigate any 
potential role of nWASP in the control of vascular endothelial cell behaviour. 
To begin to investigate the effect of altering nWASP activity on the various 
behaviours of HaCaT cells, a range of nWASP inhibitor concentrations were used 
in ECIS assays. ECIS allows the simultaneous investigation of cell attachment and 
spreading properties, barrier function and also migration following an electrical 
wounding. Both wiskostatin and 187-1 nWASP inhibitors appeared to be able to 
encourage the attachment and spreading properties of HaCaT cells at ‘low’ levels 
inhibitors, at 0.1µM wiskostatin and <10µM 187-1, as shown by the increased 
resistance following seeding compared with the control samples. This increase in 
resistance, indicative of improved attachment of cells to the electrode, is lost at 
higher levels of inhibitor and even reversed at wiskostatin levels of 10µM. These 
findings correlate with an ECIS assay carried out using nWASP knockdown HaCaT 
cell lines. No effect on the resistance is detected at the lower level of nWASP 
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knockdown (in cells treated with 0.5µg/ml siRNA) but in cells exhibiting greater 
knockdown of nWASP (in cells treated with 1µg/ml siRNA) the resistance is 
significantly decreased compared with the controls. Further repeats of this 
experiment are required to confirm this finding however. The ECIS analysis 
described here measuring the resistance at a frequency of 4kHz is assumed to 
affect the attachment and spreading properties of HaCaT cells conveyed by cell-
electrode adherence and/or cell barrier function rather than simple coverage of 
the electrode which is measured at higher frequencies. The reduction in 
attachment and spreading at high levels of nWASP inhibition and knockdown is 
unsurprising considering the extensive research detailing the role of nWASP in cell 
adhesion and motility (Wu et al., 2004, Misra et al., 2007). This could also be due 
to an inhibitory effect on cell growth which is found at 10µM levels of wiskostatin 
but not at the higher levels of 187-1 that were examined as discussed below. The 
ability of nWASP inhibitors to seemingly encourage the attachment and spreading 
behaviour of HaCaT cells has not previously been reported before however and 
raises new questions about the role of nWASP in controlling keratinocyte 
behaviour and how its activity may vary based on levels of activation or 
expression. One possible explanation for the increase in resistance at these ‘low’ 
levels of nWASP inhibitor treatment is that altering nWASP activity in HaCaT cells 
may alter their ‘stiffness’. A previous study in amoeba cells have shown that 
wiskostatin does not affect the total F-actin content but reduces the stiffness, or 
mechanical rigidity, of cells and conversely also enhances the resistance to fluid 
shear stress despite a reduction in spontaneous motility and podosome formation 
(Pfannes et al., 2012). This study hypothesises that due to the decreased plasticity 
of the actin cortex, which is thought to be the dominant contributor to cell 
stiffness for small deformations imposed on cells (Seltmann et al., 2013), that 
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extensions from the membrane are unable to be maintained resulting in increased 
attachment from the cells, making them less likely to detach in response to fluid 
shear stress. However, the exact contribution of the actin cortex to cell stiffness in 
HaCaT cells is debateable given that studies have indicated that the main 
contribution to keratinocyte stiffness is from the keratin intermediate filament 
network (Lulevich et al., 2010). A further possible indication of how nWASP 
inhibition may increase HaCaT cell resistance comes from a study which 
demonstrated that nWASP depletion enhances endothelial monolayer integrity 
according to transendothelial resistance measurements (Mooren et al., 2015). 
This study demonstrated that a decrease in nWASP activity resulted in VE-
cadherin at cell-cell contacts and altered F-actin organisation at adherens 
junctions between cells. The authors suggested that nWASP may be involved in 
the maturation of cell junctions, where regions of overlap between neighbouring 
cells are removed and mature junctions form from numerous initial adhesions, 
perhaps through the turnover of junctional molecules or retraction of 
lamellipodial protrusions. The change in cell behaviour described in the study by 
Mooren et al. following nWASP knockdown could cause an increase in resistance 
as measured by ECIS, which is what has been shown in the results of this chapter. 
These previous studies, and the findings from this chapter, demonstrate that 
altering nWASP activity can lead to identifying surprising changes in cell behaviour 
considering our current understanding of nWASP and its role in the regulation of 
the actin cytoskeleton. It is unclear what exactly is responsible for the increase in 
resistance during ECIS assays following nWASP knockdown and inhibitor 
treatment shown here but the previous work demonstrating an effect on cell 
‘stiffness’ and adherens junction integrity may also be affected in HaCaT cells and 
so should be examined in future studies. The possible implications for affecting 
187 
 
these cell behaviours in keratinocytes in the wound healing process must also be 
considered. 
MTT assays were carried out to investigate the effect of both nWASP inhibitors on 
the inhibition of growth of HaCaT cells. Wiskostatin was found to have no 
significant inhibition to the growth of HaCaT cells up to levels of 1µM but above 
this level growth was significantly impaired and the IC50 was calculated to be 
1.949µM. This effect on growth at levels over 1µM could in some way contribute 
to or be responsible for the decrease in the resistance observed in ECIS assays 
discussed earlier. 187-1 inhibitor treatment did not have the same inhibitory 
effect on growth as wiskostatin in that no significant inhibition on the growth is 
detected over the full range of 187-1 concentrations tested up to 15µM. This is 
again echoed in the ECIS assay results using 187-1 where the seemingly inhibitory 
effect of 10µM wiskostatin which caused a reduction of the resistance following 
seeding is was not seen when 187-1 was used. Several points could account for 
the differences in the inhibitory effect on growth and the varying concentrations 
at which a change in attachment and spreading is affected by each inhibitor. 
Firstly, wiskostatin is dissolved in DMSO and so this may have some additional 
effects which could alter on the levels of toxicity and the inhibitory effects of 
wiskostatin on attachment and spreading. Secondly, although these drugs both 
act in the same way, to maintain nWASP in its inhibitory conformation, they are 
not identical structures and so the concentrations at which effects on cell 
behaviour are seen are expected to vary. 
Inhibitor levels of 0.1µM wiskostatin and 10µM 187-1 were selected based on the 
consistently significant increase in resistance observed in ECIS analysis and that no 
inhibitory effect on growth was detected at these levels to carry out further 
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experiments to examine their effect on HaCaT cell behaviour. Growth assays using 
crystal violet to measure cell number over 4 days from seeding were carried out 
and showed that neither wiskostatin nor 187-1 had any effect on growth at these 
levels. It was therefore assumed that the effect observed in the ECIS experiments 
already discussed and any changes highlighted in subsequent functional assays 
were not due to an effect on cell growth but on other cell behaviours. 
To investigate the effect of 0.1µM wiskostatin and 10µM 187-1 on cell migration 
following a wounding event, ECIS analysis following an electrical wound and the 
rate of migration of a HaCaT cell monolayer following a scratch wound was 
examined. ECIS analysis examining the capacitance at a frequency of 32kHz, which 
allows analysis of cell coverage rather than cell barrier changes, demonstrated 
that no significant effect on the migration of HaCaT cells following nWASP 
inhibitor treatment was detected. Similarly, no consistent significant effect on the 
rate of scratch wound closure was detected following 0.1µm wiskostatin 
treatment, although the rate of migration in wiskostatin treated cells was 
consistently lower than in the controls. 10µM 187-1 treatment did decrease the 
rate of scratch wound healing in two of the four independent repeats of the 
experiment and yielded a significant decrease in the rate of migration of HaCaT 
cells when the means of these experiments were analysed together. The 
inconsistent results from these migration assays could be due to several 
considerations. A difference in the efficacy of each inhibitor to target nWASP and 
affect cell behaviour could be responsible for the more effective decrease in cell 
migration in 187-1 treated cells compared with when wiskostatin is used. 
Furthermore, the time period over which these inhibitors can actively inhibit 
nWASP has not been studied here and could explain why no effect on cell 
migration is found in the ECIS assays as cells would have been cultured for up to 
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96 hours or more in these experiments, at which point the effect on cell migration 
may become ineffective. For this reason, the effect of nWASP knockdown could 
not be examined in an ECIS wounding assay because the transient nWASP 
knockdown would not still be present on completion of the ECIS experiment. 
Further investigation into the effect of 0.1µM wiskostatin and 10µM 187-1 
treatment on other cell behaviours in vitro were carried out. Initially the motility 
of cells was examined through cytodex-2 bead motility assays. Here, motility is 
described as the willingness of cells to move or migrate. The number of motile 
cells that migrated from the beads that they were adhered to the base of the 
plate they were cultured in was not significantly different between the nWASP 
inhibitor and control medium treated samples. The different stages of cell 
adhesion from initial attachment through to cell spread were also examined using 
Matrigel adhesion assays and then cell spread analysis and ECIS respectively. The 
ability of HaCaT cells to initially adhere a Matrigel basement membrane over a 25-
minute period following seeding was not affected by nWASP inhibitor treatment. 
However, the ability of cells to spread and attach to the surface on which they are 
seeded was significantly improved following 0.1µM wiskostatin treatment 
according to cell perimeter measurements. These findings correlate with the 
increase in resistance measured using ECIS in cells treated with this level of 
inhibitor. These findings considered together suggest that changes to nWASP 
activity may be able to alter the attachment and spreading properties of HaCaT 
keratinocyte levels in a way that has not been previously been reported in this 
context. 
In summary, the findings detailed in this chapter show that the level of nWASP 
activity can have varied effects on the behaviour of HaCaT keratinocyte cells. This 
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is clear through ECIS analysis when using different levels of nWASP inhibitors and 
comparing these with knockdown studies which showed that high levels of 
inhibition or effective knockdown of nWASP can impair the attachment and 
spreading properties of cells but these results are not consistent at lower levels of 
nWASP inhibition. The use of nWASP inhibitors within this specific range of 
concentrations, where no effect on cell growth is found, saw the attachment and 
spreading properties of HaCaT cells increase. These findings are also novel in that 
they contradict our understanding of the role of nWASP in cell behaviour from the 
literature which has reported that lower nWASP activity decreases adhesive 
behaviour of a variety of cell types (Misra et al., 2007, Rajput et al., 2013). This 
study has also highlighted that HaCaT cell migration may be impaired slightly by 
nWASP inhibitor concentrations where an increase in attachment and spreading is 
detected. This finding is unsurprising considering the well understood relationship 
between adhesion and migration where a balance must exist between the ability 
of cells to form adhesions to their surrounding and also release those attachments 
in order to move effectively (Palecek et al., 1997, Holly et al., 2000). 
These findings have demonstrated how subtle changes and/or a balance in 
nWASP activity may be able to change the behaviour of keratinocytes. It is critical 
to fully understand how these properties are being affected when considering 
nWASP as a potential therapeutic target in the treatment of chronic wounds. 
Knowing that nWASP activity is able to alter the attachment properties of 
keratinocytes is very interesting considering the important role of adhesion and 
attachment of epithelial cells in cell migration and other processes at work in the 
wound healing process. To further explore this key unexpected finding of nWASP 
inhibitors causing an increase in the attachment and spreading properties of 
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HaCaT cells at particular concentrations, further studies into the underlying 
signalling mechanisms that are at work within the cells will have to be examined. 
The effect on cell function was also considered in HECV vascular endothelial cells. 
ECIS analysis using a range of inhibitor values was carried out to examine the 
effect of nWASP inhibitors on cell attachment and spreading following seeding 
and then after an electrical wounding event to observe the effects on migration. 
The ability of HECV cells to attach and form a stable monolayer following seeding 
was impaired by nWASP inhibitor treatment at levels of 10µM wiskostatin and 
over 1 and 10µM 187-1 as demonstrated by the decrease in the resistance 
compared with the controls. Due to the known role of nWASP in the control of 
adhesive structures in endothelial cells from the literature, this finding is 
unsurprising and may be due to a delay in the formation of attachment sites in the 
cells to the environment or to other cells or an impairment in the spreading of 
cells on the electrode surface (Mooren et al., 2015, Rajput et al., 2013). 
Analysis of the healing of an electrical wound using ECIS allowed insights into the 
effect of nWASP inhibitor treatments on the migration of HECV cells. Wiskostatin 
treatment showed no effect on the capacitance monitored after wounding except 
at 10µM levels where inhibition of nWASP activity impaired the rate at which cells 
could migrate to reform the monolayer. In contrast to this, 187-1 treatments of 1 
and 10µM concentrations caused consistently significant, although relatively 
small, decreases in the capacitance measured following electrical wounding. This 
suggests that 187-1 may have a slight effect on encouraging the healing of an 
electrical wound in HECV cells. This difference could perhaps be due to some 
effect of the DMSO which wiskostatin is diluted in upsetting the natural behaviour 
of these cells. Or perhaps these inhibitors act differentially and therefore affect 
192 
 
these cells at different concentrations as was discussed earlier in the context of 
HaCaT cells. Further repeats of this experiment using a broader range of inhibitor 
concentrations and perhaps a knockdown cell model in the future may help to 
address these queries. No significant effect on the inhibition of cell growth was 
seen in HECV cells following inhibitor treatments between 0 and 15µM 
concentrations suggesting that the effects observed in the ECIS analyses were due 
to changes to the functional properties of the cells other than growth. 
Investigation into the effect of nWASP inhibitors on angiogenic behaviour in 
vascular endothelial cells was analysed using tubule formation assays. This 
technique enables measurement of the angiogenic potential of cell lines based on 
their ability to form tubule-like structures (Francescone et al., 2011). Numerous 
methods for the calculation of tubule formation exist including tubule perimeter, 
number and length. This study uses the measure of the length of the perimeter of 
the tubule structures in order to track the formation and longevity of the 
structures over time. This assay demonstrated that the nWASP inhibitor 
wiskostatin at 10µM levels (chosen based on the significant effect on HECV cell 
behaviour during ECIS assays) has a profound effect on the tubule formation 
behaviour of HECV cells. In the control cells, tubule structures began to form after 
only 30 minutes and reached a peak after approximately 8hours and 30 minutes. 
The formation of tubule structures was delayed in wiskostatin treated cells but 
the angiogenic potential of the cells, based on the total length of the tubule 
structures that eventually formed after 8h 30m, was not impaired by wiskostatin 
treatment. Furthermore, tubule structures began to deteriorate after 8h 30m as 
cells formed clusters but wiskostatin treatment prolonged the tubule structures 
significantly. The interpretation of this in the context of the angiogenic potential 
of HECV cells is uncertain as the longevity of tubule formations may be related to 
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numerous factors including apoptosis. However, it is clear that nWASP inhibition 
alters the ability of these cells to form and maintain tubule structures and hence 
warrants further investigation into the role of nWASP in the behaviour of vascular 
endothelial cells and into the potential molecular mechanisms that may be 
responsible for this observed change in cell behaviour. 
To summarise, nWASP inhibition appears to impair the attachment and spreading 
but may be able to encourage the migratory/invasive and angiogenic capacity of 
HECV cells. These behaviours are known to go hand-in-hand in the process of cell 
migration and invasion with a balance between adhesion and migration critical for 
cell motility and are therefore important in the function of vascular endothelial 
cells in a wound healing context. Furthermore, the angiogenic behaviour of HECV 
cells appears to be affected in an unusual manner in response to nWASP 
inhibition with wiskostatin prolonging the formation of angiogenic structures. 
Vascular endothelial cells are required to migrate and undergo angiogenesis in the 
wound environment during the wound healing process and affecting these cell 
behaviours through the inhibition of nWASP may affect the progression of wound 
healing. It is therefore vital to fully elucidate the effects of nWASP inhibitor action 
in vascular endothelial cell types and the underlying signalling mechanisms at 
work to understand whether nWASP inhibitors may be a viable therapy for the 
treatment of chronic wounds. 
In conclusion, it is clear that nWASP activity can affect the in vitro function and 
behaviour of cells that model keratinocytes and vascular endothelial cells, key cell 
types in the proliferation and reepithelialisation stages of wound healing. In 
particular, the attachment and spreading properties of these cells can be altered 
by nWASP inhibition and this may be responsible for changes to their migratory 
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capacity. Attachment and spreading of cells, and of course migration, plays a 
critical role in wound healing as has been discussed. Identifying that these 
behaviours can be altered by nWASP activity in cell types which represent those 
active in the wound healing process is important considering aberrant expression 
of nWASP in chronic non-healing human wounds. These results may explain how 
elevated nWASP activity in the chronic wound tissues may be responsible for the 
non-healing behaviour of these wounds and also how particular cells may react to 
nWASP inhibitor treatments if they were to be applied as a therapy. However, this 
is the first known piece of work to examine the effect of both 187-1 and 
wiskostatin in the same study and some differences in the response of the cell 
lines used in some of the functional assays to each of these inhibitors have been 
shown. This highlights potential off-target effects, differences in efficacy in 
inhibiting nWASP and/or accumulation and degradation differences between the 
two drugs, which could all differ between cell types and have not previously been 
studied and could for unexplained changes in the functional response of cells to 
nWASP inhibition in this study. Peterson et al. first identified the chemically 
distinct 187-1 and wiskostatin (in 2001 and 2004 respectively) and described how 
wiskostatin can affect nWASP-independent actin polymerisation. Furthermore, 
wiskostatin has been shown to have nWASP-independent effects at high 
concentrations by some studies as discussed in section 1.3.2.2. This shows that 
further work into the chemical and mechanistic properties of these inhibitors 
needs to be carried out in future work, and could explain the disparities in the 
effects on cell function shown in some results reported in this study. Fully 
understanding how the behaviour of the cells at the wound site will be affected by 
nWASP inhibition may help to predict whether nWASP inhibitors will be a viable 
therapy for the treatment of chronic human wounds. 
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Chapter 5: The effect of 
nWASP inhibition in vivo 
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5.1 Introduction 
Chronic wounds predominantly affect the elderly and those suffering with venous 
disease where patients are more likely to develop venous leg ulcers (Margolis et 
al., 1999). Diabetes sufferers are also at a higher risk of developing a chronic 
wound than other members of the general population with estimates of 
developing a diabetic foot ulcer at up to 25% amongst diabetic patients (Singh et 
al., 2005). The increased risk of developing chronic wounds in these individuals 
with diabetes or vascular disease is attributed to multiple factors including venous 
insufficiency, arterial disease, prolonged pressure and/or neuropathy (Valencia et 
al., 2001). As such, healthcare professionals have a basic understanding of the 
incidence and causes of chronic wound development in people who are in these 
vulnerable groups, such as diabetics and the elderly, and so can take preventative 
measures. In cases where a chronic wound does develop, a multitude of 
treatment and management techniques exist such as dressings, debridement and 
compression therapy (Richmond et al., 2013). However, due to the difficult nature 
of chronic wounds these techniques that form the standard of care have varying 
levels of effectiveness. This could be attributed to the fact that a detailed 
understanding of exactly why these wounds develop and the molecular pathways 
that are involved is still lacking.  
In recent times, researchers have considered a more molecular focus to try and 
develop novel therapies by looking into the pathways that are involved in acute 
wound healing or dysregulated in chronic wounds and so could be targeted to 
initiate wound healing (Martin and Nunan, 2015). For instance, platelet-derived 
growth factor (PDGF) has been shown to be important in wound healing and 
reduced PDGF receptor expression was found to correlate with impaired healing 
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in diabetic mice (Heldin and Westermark, 1999, Beer et al., 1997). As such, 
recombinant PDGF has been developed as a therapy which can be topically 
applied to diabetic foot ulcers to encourage healing (Robson et al., 1992, Wieman 
et al., 1998). Other growth factors and signalling molecules have also been 
investigated with the aim of developing potential therapies. For example, GM-CSF 
is a factor which has shown promising results in encouraging the healing of 
chronic venous leg ulcers (Da Costa et al., 1999, Jaschke et al., 1999). 
Furthermore, investigation into c-myc overexpression and nuclear localization of 
β-catenin in chronic wounds identifies these as molecular markers and potential 
future targets for molecular intervention (Stojadinovic et al., 2005). 
Thus far, this study has identified nWASP as a possible therapeutic target in the 
treatment of chronic human wounds and the use of nWASP inhibitors in cell lines 
has shown to effect skin cell behaviour. However, in order to examine the 
therapeutic potential of nWASP inhibitors more comprehensively, animal models 
must be employed to give an indication of whether these drugs would have any 
efficacy in a human chronic wound setting.  
Selection of the most appropriate mouse model to represent the susceptibility of 
certain groups, such as diabetics, to develop chronic wounds and to demonstrate 
the impaired wound healing abilities of these patients is critical. Db/db mice are a 
diabetic mouse model and have been used in many studies to examine biological 
effects under diabetic conditions. This mouse strain has been well characterised 
as a model of Type 2 diabetes mellitus, exhibiting hyperglycaemia and 
hyperinsulinemia. The diabetic phenotype results from a point mutation in the 
leptin receptor gene Lepr. They have been heralded as useful models for many 
conditions and symptoms that are common in diabetic patients such as retinal 
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neurodegeneration (Bogdanov et al., 2014), dyslipidaemia (Kobayashi et al., 
2000), cardiac effects and obesity (Belke and Severson, 2012). Most importantly 
with reference to this study, they also exhibit impaired wound healing, a trait 
which is also observed in patients with diabetes and other patients with chronic 
wounds. As such, the db/db mouse strain has been studied and is deemed to be a 
good model of delayed wound healing so is commonly used in wound healing 
assays (Michaels et al., 2007, Sullivan et al., 2004, Park et al., 2014). 
This chapter examines the tolerance of nWASP inhibitors 187-1 and wiskostatin 
on CD-1 athymic and db/db mice and also examines the effect on the healing of a 
hole-punch wound to the ear of db/db mice. 
5.2 Materials and Methods 
5.2.1 Animals 
CD-1 athymic mice (Charles River Laboratories) were used in in vivo tolerance 
assays and diabetic db/db (also called Leprdb/db) strain mice (Harlan Laboratories, 
Cambridgeshire; now called Envigo), which exhibit impaired wound healing 
abilities, were also used in in vivo efficacy and tolerance tests. Mice were used 
when body weight reached 20g between 4-6 weeks of age. 
5.2.2 Reagents and treatments 
For systemic application, 187-1 was dissolved and diluted in BSS to 500µM master 
stock and then further in BSS to the required concentration. Wiskostatin was first 
dissolved in DMSO (Sigma-Aldrich) at concentration of 5mg/ml and then gradually 
diluted in BSS. The solutions were prepared in 100µl aliquots at the desired 
concentrations and were stored at -20°C until used.  
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5.2.3 In vivo tolerance assay 
After CD-1 and db/db mice were settled for 1 week in the laboratories, 187-1 and 
wiskostatin were injected via the intraperitoneal route on a daily basis. 1µM and 
10µM dosages in 100µl volumes for each compound were administered. The mice 
were observed daily and weighed twice weekly. 
5.2.4 In vivo wound healing assay 
Db/db mice were used in in vivo wound healing assays. Creation of a wound was 
by using an ear punch method to create a wound (hole) of 1mm in diameter in the 
pinna. The wound site on the ear was chosen over other commonly used wound 
sites in wound healing assays, such as the back of the mouse, as a model of 
severely impaired wound healing. The following day the mice were weighed and 
the wound photographed using a digital camera (Nikon) equipped with a special 
lens for close-up photography, and also on days 7, 15, 21 and 24 following 
wounding, at a distance from the ear of approximately 12cm. Treatment was 
given systemically (as described in section 5.2.3) or topically every other day 
(Monday, Wednesday Friday). For topical application, treatments that were 
diluted in Topical carrier gels A or B from stock solutions were applied in 150µl 
amounts by gently rubbing onto the wounded area using fingers. For systemic 
application, 187-1 was applied at 0.5 and 5µM and wiskostatin was applied at 1 
and 10µM.  
5.2.5 Data analysis 
The size of the wounds was determined using image analysis software (ImageJ). 
Data are presented as the area of the wounds in pixels, where t-tests were used 
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for statistical analysis. Data were then normalised by subtraction to the average 
wound size (in pixels) at Day 1 using and the percentage change in wound size 
from Day 1 was calculated for each wound measurement. In this case 2-way 
ANOVA was used for data analysis.  
5.3 Results 
5.3.1 187-1 and wiskostatin are well tolerated in CD-1 and 
db/db mice 
The compounds 187-1 and wiskostatin were delivered systemically on a daily basis 
as part of a tolerance assay for a two-week period in athymic CD-1 and db/db 
mouse strains. Throughout the study no side effects were observed following 
treatments with both drugs at all dosages. There was no weight loss and no signs 
of any changes in the skin in any of the groups.  
5.3.2 187-1 and wiskostatin accelerate wound healing in db/db 
mice without producing any side effects 
187-1 and wiskostatin were applied systemically and topically to db/db mice 
following wounding to the ear using a hole punch technique. In both cases, no 
side effects were detected during the treatment period. Furthermore, wound 
healing was improved in all cases as described below. Example images of the 
healing of the hole punch wound following treatment in db/db mice are shown in 
Figure 5.1.   
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5.3.3 187-1 improved wound healing when administered 
systemically and topically 
Two concentrations of 187-1 were given systemically, 0.5 and 5 µM. Healing of 
the hole punch wounds was encouraged in db/db mice following both systemic 
and topical administration of 187-1 with both methods showing a significant 
reduction in wound size after 24 days, see Figure 5.2 A and B respectively. Tables 
5.1 and 5.2 detail results of statistical analysis. After 24 days, wounds treated with 
0.5 and 5µM 187-1 were significantly smaller than the control group (p<0.0001 in 
both cases) as shown in Figure 5.2. Topical application of 187-1 in both carrier gel 
A and B also showed a significant effect on reducing the hole punch wound size in 
db/db mice compared with the control wounds after 24 days (p<0.0001 in both 
cases) as shown in Figure 5.2. 187-1 application in Topical carrier gel B appeared 
to encourage wound healing at a faster rate compared with the other treatments 
as wound size was significantly smaller than the control group after only 7 days, 
whereas the other treatments saw a significant difference after 15 days. Statistical 
information is summarised in Tables 5.1 and 5.2. 
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5.3.4 Wiskostatin improved wound healing when administered 
systemically and topically 
Two concentrations of wiskostatin were given systemically, 1 and 10µM. Healing 
of the hole punch wounds was encouraged in db/db mice following both systemic 
and topical administration of wiskostatin with both methods showing a significant 
reduction in wound size after 24 days, see Figure 5.3 A and B respectively and 
Table 5.1. After 24 days, wounds treated with 1 and 10µM wiskostatin were 
significantly smaller than the control group (p<0.0001 in both cases) as shown in 
Figure 5.3. Topical application of wiskostatin in both carrier gel A and B also 
showed a significant effect on reducing the hole punch wound size in db/db mice 
compared with the control wounds after 24 days (p<0.0001 in both cases) as 
shown in Figure 5.3. Wiskostatin treatment appeared to encourage the healing of 
hole punch ears at a faster rate than 187-1 as a significant reduction in the wound 
size compared with the control wounds was observed in all the treatment 
methods after only 7 days from wounding. Statistical information is summarised 
in Tables 5.1 and 5.2. 
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Table 5.1: P-values from statistical analysis comparing wound size on a given day 
to day 1 in each treatment group. T-test analysis was used. P-values correspond 
to data presented in Figure 5.2 A and B and Figure 5.3 A and B. Significant findings 
(p<0.05) appear in bold. 
  Day 7 Day 15 Day 21 Day 24 
187-1 
Systemic 0.5µM 0.972161 0.03467 0.217004 0.075775 
Systemic 5µM 0.929879 0.049857 0.000414 0.004618 
Topical A 0.940357 0.000224 0.000129 0.009956 
Topical B 0.087243 0.04162 0.00859 0.001387 
wiskostatin 
Systemic 1µM 0.010391 0.00215 0.001452 0.019708 
Systemic 10µM 0.19916 0.352638 0.048453 0.099155 
Topical A 0.665838 0.014377 0.002878 0.000183 
Topical B 0.315061 0.007243 0.000466 1.28E-05 
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Table 5.2: P-values for comparing percentage change in wound area from day 1 
between each treatment group versus the control at each time. 2-way ANOVA 
analysis was used. P-values correspond to data presented in Figure 5.2C and 5.3C. 
Significant findings (p<0.05) appear in bold. 
  Day 7 Day 15 Day 21 Day 24 
187-1 
Systemic 0.5µM 0.137 < 0.0001 < 0.0001 < 0.0001 
Systemic 5µM 0.1185 < 0.0001 < 0.0001 < 0.0001 
Topical A 0.1683 < 0.0001 < 0.0001 < 0.0001 
Topical B 0.0001 < 0.0001 < 0.0001 < 0.0001 
wiskostatin 
Systemic 1µM < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Systemic 10µM 0.0008 0.003 < 0.0001 < 0.0001 
Topical A 0.0267 < 0.0001 < 0.0001 < 0.0001 
Topical B 0.0053 < 0.0001 < 0.0001 < 0.0001 
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5.4 Discussion 
Many therapies exist for the treatment and management of chronic wounds 
which are found in many forms including dressings, cream and ointments, 
cleaning mechanisms, oxygen delivery systems and injections (Richmond et al., 
2013). These treatments all aim to encourage the wound healing by acting on 
particular aspects of the wound which are thought to be important for wound 
healing. For instance, dressings and debridement techniques act to maintain a 
sterile wound environment. Creams and ointments help to maintain a moist 
wound environment which is conducive to healing.  
However, the non-healing nature of chronic wounds indicates that good wound 
management techniques are often not sufficient to encourage wound closure 
alone. This has initiated an upsurge in research into the molecular mechanisms 
that are involved in the formation of chronic wounds and in the normal wound 
healing process in order to identify molecular targets and pathways which can be 
targeted in order to encourage healing in these difficult wounds. Several therapies 
which have been trialled recently involve targeting the pathways known to be 
involved the wound healing process. For instance, the application of PDGF and 
GM-CSF, factors known to be able to encourage wound healing, have shown 
promising results in the treatment of chronic wounds (Wieman et al., 1998, Da 
Costa et al., 1999). The use of drugs and treatments that target molecular 
mechanisms and pathways in combination with good wound management 
techniques therefore opens up new potential ways to treat these difficult wounds. 
In this chapter, the tolerance and efficacy of nWASP inhibitors wiskostatin and 
187-1 as both systemically and topically applied treatments are explored in a 
wound healing context. 
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CD-1 athymic mice were used initially in a tolerance study where wiskostatin and 
187-1 were given systemically. This immunodeficient mouse strain was selected 
for this experiment in part due to their hairlessness which would allow easy 
observations to any changes to the skin. Both drugs were well tolerated at all 
concentrations with no significant weight loss and no severe side effects 
observed. In order to further examine the tolerance of wiskostatin and 187-1, the 
response in db/db mice was also observed in addition to measuring their effect on 
healing in this diabetic mouse model. The treatments were well tolerated in both 
of these application methods in the db/db strain, as they were in the CD-1 strain, 
with no adverse side effects or significant weight loss. 
To examine the effect of the nWASP inhibitors on wound healing in db/db mice, 
both inhibitors were applied at two different concentrations both systemically 
and topically at the site of a wound. The wounding involved the application of a 
hole punch of 1mm in diameter to the ear. This ‘hole-punch’ method is a common 
practise and is used frequently in wound healing assays in animals as a model of 
the wound environment (Cho et al., 2006, Saaristo et al., 2006, Deoliveira et al., 
2011) although more often the wounds are applied to the back of the mice where 
the wound environment is more representative of chronic wounds found in 
human patients with the underlying tissue and blood supply present. Chronic 
wound sufferers will most often have wounds on the feet or legs whereas in this 
mouse model, wounds have been applied to the ear where the blood supply, 
tissue composition and infection occurrence would differ significantly. 
Furthermore, although the db/db mouse strain is a diabetic model, the 
physiological conditions in these mice will not fully reflect human diabetic 
complications and variability. Application of the wound to the ear however 
minimises the suffering of the animals as it causes very little harm and distress, as 
210 
 
per the Home Office principles regarding animal studies, whilst still enabling the 
examination of the effect on wound healing. Furthermore, the deliberate use of 
the ear for the wounding site, where wound healing is even more significantly 
impaired in this mouse model as shown by the increase in wound size in the 
control group, emphasises the efficacy of the drugs used in this study as a means 
to encourage wound healing, given the extremely poor wound healing exhibited 
under normal conditions. In addition to these benefits of this chosen wounding 
method enables easy examination of the reepithelialisation stage of wound 
healing which has been the main focus of this study, despite that the hole punch 
to the ear may not be the best possible representation of a target wound site in 
humans (Nunan et al., 2014), as discussed. However, the use of the nWASP 
inhibitors in this study was found to encourage wound healing compared with the 
control group, where no healing behaviour was seen. These findings are therefore 
very supportive of the idea that these treatments can induce wound healing in an 
impaired wound healing setting. 
Diabetic mice were selected for the wound healing study due to their impaired 
wound healing abilities which were thought to best represent the human setting. 
The status of nWASP expression in the tissues of db/db mice has not been studied 
and so whether they represent the setting in human venous leg ulcers where 
nWASP was found to be overexpressed is unknown. However, they do represent 
the diabetic environment well (Bogdanov et al., 2014, Kobayashi et al., 2000, 
Belke and Severson, 2012) and are frequently used in wound healing studies due 
to their impaired wound healing ability and so offer a good representation of the 
environment of many chronic wounds (Ansurudeen et al., 2012, Michaels et al., 
2007). In particular Sullivan (2004) reported that db/db mice are an excellent 
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model of delayed wound healing and so were deemed an appropriate animal 
model for this study (Sullivan et al., 2004). 
This study shows that nWASP inhibitor application encourages wound healing in 
db/db mice that exhibit impaired wound healing abilities under normal 
conditions. However, despite these encouraging findings, some downfalls in the 
experimental design are evident and must be discussed. Firstly, due to restraints 
on the use of animals and the principles held by Cardiff University to reduce the 
number of animals used per experiment, only one control group was used 
throughout the whole experiment. This has obvious flaws as there is no proper 
control for the massaging of topically applied treatments, no control for the 
individual efficacy of the carrier gels and no vehicle control for the effect of DMSO 
which wiskostatin is dissolved in. The hole punch wound does in all cases of the 
treatments show improved wound healing though which is encouraging. This 
finding has the most significance in the case where systemically applied 0.5 and 
5µM 187-1 was found to encourage wound healing because this is the only 
treatment group that is properly controlled. Both concentrations of the drug 
showed a significant reduction of the wound size compared to day 1 at numerous 
time points from Day 15 (but only at 1 time point for 0.5µM 187-1 treatment), 
whereas the control showed an increase in the wound size. The wound size was 
found to be significantly lower than the control wound size measurement on the 
same day at all time points after 15 days from the wounding in all treatment 
groups. This reduction in the wound size compared with the control observed 
with systemic 187-1 treatment was significant but was slightly less effective than 
the other treatment options which in many cases led to a significant improvement 
in the wound size after just 7 days. However, as discussed, this could be due to 
influence from the vehicle or method of application. The fact that wound healing 
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is observed in all of the treatment groups is also very positive especially because, 
as previously discussed, this mouse model exhibits impaired wound healing, a 
characteristic that would be especially prevalent on the ear at the site of the 
wound where poor blood flow and a lack of underlying matrix are not conducive 
to wound healing. These factors explain why no healing and an increase in the 
wound size are observed in the control group, making the healing behaviour in 
the treatment groups even more promising.  
Furthermore, the similarities in the improved healing between the groups that 
received each drug topically and systemically suggests that the bioavailability of 
187-1 and wiskostatin at the wound site is sufficient for the drug to have an effect 
when applied systemically. However, the selectivity, bioavailability and 
accumulation/degradation of these drugs in vivo has not been extensively studied 
and hence further research into these activity of these drugs is clearly required if 
nWASP inhibition is to be considered as a therapy in the clinic. This is especially 
desirable given the sometimes-contrasting response of the different cell types 
used in this study in Chapter 4. Understanding how these inhibitors are having 
differing effect on cell attachment and spreading between HaCaT and HECV cells, 
as shown in chapter 4, and how this may be representative of cell types in the in 
vivo wound model used in this chapter to improve wound healing is not 
understood. 
This work supports the idea that nWASP inhibitors may be a viable treatment 
option for the treatment of chronic wounds in humans. These drugs have been 
shown to be able to effectively encourage healing in a setting which exhibits 
impaired wound healing. The effectiveness of topical application of these drugs 
also highlights a potential method of application to humans which involves very 
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little discomfort and intrusion and allows the treatment to be administered 
directly to the affected area rather than in the blood stream. 
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Chapter 6: nWASP 
inhibition affects TrkB 
signalling in the HaCaT 
cell line 
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6.1. Introduction 
The development of chronic wounds can be attributed to several factors and the 
occurrence of these wounds is accompanied by a change in the pattern and levels 
of signalling molecules in the cells and tissues in the wound. Identifying patterns 
in protein and gene expression changes which coincide with the development of 
chronic wounds is critical in order to recognise key signals and pathways that may 
be responsible for their development or that could be altered to encourage their 
healing. 
Growth factors and cytokines and their respective receptors are important in the 
proper functioning of cells in a variety of contexts throughout the body but are 
vital in orchestrating the correct response of cells involved in the wound healing 
process. Signalling networks involving numerous growth factors, chemokines and 
cytokines, including the EGF, VEGF, TGFβ, IL, FGF and PDGF families to name a 
few, and their respective membrane bound receptors control and direct the 
activity of a variety of cells types in wound healing (Barrientos et al., 2008, Werner 
and Grose, 2003). As such, therapies involving the topical application of growth 
factors have been explored in the clinic. 
Many of the signals and growth factors mentioned above have been well studied 
and their roles and the activities of their receptors are well understood in the 
context of wound healing. In addition to these, some other families of proteins 
which aren’t traditionally associated with wound healing and the wound 
environment have been implicated in the control of wound healing and in the 
development of chronic wounds. For example, neurotrophins, neuropeptides and 
neurohormones have been studied in the context of the skin and wound healing. 
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The skin has a constant interaction with the nervous, immune and endocrine 
systems and the action of these neurotrophin, neuropeptides and 
neurohormones with their specific receptors, which are expressed in neuronal 
and skin cells, allows communication between the different cells types in these 
systems (Cheret et al., 2013). 
Neurotrophins are a family of growth factors that can act as signals between a 
variety of cell types such as nerve, immune and skin cells through their specific 
receptors. There are four members of the neurotrophin family, neurotrophin 3 
(NT3), neurotrophin 4/5 (NT4/5), brain-derived neurotrophic factor (BDNF) and 
nerve growth factor (NGF), and four receptors which have varying affinities for 
specific neurotrophins. p75NTR is a low affinity receptor for all four 
neurotrophins, and the high affinity tyrosine kinase receptors (Trk) bind NGF 
(TrkA), BDNF and NT4/5 (TrkB) and NT3 (TrkC) with ligand specificity (Skaper, 
2012). 
Many studies have examined the role of neurotrophins, particularly NGF, in the 
context of the skin and wound healing (Aloe et al., 2008, Sun et al., 2010). NGF 
has been implicated in the control of wound healing through release by 
keratinocytes in response to tissue injury and encouraging reepithelialisation 
(Cheret et al., 2013), and was also found to improve the impaired, diabetic 
response to wound healing (Matsuda et al., 1998). The role and importance of the 
neurotrophin receptor TrkB and its ligand BDNF in skin cells and wound healing 
has been examined in limited studies but is not well understood. Studies have 
demonstrated that BDNF, and truncated-TrkB, are expressed in pre-confluent 
keratinocytes but was not shown to stimulate their proliferation (Marconi et al., 
2003). BDNF has been shown to promote migration and formation of the tubular 
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structures of endothelial cells (Matsuda et al., 2012, Sun et al., 2009) and has also 
been shown to be synthesised in dermal fibroblasts and may be able to induce 
their differentiation (Palazzo et al., 2012). 
TrkB activates several common and well-known intracellular signalling pathways 
upon binding of its ligands BDNF and/or NT4 including the Ras-mitogen-activated 
protein kinase pathway (MAPK), the phospholipase-Cγ-Calcium pathway and the 
phosphatidylinositol 3-kinase (PI3K)-Akt pathway (Huang and Reichardt, 2003, 
Minichiello, 2009). Upon ligand binding to the full length TrkB receptor, 
dimerization and auto-phosphorylation of tyrosine residues on the intracellular 
kinase domains occurs. Phosphorylation of various tyrosine residues on the 
intracellular domain of TrkB can act as docking sites for adaptor molecules. For 
instance, Shc adaptor molecules interact with phosphorylation sites on TrkB 
through their phosphotyrosine binding (PTB) domains (Kavanaugh and Williams, 
1994). Also, phosphorylation at Y816 recruits PLCγ1 through a Src-homology 2 
(SH2) domain leading to its phosphorylation and downstream signal transduction. 
The importance of Y816 and downstream PLC γ1 signalling has been highlighted in 
a number of contexts including limbic epileptogenesis (a type of epilepsy) (He et 
al., 2010), taste bud innervation during development (Koudelka et al., 2014) and 
neuronal plasticity and long-term potentiation (Rantamaki et al., 2007, Minichiello 
et al., 2002). Research into the role of TrkB in the skin is lacking however, as 
previously mentioned, especially with regards to the importance of the TrkB-PLC 
γ1 signalling pathway. Furthermore, growth factor receptor-bound protein 2 
(Grb2) and/or SOS bind to adaptor proteins that are recruited to TrkB and can 
lead to downstream MAPK pathway activation. More information on TrkB 
signalling, its interaction partners and downstream pathways is found in Figure 
6.1.  
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Figure 6.1: TrkB signalling pathways. Activation of the TrkB receptor has been 
shown to activate a number of intracellular signalling pathways including the 
MAPK pathway which promoted neuronal growth and differentiation through 
MEK and Erk. Survival and growth of other cells can also be stimulated through 
the PI3K cascade. PLCγ1 recruitment to Y816 leads to PKC and calcium signalling 
which can affect plasticity and differentiation in different cell types. Numerous 
adaptor proteins coordinate the activation of these signalling pathways such as 
Grb2 and SHC. Image from (Minichiello, 2009). 
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nWASP is known to have several functions at the cell membrane in a variety of 
contexts. The ability of nWASP to control the actin-rich membrane protrusions at 
cell membranes has been studied in depth, as discussed in Chapter 1. nWASP and 
the other WASP/WAVE family members have also been implicated in a range of 
functions related to membrane deformation including endocytosis and vesicle 
trafficking. The role of nWASP and other family members in the control of cell 
membrane functions is reviewed by Takenawa and Suetsugu in detail (Takenawa 
and Suetsugu, 2007). Many studies have focussed on the role of nWASP in 
receptor-mediated endocytosis and membrane trafficking (Kessels and Qualmann, 
2002, Bu et al., 2010, Guerriero and Weisz, 2007). Several binding partners and 
adaptor proteins have been shown to activate and facilitate these activities of 
nWASP in the proximity of the cell membrane, such as Grb2 and other SH3 
containing adaptor proteins like Nck (Carlier et al., 2000).  
In this study, nWASP expression has shown to be elevated in chronic and non-
healing human wounds. This novel finding highlighted nWASP as a potential 
therapeutic target in the treatment of human chronic wounds. Functional assays 
using nWASP inhibitors and knockdown cell models have demonstrated that 
nWASP inhibition can alter the behaviour of keratinocytes, a cell type involved in 
the healing process. It is clear that nWASP has been implicated in a variety of roles 
within the cell through many potential binding partners and pathways. In order to 
understand how nWASP inhibition alters the behaviour of these cells and to 
determine what signalling pathways may be affected by the application of nWASP 
inhibitors in a wound setting, studies into the pathways affected by nWASP 
inhibitor treatments are required. In this chapter, the effect of nWASP inhibitor 
treatments on the signalling mechanisms active in HaCaT keratinocytes are 
studied with particular focus towards TrkB signalling. 
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6.2. Materials and Methods 
6.2.1. Cell lines and culture methods 
HaCaT cells, and also an nWASP knockdown cell line based on the HaCaT model 
(see section 3.3.4), were cultured and maintained in normal culture medium as 
described in Section 2.4. Briefly, cells were trypsinised and counted using 
Invitrogen™ Tali™ Image-based Cytometer (ThermoFisher). Cell solution was 
diluted to obtain the desired seeding densities, described in the results, and 
plated into appropriate culture ware in order to achieve varying levels of 
confluency for experiments. Cells cultures ahead of protein extraction, SDS-PAGE 
and Western blot were cultured in 6-well plates with 1ml applied to each well. 
Cells were cultured in normal culture medium supplemented with 10% FBS but 
were often subjected to a period of serum starvation which involved washing the 
cells with an appropriate volume of SFM and then replacing the medium with SFM 
for a specified period of time – often 4 hours. 
6.2.2. Antibodies, reagents and treatments 
nWASP inhibitors, 187-1 and wiskostatin (TOCRIS and Enzo Life Sciences 
respectively) were stored as previously described. These inhibitor stocks were 
diluted in normal culture medium or SFM to the desired concentration for each 
experiment. Appropriate vehicle controls were used in each assay. Calf intestinal 
alkaline phosphatase (CIP; M02905) and a Protein deglycosylation kit (P6039S) 
were both purchased from New England Biolabs Inc. (Hitchen, UK) and stored at 
4°C until use according to the manufacturer’s instructions. Recombinant human 
BDNF (rhBDNF) was purchased from Sigma-Aldrich and diluted to 2000ng/ml in 
PBS/BSA (0.1% v/v) and frozen. SOS1 (BML P3050001, Enzo Life Sciences) was 
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diluted in sterile PBS to achieve 500µM stock concentration which was stored at -
20°C until use. BDNF and SOS1 were diluted using culture medium or SFM to the 
desired concentration for application to cells, as with 187-1 and wiskostatin, when 
required. Antibodies used in this study are detailed in section 2.1.4. 
6.2.3. RNA isolation, RT-PCR and Gel Electrophoresis 
RNA was extracted from cultured cells and complementary DNA was generated in 
through reverse transcription as described in section 2.5.4. Primer sequences are 
shown in Table 2.3. The following cycling conditions were used: 94°C for 5 
minutes, then 34 cycles of 94°C for 30 s, 55°C for 40 s, 72°C for 60 s with a final 
extension of 10 minutes at 72°C. The products were run on a 2% agarose gel and 
visualised using SYBR safe.  
6.2.4. qPCR 
Amplifluor quantitation technology using gene specific primers (Table 2.4) and 
Uniprimer probes (Intergen, USA) in combination with a qPCR mastermix. The 
reaction was carried out in an ICycleIQ (Bio-Rad) with the following conditions: 
95°C for 15 minutes, followed by 60 cycles of 95°C for 20 s, 55°C for 30 s and 72°C 
for 20 s. GAPDH was amplified as a housekeeping gene and ΔΔCT analysis was 
used to analyse transcript expression. 
6.2.5. Protein extraction, SDS-PAGE and Western blotting 
Protein was extracted from HaCaT cells which were cultured in 6-well plates at 
varying levels of confluency using lysis buffer (15-50µl per well). Proteins were 
extracted as previously described (section 2.6) and used for SDS-PAGE. Proteins 
were transferred onto Immobilon® PVDF membranes (Merck Millipore, Watford, 
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UK) which were blocked and probed with primary antibodies and then incubated 
with the corresponding peroxidase conjugated secondary antibodies (1:1000), see 
section 2.1.4 for full details of antibodies used. Proteins were visualised using EZ-
ECL Kit (Biological Industries, Israel). The integrated density of the resulting bands 
following visualisation was measured using ImageJ to calculate the protein 
expression levels. 
In some experiments, cells or lysates were treated with regents to adjust the 
phosphorylation of proteins. Cultured cells were treated with 1mM sodium 
orthovanadate and 3mM hydrogen peroxide (Sigma-Aldrich) for 1hour to induce 
phosphorylation of proteins prior to protein extraction using the normal 
methodology. Protein lysates were treated with CIP to dephosphorylate protein 
extracts of or phosphorylating reagents prior to SDS-PAGE and Western blot. CIP 
was added directly to protein lysates (0.6uits per µg of protein) and incubated at 
37°C for 1 hour. Laemmli (Sigma-Aldrich, 1:1 dilution) was then added to the 
samples which were then processed for SDS-PAGE as normal through a 10-minute 
denaturation at 100°C and placed on ice until loading.  
For protein deglycosylation prior to SDS-PAGE and Western blot, a kit containing 
the necessary reagents was employed. 2µl of 10 x Glyc. Denaturing Buffer was 
added to 18µl volumes of protein lysate (containing approximately 50µg of 
protein) and the samples were denatured at 100°C for 10 minutes. 3µl of 10 
Glycobuffer 2, 5µl of 10% NP40, 15µl of H20 were added to each reaction mix. 5µl 
of Deglycosylation buffer was then added to each reaction mix and samples were 
incubated at 37°C for 1 hour 30 minutes. Appropriate controls were used for each 
stage of the deglycosylation process. 35µl of 2 x Laemmli buffer was then added 
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to each reaction mix and samples were loaded for used in SDS-PAGE and Western 
blot. 
6.2.6. Protein array 
HaCaT cells cultured in T75 flask were serum starved for 24 hours and then 
treated with 0.1µM wiskostatin or control medium for 1 hour. Cells were then 
washed with PBS and protein was extracted and measured using the protocol 
described in section 2.6.1.6. Samples were diluted to 4mg/ml and dispatched to 
Kinexus Bioinformatics, Vancouver for Kinexus™ Antibody Microarray analysis. 
The normalised protein expression data calculated along with %CFC values and z-
ratios were returned and examined. 
6.2.7. Immunofluorescence staining 
HaCaT cells were cultured in Millicell EZ 8-well chamber slides (Merck Millipore, 
Watford, UK) for 18hours at a variety of seeding densities. Cells were fixed in 
500µl of ice cold 100% ethanol at -20°C. Cells were permeabilised with 0.1% Triton 
X 100 for 1 minute (Sigma Aldrich) and then blocked in 7.5% donkey serum in PBS 
for 3 hours. Primary and secondary antibodies (1:500 for AlexaFluor antibodies 
and 1:1000 for DAPI) were prepared in blocking buffer and applied in volumes of 
150µl per well. Full details of the antibodies used in this study are given in section 
2.1.4. 
6.2.8. IHC 
Tissue samples from cohort 2 (described in section 2.3.1) collected from the 
wound edge of healing or non-healing chronic wounds. Tissue samples were 
frozen and sectioned into 7µm sections and mounted for IHC. 
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Immunohistochemical staining was carried out the avidin-biotin peroxidase 
technique described in section 2.2.5. Briefly, tissue sections were fixed in dried 
acetone blocked and then incubated in primary antibodies at 2µg/ml for 1 hour at 
room temperature. Full details of the antibodies used are found in Table 2.5. 
Sections were then incubated in secondary antibodies and processed for 
visualisation. Tissues were visualised at x 20 magnification and the intensity and 
localisation of staining was qualitatively graded blindly by two independent 
people. 
6.2.9. ECIS 
Z-theta ECIS instruments (Applied Biophysics Inc., NJ, USA) were used to 
electrically monitor coverage of gold electrodes by cells on the base of 96W1E+ 
arrays by measuring the resistance 4kHz. 4 x 104 cells/well were seeded in normal 
culture medium containing treatments or vehicle controls. At least 3 replicate 
wells per treatment/control were used. Cells were constantly monitored following 
seeding for up to 20 hours. The resistance data was normalised by division to the 
first time point after seeding and analysed for statistical significance between the 
groups using 2-way ANOVA analysis using GraphPad Prism. 
6.2.10. Statistical analysis 
Statistical analysis was carried out using GraphPad Prism software using t-tests or 
2-way ANOVA where appropriate. Each experiment was performed at least three 
times unless stated otherwise and data is generally presented as the mean of 
repeats normalised to the control, unless stated otherwise. Results from ECIS 
assays are presented as representative data. Error bars show standard deviation. 
A p-value of less than 0.05 is considered statistically significant. 
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6.3. Results 
6.3.1. Protein signalling changes following wiskostatin treatment 
To begin to examine the protein signalling changes that take place in HaCaT cells 
in response to nWASP inhibitor treatment, a protein array experiment was carried 
out. Protein samples from cells treated for 1 hour in 0.1µM wiskostatin were 
analysed and the % change from control (%CFC) of hundreds of phosphorylation 
sites and total protein levels was measured. The most significantly decreased 
protein signals based on the z-ratio are presented in Figure 6.2. 
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Figure 6.2: Protein signalling changes in response to wiskostatin treatment. The most significantly decreased changes in total protein expression or of 
particular phosphorylation sites in response to 0.1µM wiskostatin treatment for 1 hour according to the z-ratio are shown. Distinction has been made 
between total protein changes (where a pan-specific antibody has been used) and changes to expression at a protein phosphorylation site. 
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A full description of the changes in protein expression or phosphorylation of the 
most significantly increased or decreased signals according to the z-ratio (i.e. -1.96 
< z-ratio < 1.96) is found in Table 6.1. Amongst the most significantly increased or 
decreased proteins, several membrane-bound proteins and receptors were 
identified and are highlighted in grey. These include integrin-a4, EGFR, VEGFR2, 
VEGFR3 and the Progesterone Receptor. Many of these membrane proteins and 
receptors have been characterised and their common signalling pathways are well 
understood. Several of the other protein signals highlighted in Table 6.1 are well-
known signalling molecules, many of which have been shown to act downstream 
of some of the highlighted receptors such as members of the MAPK/ERK family. 
The most significantly decreased protein signal is of PKC which exhibited a %CFC 
of -95% in wiskostatin treated cells compared with the control cells. 
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6.3.2. Wiskostatin treatment affects TrkB signalling in HaCaT 
cells 
Following the identification of several signalling and receptor proteins that are 
affected by wiskostatin treatment through the protein array study, further 
investigation into molecules and signalling pathways of interest was carried out. 
The phosphorylation and expression of receptors was of particular interest, 
especially of those known to be upstream of the signalling molecules highlighted 
in Figure 6.2 and Table 6.1. Through further experiments to examine the protein 
signalling changes following 0.1µM wiskostatin treatment, TrkB signalling was 
found to be significantly affected by inhibitor treatment as is described in the 
following sections. 
6.3.2.1. TrkB phosphorylation at tyrosine 816 is affected by 
wiskostatin treatment 
Screening of protein samples from cells treated with 0.1µM wiskostatin, 
compared with control samples, was carried out using a selection of different 
antibodies in order to highlight any resultant changes in protein expression or 
phosphorylation. Western bot analysis using protein extracts from HaCaT cells 
treated with 0.1µM wiskostatin or control medium following 4 hours of serum 
starvation highlighted that TrkB phosphorylation at tyrosine 816 (Y816) is 
significantly down-regulated in wiskostatin treated samples (p=0.0011, n=3), 
Figure 6.3A.  
This signal was lost in samples treated with CIP, a reagent which removes 
phosphorylation from protein samples, whereas no effect on total protein 
expression was seen in the actin positive control bands, Figure 6.3A. This 
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demonstrates that this signal, detected using the ABN1381 TrkB Y816 antibody, is 
a phosphorylation signal as intended. Furthermore, no significant difference 
between the TrkB Y816 phosphorylation in samples from wiskostatin and control 
treated cells that had been exposed to hydrogen peroxide and sodium 
orthovanadate was detected, Figure 6.3B. This suggests that the differential 
expression of TrkB Y816 that is detected between wiskostatin and control treated 
samples is due to a change in the phosphorylation of TrkB at tyrosine 816 not due 
to a change in total protein. This is supported by data from the protein array study 
described in section 6.3.1 which demonstrated that no significant change in TrkB 
total protein was detected between 0.1µM wiskostatin treated cells and the 
control samples. TrkB total protein was found to have a 23% CFC with a z-ratio of 
0.27 which is not deemed significant, Figure 6.3D. The integrated density 
measured over three independent repeats of these experiments were calculated, 
normalised to the expression of the housekeeping genes and then presented as 
the change in TrkB Y816 phosphorylation in wiskostatin treated cells from the 
controls, Figure 6.3C. 
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Figure 6.3: TrkB Y816 phosphorylation is affected by wiskostatin treatment. 
HaCaT protein samples from cells at ~35% confluency which had been serum 
starved for 4 hours and treated with 0.1µM wiskostatin, or appropriate controls, 
were used for Western blotting and probed for TrkB Y816 and housekeeping 
genes (actin or GAPDH). Protein samples were treated with CIP at 0.6units/µg for 
1 hour (A). Cells were treated with 1mM sodium orthovanadate and 3mM 
hydrogen peroxide for 1 hour prior to protein extraction (B). Integrated densities 
were measured over 3 independent repeats of the experiments and presented as 
a change from the control (C). Globally normalised expression of total TrkB 
protein in control and wiskostatin treated cells and %CFC according to protein 
array analysis is shown (D). 
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As shown in figure 6.3, tyrosine 816 phosphorylation of TrkB is affected by 
wiskostatin treatment. However, some concerns that needed to be addressed 
were highlighted in these experiments. Firstly, the clear band that is detected 
during Western blotting using the phospho-specific antibody ABN1381 for TrkB 
Y816 was visualised at approximately 180kDa. From the literature and antibody 
data sheet it is expected that the TrkB protein is usually detected between 110-
145kDa. Furthermore, use of TrkB pan-specific antibodies yielded no band at 
180kDa which corresponds with the strong signal detected using the TrkB Y816 
antibody.  
6.3.2.2. TrkB is expressed in HaCaT cells and is glycosylated 
In order to explain the larger-than-expected band observed in the Western blot 
results shown in Figure 6.3, experiments were initially carried out to validate that 
TrkB is expressed in the HaCaT cell line and then to explore whether the TrkB 
protein may exist in a glycosylated state. 
PCR was initially carried out on HaCaT wild type cDNA to investigate whether TrkB 
was expressed at a transcript level. TrkB was found to be expressed in HaCaT cells 
at the transcript level as shown in Figure 6.4A. 
Following the confirmation that TrkB is expressed at a transcript level in the 
HaCaT cell line, further experiments were carried out to determine why the 
observed band size using western blot for TrkB Y816 was at 180kDa, higher than 
expected based on the literature, and why no corresponding band size could be 
seen using TrkB-pan antibodies. HaCaT protein samples were treated with 
deglycosylation reagents for 0, 1, 2 or 4 hours and then Western Blot using TrkB-
pan antibodies was carried out, Figure 6.4B. After 1 hour of deglycosylation 
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treatment, TrkB expression could be detected at ~140kDa using a TrkB-pan 
antibody, whereas no signal could be detected without deglycosylation treatment. 
This signal was not detectable using the usual, previously described protein 
extraction and denaturation techniques (section 2.6.1) which did not include a 
deglycosylation step. This experiment shows that TrkB is in fact expressed in 
HaCaT cells but was not previously detected using ABN6180 TrkB antibody due to 
glycosylation which may have blocked access of the antibody to the target site.  
Having shown that TrkB is present in HaCaT cells with a size of ~140kDa following 
deglycosylation, it was hypothesised that the TrkB Y816 signal should shift size 
from ~180kDa to ~140kDa after deglycosylation. Protein samples collected from 
HaCaT cells treated with 0.1µM wiskostatin/vehicle control were denatured and 
treated with deglycosylation reagents for 1 hour and then probed for TrkB-Y816 
and actin as positive control using Western Blot. Following deglycosylation 
treatments, there was an obvious shift in the size of the protein detected using 
the TrkB Y816-specific antibody from ~180kDa to ~140kDa, Figure 6.4C. No 
significant change in the level of phosphorylation of Y816 was observed following 
deglycosylation but the reduced phosphorylation at Y816 in wiskostatin treated 
cells compared with the control was still apparent, as has been shown previously 
Figure 6.3A. This experiment demonstrates that TrkB is glycosylated in HaCaT cells 
causing the observed band size in Western blot to be larger than has been shown 
previously in the literature. 
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Figure 6.4: TrkB is expressed in HaCaT cells and is heavily glycosylated. PCR was 
used to examine TrkB transcript expression in the HaCaT cell line (A). Protein 
extracts from HaCaT cells were treated with denaturation and deglycosylation 
reagents. Deglycosylation of samples from wild-type, untreated cells was carried 
out for 1, 2 or 4 hours and followed by Western blot using a TrkB pan antibody 
(B). The denaturation and deglycosylation reagents (‘deglyc. mix’) and also protein 
samples collected using normal protein extraction and denaturation techniques 
(‘Laemmli’) as previously described were also used for Western blot analysis. Actin 
was used as a positive control. Samples from cells treated with 0.1µM wiskostatin 
or control medium (after a 4hour serum starvation) were denatured and then 
deglycosylated for 1 hour then Western blot was used to examine TrkB Y816 
activity with actin as a positive control (C).  
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6.3.2.3. The TrkB signalling pathway is affected by confluency, 
serum availability and nWASP inhibitor treatment in HaCaT cell 
Having identified that wiskostatin treatment can alter the phosphorylation of TrkB 
at tyrosine 816 in HaCaT cells, investigation into other protein signals that are 
related to the TrkB pathway was carried out. The effect of the additional nWASP 
inhibitor 187-1 over a range of concentrations (0, 0.1, 1 and 10µM) on TrkB 
phosphorylation and signalling was also examined (Figure 6.5). The Y816 
phosphorylation site on TrkB is known to be the binding site for PLCγ1 (Gu et al., 
2015) and TrkB activation is known to be upstream of Erk1/2 signalling (Slack et 
al., 2005). As such the effect on PLCγ1 phosphorylation at tyrosine 1253 and 
Erk1/2 was studied following 1 hour 0.1µM wiskostatin or a range of 187-1 
treatments after a 4-hour serum starvation period. The results of these 
experiments mirrored those observed at the TrkB Y816 site in that nWASP 
inhibitor treatment significantly decreased the phosphorylation of TrkB Y816 and 
PLCγ1 Y1253, and the expression of Erk1/2, Figure 6.5A. This effect on TrkB Y816 
signalling was only observed at 10µM 187-1 concentrations. No effect on nWASP 
expression was found. The integrated density from three independent repeats of 
this experiment was analysed and normalised to the control values to show that 
under these conditions PLCγ1 Y1253 phosphorylation and Erk1/2 expression were 
significantly decreased in wiskostatin treated cells (Figure 6.5B). No significant 
different in PLCγ1 Y1253 phosphorylation between wiskostatin and control cells 
following hydrogen peroxide and sodium orthovanadate treatment was detected, 
Figure 6.5C. This suggests that the differential phosphorylation of PLCγ1 Y1253 
that is detected between wiskostatin and control treated samples is due to a 
change in the phosphorylation of status of PLC γ1, not due to a change in total 
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protein. This is supported by Western blot analysis using PLCγ1 pan antibodies, 
also shown in Figure 6.5C. Immunofluorescence studies also confirmed the effect 
of nWASP inhibitors causing a decrease in TrkB Y816 expression, Figure 6.5D. The 
TrkB Y816 signal is observed intensely at the cell membranes in control cells but 
following nWASP inhibitor treatment this signal is visibly reduced. 
Inconsistencies in the observations of the change in TrkB Y816 phosphorylation in 
the HaCaT cell line prompted investigation into the effect of confluency and 
serum availability on the activation of this pathway and under what conditions 
nWASP inhibitors affected TrkB signalling. HaCaT cells were serum starved for 0, 2 
and 4 hours and then treated with 0.1µM wiskostatin for 1 hour. The 
phosphorylation of tyrosine 816 on the TrkB protein appeared to develop over 4 
hours, Figure 6.6A. As such, the effect of inhibiting TrkB Y816 phosphorylation 
following wiskostatin treatment is evident after serum withdrawal. 
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Figure 6.5: The TrkB signalling pathway is affected by nWASP inhibitor treatment. Figure legend on following page.
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Figure 6.5: The TrkB signalling pathway is affected by nWASP inhibitor 
treatment. Western blot analysis of TrkB Y816, PLCγ1 Y1253 and Erk1/2 using 
protein extracts from HaCaT cells which were serum starved for 4 hours and then 
treated for 1 hour with 0.1µM wiskostatin or 10µM 187-1 is shown (A). The 
integrated density was calculated and normalised to the control values (B). Cells 
were treated with 1mM sodium orthovanadate and 3mM hydrogen peroxide for 1 
hour prior to protein extraction and analysed for PLCγ1 Y1253 expression and also 
PLCγ1 pan expression following 0.1µM wiskostatin treatment for 1 hour (C). 
Immunofluorescence analysis of TrkB Y816 phosphorylation in HaCaT cells serum 
starved for 4 hours and treated with nWASP inhibitors, or appropriate controls, 
for 1 hour (D). Arrows indicate high intensity of TrkB Y816 signalling. Scale bar 
represents 100µm. 
 
 
Figure 6.6: The TrkB signalling pathway in HaCaT cells is affected by serum 
starvation. TrkB Y816 and PLCγ1 Y1253 signalling is more pronounced in control 
cells after serum starvation and is inhibited by wiskostatin treatment at 0.1µM for 
1 hour.  
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Further investigation into the effect of confluency on TrkB signalling and how this 
is affected by nWASP inhibition demonstrated that TrkB Y816 phosphorylation, 
which is evident after 4 hours of serum starvation, is also influenced by seeding 
densities in HaCaT cells, Figure 6.7. At low seeding densities of 2 x 105 cells per 
well of a 6-well plate, the phosphorylation of Y816 on TrkB is clearly visible after 
4-hour serum starvation and is decreased in wiskostatin treated cells as has been 
demonstrated numerous times previously in this study. However, under the same 
conditions but at higher seeding densities of 7- or 10- x 105 cells per well, this 
signal is decreased, so much that it is not visible on blots when visualised on the 
same blot as the signal from low seeding densities. However, the TrkB Y816 signal 
at higher seeding densities can be detected despite the comparably low 
expression and is found to show contrasting results to those from cells at low 
confluency. TrkB Y816 in cells seeded at 8 x 105 cells/ml (800,000 cells per well) is 
increased in nWASP inhibitor treated cells, Figure 6.7. 
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Figure 6.7: The effect of nWASP inhibition on TrkB signalling varies according to 
confluency in HaCaT cells. TrkB Y816 and PLCγ1 Y1253 signalling is evident in 
control cells at low confluency levels (2 x 105 cells per well seeding density) and is 
inhibited by wiskostatin treatment at 0.1µM for 1 hour, cells are serum starved 
for 4 hours (A). Scale bar represents 400µm in images demonstrating seeding 
densities. TrkB Y816 signalling at 8 x 105 cells/ml seeding density following 4-hour 
serum starvation and in response to 1 hour 0.1µM wiskostatin (W) or 10µM 187-1 
treatment is also shown (B). GAPDH is used as a positive control. 
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6.3.2.4. BDNF is linked to TrkB signalling and functional changes 
in HaCaT cells 
BDNF is the putative ligand of the TrkB receptor. Following the discovery of a 
relationship between serum availability and signalling of TrkB through tyrosine 
816, examination of BDNF and its activity in and effect on HaCaT cell signalling 
and behaviour was examined. 
BDNF and TrkB transcript expression was examined using PCR and qPCR in HaCaT 
cells under 0, 2 and 4-hour serum starvation periods and also with and without 
0.1µM wiskostatin treatments for 1 hour, Figure 6.8. Analysis of the band 
intensities resulting from conventional PCR revealed that BDNF expression 
decreases according to serum starvation in HaCaT cells (n=2, Figure 6.8A). QPCR 
analysis was also performed and the results were normalised to the 0-hour serum 
starvation value (Figure 6.8B) and also to the controls to compare with 0.1µM 
wiskostatin treated samples (Figure 6.8C). BDNF is expressed in HaCaT cells under 
normal, serum-supplemented culture conditions but following serum withdrawal 
the expression of BDNF transcript is significantly reduced, as was observed 
through conventional PCR. Treatment with 0.1µM wiskostatin appeared to have a 
slight effect on reducing BDNF transcript expression during normal culture 
conditions and also on increasing BDNF expression following serum starvation in 
qPCR analysis (Figure 6.8C). This change was very small though and not found to 
be significant through conventional PCR analysis. TrkB transcript expression was 
found to increase following serum withdrawal according to qPCR analysis - 
significantly so after 4 hours compared with the controls (Figure 6.8D). 0.1µM 
wiskostatin has no effect on TrkB transcript under normal culture conditions but 
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after 2 hours, TrkB expression was found to increase when cells were treated with 
wiskostatin (Figure 6.8E). This finding will need further repeats to be validated. 
Further investigation into the effect of BDNF on TrkB signalling in HaCaT 
keratinocytes was carried out. Under normal serum conditions, where cells were 
cultured under normal culture conditions with no serum withdrawal, TrkB Y816 
phosphorylation is relatively low, as previously shown in Figure 6.6. The addition 
of BDNF to HaCaT cells growing at low confluency under these conditions induces 
TrkB Y816 signalling, n=1, Figure 6.9. After serum starvation, where TrkB Y816 
phosphorylation increases (Figure 6.6), the addition of BDNF appears to reduce 
TrkB Y816 signalling in a similar fashion to nWASP inhibitor application, Figure 6.9. 
The results of this experiment have been shown to be variable though so will need 
to be repeated for confirmation. 
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Figure 6.8: BDNF and TrkB transcript expression in HaCaT cells. PCR and qPCR 
analysis of BDNF and TrkB transcript expression in HaCaT cells treated with 0.1µM 
wiskostatin or appropriate controls after 0, 2 or 4-hour serum starvation. Bands 
resulting from PCR for BDNF are shown (A). qPCR data was normalised to 0h 
serum starvation time point for control treated samples (B) or according to the 
control samples to compare with wiskostatin treated samples at each serum 
starvation time point (C). qPCR analysis of TrkB transcript expression was also 
carried out in HaCaT cells serum starved over 0, 2 and 4 hour periods normalised 
to 0h for control treated samples (D) or to the control samples over each time 
point (E). qPCR data was analysed using ΔΔCT method with 4 replicated per 
samples, n=1. Mean normalised transcript + SD shown. Significance analysed using 
t-test and is represented using * = p<0.05, etc. or ‘ns’ where no significance is 
found. 
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Figure 6.9: The effect of BDNF on TrkB Y816 phosphorylation. The effect of 
rhBDNF at 100ng/ml for 1 hour treatment period on TrkB phosphorylation at Y816 
under normal culture conditions and following serum starvation is shown through 
Western blot analysis. Representative data is shown. 
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In some cases, the addition of nWASP inhibitors appears alongside BDNF is found 
to increase the phosphorylation of TrkB at Y816 compared with the control 
samples which only received BDNF treatments. This is in contrast to previously 
reported findings that BDNF and nWASP inhibitors separately cause a reduction in 
TrkB Y816 phosphorylation at low confluency and low serum conditions. However, 
these results are very inconsistent and as such warrant further investigation and 
haven’t been presented here. 
The effect of BDNF treatment on HaCaT cell behaviour using ECIS to monitor cell 
attachment and spread was examined. The addition of BDNF between 50 and 
150ng/ml concentrations increased the resistance measured at 4kHz following cell 
seeding, Figure 6.10A and B. This suggests that BDNF may be able to increase the 
attachment and spreading behaviour of HaCaT cells in a similar way to that 
observed following the addition of nWASP inhibitors (see Chapter 4). The effect of 
dual treatments with 0.1µM wiskostatin and 50ng/ml or 100ng/ml BDNF was also 
observed (Figure 6.10C and D respectively). No significant different between the 
resistance of the wiskostatin and BDNF treated cells was observed which may 
suggest these reagents affect cell behaviour in the same way or potentially 
through the same pathway. 
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Figure 6.10: The effect of BDNF and wiskostatin on cell behaviour during ECIS. 
HaCaT cells seeded at 4 x 105 cells per well in a 96W1E+ ECIS array were 
electrically monitored using the measurement of resistance at 4kHz. Cells were 
treated with rhBDNF, or control medium, at 50 and 100ng/ml (A) and 150ng/ml 
(B) and monitored for up to 18 hours following seeding. Cells treated with 50 and 
100ng/ml BDNF were also treated with 0.1µM wiskostatin (C and D respectively). 
Significant differences in the resistance of the control and treated wells, analysed 
using 2-way ANOVA tests, are demonstrated by * = p<0.05, etc. Mean normalised 
resistance ±SD is plotted, at least n=3 replicate wells used. 
247 
 
6.3.2.5. nWASP inhibitor treatment may affect TrkB signalling 
through Grb2 
In an attempt to explore how nWASP inhibitors may be able to alter the 
phosphorylation status of TrkB, the effect of SOS1, a small molecule inhibitor 
which acts to inhibit the activity of Grb2, on TrkB Y816 was examined. Grb2 is a 
molecule which has been shown to have physical interactions with both TrkB and 
nWASP through interactions with its SH2 and SH3 domain respectively. SOS1 acts 
to inhibit its activity by blocking the SH3 binding site on SOS, a Grb2 interactor 
that mediates downstream signalling in the Ras pathway. SOS1 treatment at 0.1 
and 1 µM concentrations inhibits TrkB Y816 phosphorylation in HaCaT cells at low 
confluency and serum-starved conditions, Figure 6.11. This pattern is very similar 
to that seen following nWASP inhibitor treatment as shown in previously. Further 
to this, the addition of nWASP inhibitors appears to work in synergy with SOS1 on 
the inhibition of TrkB Y816 phosphorylation. However, results from experiments 
using both nWASP inhibitors and SOS1 together are very inconsistent as with 
findings using BDNF and nWASP inhibitor described above. As such results from 
these experiments have not been presented here as they warrant further 
experiments to fully elucidate the effect of dual inhibition with SOS1 and nWASP 
inhibitors. 
248 
 
 
 
 
Figure 6.11: The effect of SOS1 on TrkB Y816 phosphorylation. The effect of SOS1 
at 0,0.1 and 1µM concentrations for 1 hour treatment periods on TrkB 
phosphorylation at Y816 following 4-hour serum starvation periods is shown 
through Western blot analysis (A). The integrated density was normalised to the 
control values by division and the mean normalised integrated density + SD over 3 
independent repeats of this experiment is shown (B). Statistical analysis was 
carried out using t-tests and is represented by * = p<0.05, etc. 
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The effect of SOS1 on HaCaT cell behaviour during ECIS was briefly examined 
(n=1). SOS1 treatments appears to encourage the attachment and spreading 
behaviour of HaCaT cells following seeding as shown by the increase in resistance 
measured at 4kHz compared with the control wells, Figure 6.12. This is a similar 
result to the effect of BDNF and nWASP inhibitor treatments which have 
previously been discussed. The effect of dual inhibition using SOS1 and nWASP 
has not been explored. 
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Figure 6.12: The effect of SOS1 on cell behaviour during ECIS. HaCaT cells seeded 
at 4 x 105 cells per well in a 96W1E+ ECIS array were electrically monitored using 
the measurement of resistance at 4kHz. Cells were treated with SOS1, or control 
medium, at 1µM and 3.6µM and monitored for 15 hours following seeding. 
Significant differences in the resistance of the control and SOS1 treated wells, 
analysed using 2-way ANOVA tests, are demonstrated by * = p<0.05, etc. Mean 
normalised resistance ± SD is plotted, at least n=3 replicates used, representative 
data shown. 
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6.3.3. nWASP knockdown and TrkB signalling 
The effect of nWASP knockdown on TrkB signalling in HaCaT cells was examined. 
Cells at a seeding density of 2 x 105 cells/ml were serum starved for 4 hours as 
previously described and the effect on TrkB Y816 and PLCγ1 Y1253 
phosphorylation was then examined using Western blotting, Figure 6.13A. This 
experiment was only carried out once so further repeats would need to be carried 
out to validate the results of this experiment. nWASP knockdown was found to 
increase TrkB signalling through tyrosine 816 under serum starved and low 
confluency conditions. These findings contrast with previously reported work 
using wiskostatin and 187-1 nWASP inhibitors. To explore whether the disparities 
in these findings may be due to a difference in the length of time that nWASP 
activity is affected, TrkB Y816 activity was examined following prolonged nWASP 
inhibitor and serum starvation for 4 hours. These results (n=1) demonstrated that 
nWASP inhibitor treatment had the same effect of inhibiting TrkB Y816 
phosphorylation even when applied from the beginning of the serum withdrawal 
period, Figure 6.13B. 
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Figure 6.13: The effect of nWASP knockdown and prolonged nWASP inhibition 
on TrkB Y816 phosphorylation. The effect of nWASP inhibition following 4-hour 
serum starvation in HaCaT cells seeded at 2 x 105 cells/ml on TrkB 
phosphorylation at Y816 through Western blot analysis is shown (A). The effect of 
nWASP inhibitors (0.1µM wiskostatin and 10µM 187-1 or appropriate vehicle 
controls) on TrkB Y816 phosphorylation in HaCaT cells seeded at 2 x 105 cells/ml 
following 4 hour treatments in serum-free medium is also shown (B). 
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6.3.4. TrkB expression in human chronic wound tissues 
Following the discovery of a link between nWASP and TrkB and the finding that 
nWASP is overexpressed in human non-healing chronic wounds, the expression of 
TrkB in chronic wounds was examined using IHC on human chronic wound 
samples. TrkB was found to be expressed at higher levels in the basal epidermal 
cells at sites distal from the wound edge in samples taken from non-healing 
wound tissues compared with healing tissues, Figure 6.14. 
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Figure 6.14: TrkB expression in human chronic wound tissues. IHC analysis of 
TrkB protein expression in healing and non-healing human chronic wound tissues. 
Arrows indicate areas of high intensity staining. Two representative images of 
each group are shown. x20 magnification used. 
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6.4. Discussion 
To begin to understand how nWASP inhibitors affect cell behaviour and may act in 
the context of a chronic wound, investigation into the effect of altering nWASP 
activity on the signalling mechanisms in cell models that represent the skin and 
wound environment needs to be examined. This study has focussed mainly on 
models of cells types involved in the proliferation and reepithelialisation stages of 
wound healing: HaCaT keratinocytes and HECV vascular endothelial cells. The 
HaCaT cell model was chosen as the main focus for this chapter to begin 
examining the effect of nWASP inhibition on affected protein signalling pathways 
in keratinocytes. 
Initially, a protein array experiment was carried out which highlighted changes in 
the expression and phosphorylation of hundreds of kinases and other common 
signalling proteins following treatment with the nWASP inhibitor wiskostatin in 
HaCaT cells. Of the most significantly altered proteins, several belonging to very 
common signalling pathways were highlighted, including members of the Ras-Raf-
Mek-Erk, Akt-mTOR and Jak-STAT pathways. Numerous receptors and membrane 
bound proteins were also identified as being significantly altered by wiskostatin 
treatment, including VEGFR2 and 3, EGFR and the progesterone receptor which 
have been shown to be upstream some of these common signalling cascades. 
Previous studies have highlighted connections between nWASP and the control of 
signalling and trafficking of receptors such as EGFR (Galovic et al., 2011), which 
was found to have significantly altered activity in the result of the protein array. 
Due to the known function of nWASP at the cell membrane and possible 
interactions with membrane bound receptors and trafficking, further 
investigations into other receptors that may be affected by wiskostatin was 
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carried out, especially towards those known to be upstream of the common 
signalling pathways already mentioned. Through Western blot studies, TrkB 
signalling was found to be significantly altered by nWASP inhibitor treatments in 
HaCaT cells and as such, the effect of nWASP activity on TrkB signalling became 
the focus of this chapter. 
nWASP inhibitor treatment was found to significantly alter the phosphorylation of 
TrkB at tyrosine 816. Difficulties detecting TrkB total protein using a TrkB-pan 
antibody in keratinocyte protein extracts, and previous reports that full length 
TrkB was not detected in keratinocytes (Marconi et al., 2003), combined with the 
TrkB Y816 signal being detected at ~180kDa, higher than expected from the 
literature, raised concerns about whether the observed changes to TrkB Y816 
were in fact from changes to the TrkB protein. Deglycosylation experiments 
enabled the detection of TrkB at the expected size using a pan-specific antibody 
(ABN6180) which targeted a site that coincides with a common glycosylation site 
at Asn67 (Haniu et al., 1995, Liu et al., 2005). Furthermore, a clear change in the 
size of the TrkB Y816 signal to around 140kDa following deglycosylation, and that 
TrkB is expressed at a transcript level in HaCaT cells, supports the novel finding 
that full-length TrkB is expressed in HaCaT keratinocytes and is glycosylated. 
Further investigation into the expression and activity of TrkB in other keratinocyte 
models and cell types needs to be examined to fully understand the importance of 
this neurotrophin receptor in skin cell behaviour and signalling. 
Once TrkB expression was confirmed in HaCaT cells, the effect of nWASP 
inhibitors on TrkB signalling and on the activity of proteins known to be 
downstream of the TrkB receptor was examined. Tyrosine 816 on TrkB is known 
to be the putative binding site for PLCγ1 and phosphorylation of this protein at 
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Y1253 was also found to be affected by nWASP inhibitor treatment with the same 
pattern of phosphorylation mirrored in TrkB and PLCγ1. Erk1/2 activity was also 
found to be downregulated, another signalling molecule known to be 
downstream of TrkB. The effect on TrkB and PLCγ1 total protein was not found to 
be significantly affected by wiskostatin treatment. An increase in TrkB total was 
detected in the microarray study and Western blotting but this was not 
significant. 
This observed effect of nWASP inhibitors wiskostatin (0.1µM) and 187-1 (10µM) 
altering the signalling at Y816 on TrkB was found to be very sensitive to culture 
conditions. Firstly, confluency was found to have a profound effect on TrkB 
signalling with phosphorylation being extremely high at low confluency levels and 
being reduced following nWASP inhibitor treatment. However, at high confluency 
of more than 2 x 105 cells/ml seeding densities, the phosphorylation of TrkB is 
relatively low in the control cells. It is still visible at higher exposure levels but 
appears to have a variable response to nWASP inhibitor treatment with increased 
levels being detected. This finding needs to be confirmed with strictly controlled 
experimental conditions though to fully explore the effect of TrkB Y816 signalling 
in response to confluency and nWASP inhibition. Secondly, serum availability was 
also found to have a significant effect on TrkB signalling and BDNF expression in 
HaCaT keratinocytes and nWASP activity was found to influence TrkB signalling in 
a serum starvation dependent manner. Due to the clear phosphorylation of TrkB 
Y816 found at low confluency, further investigation into the effect of inhibitor 
treatment and serum availability were carried out at 2 x 105 cells/ml seeding 
density. TrkB Y816 phosphorylation was found to develop after serum starvation 
with cells under normal culture conditions in 10% FBS supplemented medium 
showed relatively low levels of TrkB Y816 phosphorylation. As such, the effect of 
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nWASP inhibitor treatment on reducing TrkB Y816 phosphorylation was 
increasingly evident after 2- and 4-hour serum starvation.  
Interestingly, BDNF transcript expression was also found to be significantly 
decreased following serum starvation whereas TrkB transcript expression was 
slightly increased. Wiskostatin treatment did not appear to have a consistent 
significant effect on the transcript expression of TrkB or BDNF but further repeats 
of this experiment need to be carried out to further explore this. It is unclear 
whether the withdrawal of serum influences BDNF transcript expression as a 
result of TrkB signalling in a possible feedback loop, or vice versa, or neither. 
There seems to be an inverse correlation between the decreasing BDNF transcript 
expression following serum withdrawal and the transcript expression and 
phosphorylation of TrkB Y816. BDNF was found to increase TrkB Y816 signalling 
under normal, serum-supplemented conditions (n=1) but following serum 
starvation, BDNF (100ng/ml) treatment decreased the phosphorylation of TrkB at 
Y816. Again, this finding was often found to be inconsistent though. Parallels can 
also be drawn between the effect of BDNF and nWASP inhibitors on cell 
attachment and spreading according to ECIS, as with their effect on TrkB Y816 
signalling. BDNF is also shown to increase the resistance of HaCaT cells following 
seeding, as with nWASP inhibitors. Dual treatments with nWASP inhibitors and 
BDNF does not seem to have any further effects on cell behaviour as measured by 
ECIS. As such, it is suggested that BDNF and wiskostatin may be acting through the 
same pathways to have comparable effects on cell behaviour but further 
investigation to validate this theory needs to be carried out.  
In neurons, BDNF has been shown to be a pro-survival protein during 
development and involved in synaptic plasticity and long-term potentiation (Poo, 
259 
 
2001, Cohen-Cory et al., 2010, Almeida et al., 2005). BDNF has also been shown to 
stimulate mobilisation of synaptic vesicles and disrupt cadherin-β-catenin 
interactions in neurons (Bamji et al., 2006). BDNF and TrkB have also been 
suggested to be involved in neuron mechanosensitivity (Carroll et al., 1998) as 
well as many more functions in neuronal cells and development. Perhaps these 
functions of BDNF and TrkB signalling in neuronal cells could hint to the 
underlying mechanisms being affected in the HaCaT keratinocyte model used in 
this study. However, as previously discussed, the role of BDNF and TrkB in the 
function of skin cells is unclear and so whether the functions of this neurotrophin 
and its receptor are somewhat conserved in keratinocytes and neurons is yet to 
be explored. This study has shown that BDNF can stimulate phosphorylation of 
TrkB at tyrosine 816 in HaCaT keratinocytes, as is seen in neuronal cells 
(Rantamaki et al., 2007). However, this study has also highlighted numerous 
factors which can subtlety affect TrkB signalling and BDNF expression in 
keratinocytes, such as confluency and serum availability, which have not 
previously been described in other cell types. This could suggest a completely 
different method of regulation of TrkB signalling in these cells and perhaps 
completely diverse functions. Inversely, due to the profound effect of nWASP 
activity on TrkB signalling in keratinocytes shown in this study and the known 
activity of nWASP in neural cell types, a large area of future study has been 
identified where the relationship between nWASP and TrkB in the context of 
neuronal development and function could be explored. 
nWASP knockdown in HaCaT cells did not show the expected effect on TrkB Y816 
phosphorylation based on the inhibitor studies. nWASP knockdown cells exhibited 
increased TrkB Y816 phosphorylation compared with the control cells in low 
confluency, 4-hour serum starved cells. These contrasting results could indicate 
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several findings. It is possible that nWASP inhibitors may have unanticipated off-
target effects on other protein interactions, perhaps through the conformational 
changes to nWASP in its inhibited state, that could have an effect on the cells. This 
has already been discussed in Chapter 4 as a possible explanation for the 
sometimes-contrasting responses to inhibitors at different concentrations and in 
different cell types and could also be responsible for the differences observed 
between knockdown and inhibitor-treated cells. Alternatively, the level of nWASP 
activity as a result of knockdown may be significantly more than in inhibitor 
treated cells.  This is possible as high levels of nWASP inhibitor treatments has 
been shown to have similar effects to knockdown, which both contrast with low 
levels of nWASP inhibitors, through examining the functional behaviour of cells 
using ECIS, as discussed in chapter 4. This experiment was only carried out once so 
the effect of nWASP knockdown will need to be examined again to confirm the 
findings and explain the outcome.  
Serum starvation as a factor that affects TrkB Y816 phosphorylation and is 
sensitive to nWASP inhibition is interesting considering that serum availability has 
been shown to be a factor that can control keratinocyte differentiation (Borowiec 
et al., 2013). Furthermore, PLCγ1-PKC signalling, which has been shown to be 
altered in keratinocytes under serum starved conditions and through nWASP 
inhibition, has been implicated in keratinocyte differentiation (Tu and Bikle, 2013).  
Additionally, in neuronal cells, TrkB signalling pathways have been shown to 
control differentiation (Kaplan et al., 1993) and TrkB and other neurotrophin 
receptors have been shown to be important in dermal fibroblast differentiation 
into myofibroblasts (Palazzo et al., 2012). In healing wounds, keratinocytes are 
required to undergo carefully controlled switches from a proliferative phenotype 
to differentiating one. In chronic wounds, cells fail to differentiate effectively and 
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sustain a proliferative phenotype as well as exhibiting impaired migration 
(Wikramanayake et al., 2014). In chronic wounds which healed in the 12-week 
period following tissue collection, TrkB expression was found to be low in basal 
cells, the epidermal cells which are actively involved in the proliferation and 
reepithelialisation stage of wound healing. However, in basal cells of non-healing 
chronic wounds, TrkB expression was relatively high. This suggests that TrkB 
activity may be related to the behaviour of basal keratinocytes in non-healing 
wounds, perhaps through the control of keratinocytes differentiation which is 
critical for successful reepithelialisation. This is supported by nWASP is also known 
to have aberrant expression in chronic wound tissues with transcript levels 
significantly higher in non-healing tissues suggesting a further potential parallel 
between nWASP and TrkB signalling. This chapter has shown that nWASP activity 
can alter TrkB activity. Perhaps these two molecules are linked in the control of 
keratinocyte cell behaviour and hence the healing of chronic wounds. However, 
the exact cell type in which nWASP activity is aberrant within chronic wounds is 
unknown. A previous study has already highlighted BDNF in the control of dermal 
fibroblast contractility and of TrkB in fibroblast differentiation (Palazzo et al., 
2012) and BDNF has also been shown to be elevated in serum and skin levels of 
patients with chronic spontaneous urticaria, an inflammatory skin problem 
(Rossing et al., 2011). Neurotrophin signalling in the context of skin function and 
the wound healing environment and how nWASP may regulate/affect it has 
therefore been highlighted in previous work and by this study as an area of 
research that may offer interesting findings in the future.  
Clear down falls in this piece of work are highlighted by the difficulties using TrkB 
pan antibodies to examine the dynamics of TrkB total protein under serum-
stressed, varying confluencies and following BDNF and nWASP inhibitor 
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treatment. Although it has been shown that TrkB total protein is not significantly 
affected by wiskostatin treatment, transcript expression is shown to increase 
under serum starvation which may affect the protein signalling changes. The role 
of nWASP in receptor and vesicle endocytosis, for instance in PDGF internalisation 
in fibroblasts (King et al., 2011) and of EGFR (Galovic et al., 2011), also highlights a 
possible role of nWASP in the recycling, degradation or trafficking which could be 
affecting TrkB signalling. Immunofluorescence studies show that although TrkB 
Y816 signalling is reduced following nWASP inhibitor treatment in HaCaT cells, 
there is increasing accumulation inside the cells rather than at the cell membranes 
in the control cells. This could be indicative of an effect of nWASP activity on TrkB 
trafficking/localisation, in contrast to previous reports which demonstrate that 
nWASP depletion in neurons doesn’t interfere with BDNF-TrkB endocytosis (Xu et 
al., 2016). 
The findings that have been reported here appear to demonstrate that TrkB 
activity in HaCaT cells is extremely sensitive to confluency, serum starvation, 
BDNF application and nWASP inhibition. Furthermore, TrkB activity is found to be 
increased in basal keratinocytes in chronic wounds tissues. How TrkB, BDNF and 
nWASP activity may be linked in the context of chronic wounds requires 
significant further investigation especially considering the sensitivity to factors 
such as confluency and serum availability of the TrkB pathway. The novel 
relationship between nWASP and TrkB and the downstream PLCγ1 signalling 
pathway that is affected by changes in signalling may have implications in terms 
of cell differentiation.  As such further investigation into the factors that affect 
this signalling and how this may translate into the wound environment needs to 
be explored. 
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It is clear that nWASP and TrkB signalling are linked in HaCaT cells and possibly in 
the chronic wound environment. How nWASP activity alters TrkB signalling and 
why this pathway is sensitive to factors such as confluency and serum starvation 
are yet to be answered. Considering the known role of nWASP in endocytosis and 
receptor trafficking (Takenawa and Suetsugu, 2007) and that receptor 
recycling/degradation appears to be a regulatory mechanism for TrkB 
(Sommerfeld et al., 2000), this is suggested as one possible link. nWASP and TrkB 
have been shown to share numerous interaction partners which may facilitate this 
activity, for instance, Grb2, pacsin and Nck (see Figures 1.5 and 6.1). A link 
between nWASP and TrkB through the common binding partner Grb2 has begun 
to be explored in this chapter through the use of SOS1. This is an inhibitor of Grb2 
activity which acts through blocking the SH3 binding domain of the guanine 
nucleotide exchange factor SOS, the ligand for the adaptor protein Grb2. This 
blocks the SOS/Grb2 interaction and prevents Ras activation via receptor tyrosine 
kinases such as TrkB. SOS1 was found to act in the same way as nWASP inhibition 
in that TrkB Y816 phosphorylation was significantly reduced at low confluency and 
after 4-hour serum starvation in HaCaT cells. Similarly, Grb2 inhibition was found 
to increase the resistance of HaCaT cells using ECIS, similarly to nWASP inhibitors. 
Grb2 has been implicated in numerous activities in the cell that overlap with the 
known roles of nWASP including endocytosis (Jiang et al., 2003, Sorkin and Duex, 
2010). This is clearly not conclusive and is only the first step in exploring the link 
between TrkB and nWASP but this work has highlighted Grb2 as a possible 
mediator for the control of TrkB signalling through nWASP activity and has 
identified an avenue for further study. 
This study is the first to highlight a direct influence of nWASP inhibitors on TrkB 
signalling in keratinocytes. Clearly there is a complex network of signalling 
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molecules at work here with changes to the system including confluency, serum 
availability, ligand application and nWASP inhibition affecting the signalling of 
TrkB in HaCaT cells. This study has only highlighted that this signalling pathway 
may be important in the control of cell behaviours and that it may have a role in 
wound healing. A lot of questions remain unanswered. A lot more research into 
the activity of TrkB in HaCaT cells and other skin cell types needs to be carried out 
to examine how these proteins are important for the function of cells and what 
signalling mechanisms are in place to affect these cell behaviours. 
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Chapter 7: The role of 
nWASP in lung cancer 
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7.1. Introduction 
Lung cancer is one of the most commonly diagnosed cancers accounting for 13% 
of total cases worldwide (Jemal et al., 2011). It is also one of the leading causes of 
cancer death globally with survival rates much lower in patients diagnosed with 
distal metastases (Siegel et al., 2015, Edwards et al., 2014). This highlights the 
importance of understanding the mechanisms involved in lung cancer metastasis 
and considering how molecular pathways involved in this process could form 
novel potential therapeutic targets. 
The critical initial steps in lung cancer metastasis involves the detachment and 
invasion into the surrounding tissues of tumour cells which requires changes to 
their adhesive and migratory properties (Steeg, 2006). This is achieved partly 
through cell polarisation and the extension of actin-rich membrane structures in 
the direction of movement such as filopodia, lamellipodia or invadopodia which 
are found in invasive cancer cells. Focal adhesions on the leading edge of these 
protrusions connect the actin cytoskeleton in the migrating cells to their 
surroundings through the coordination of numerous signalling and structural 
proteins, such as integrins, focal-adhesion kinase (FAK) and paxillin, allowing them 
to gain traction and move (Mierke, 2013). The formation of membrane 
protrusions, which are crucial for cell motility, is controlled by the rearrangement 
of the actin cytoskeleton (Ridley et al., 2003, Linder et al., 2011, Insall and 
Machesky, 2009, Ridley, 2011, Buccione et al., 2004).  
As previously described, nWASP is a 65kDa cytoplasmic protein which responds to 
several cellular signalling molecules to mediate actin polymerisation through 
interactions with the Actin-related protein 2/3 (Arp2/3) complex. When inactive, 
nWASP exists in an auto-inhibited, folded confirmation whereby the main 
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catalytic domain, the VCA domain on the C-terminus, is shielded by the N-
terminus regions. Signalling molecules, such as the small GTPase Cdc42, bind to 
and activate nWASP by destabilising the auto-inhibited state and exposing the 
VCA region allowing interactions with the Arp2/3 complex which, when bound to 
nWASP in conjunction with an actin monomer, becomes activated and actin 
polymerisation can be initiated (Takenawa and Suetsugu, 2007, Rohatgi et al., 
1999, Kim et al., 2000, Prehoda et al., 2000, Takenawa and Miki, 2001). Through 
this role, as a reorganiser of the actin cytoskeleton, nWASP has been implicated in 
the control of many cellular processes such as vesicle trafficking, pathogen 
infection and neurite extension to name a few. However, more interestingly with 
respect to cancer studies, nWASP has been shown to be involved in changes to 
cell morphology, such as invadopodium formation, growth and also correlates 
with certain cancer phenotypes. Hence, nWASP has been highlighted as a 
potential therapeutic target in a range of contexts, particularly in the control of 
cancer progression (Takenawa and Suetsugu, 2007, Takenawa and Miki, 2001, 
Frugtniet et al., 2015, Fernando et al., 2009, Albiges-Rizo et al., 2009, Kurisu and 
Takenawa, 2010, Yamaguchi et al., 2005, Murphy and Courtneidge, 2011, Wegner 
et al., 2008, Snapper et al., 2001). 
In light of the findings presented in the earlier chapters of this study, namely that 
nWASP is a key regulator of cell adhesion and spreading and potential therapeutic 
target in chronic wounds, in combination with the underlying similarities in the 
biological processes of wound healing and cancer progression, it was also one of 
the aims of this project to investigate the role of nWASP in the function of lung 
cancer cells. Therefore, the primary aim of this chapter is to explore the role and 
therapeutic potential of targeting nWASP with reference to lung cancer. This is 
achieved by examining the activity of nWASP in human lung cancer tissues and by 
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studying the effects of the nWASP inhibitor wiskostatin (Peterson et al., 2004) on 
lung cancer cell behaviour, with particular focus towards migratory, invasive, 
adhesive and proliferative properties.  
7.2. Materials and Methods 
7.2.1. Tissue collection and processing 
Fresh frozen lung carcinoma tissues with matched normal tissues, were obtained 
from 150 patients who received curative resection in Peking University Cancer 
Hospital. Ethical approval was provided by hospital’s Ethics Committee. Tissues 
were stored in the Tissue Bank of Peking University Oncology School. Tissues were 
sectioned on a cryostat (Leica, Microsystems Ltd.) at 20µm thickness and 
processed for RNA extraction. 
7.2.2. Cell lines and culture conditions 
A-549 and SK-MES-1 cells were routinely cultured in DMEM as described in 
section 2.4. 
7.2.3. siRNA transfection 
Cells were seeded in a 24-well plate in serum-free DMEM (no antibiotics) at 2 x 
105 cells/well. After 24 hours, cells were transfected with 0.17µg (0.5µg/ml) 
nWASP siRNA (sc36006, Santa Cruz Biotechnology Inc., USA), or non-targeting 
siRNA (NT), delivered in antibiotic free DMEM supplemented with 5% FBS with 1µl 
Lipofectamine 3000 reagent (ThermoFisher Scientific, MA, USA) per well. 24 hours 
following treatment with siRNA/NT, cells were then used for RNA/protein 
extraction or functional assays where normal culture medium was used. 
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7.2.4. Genomic DNA extraction, RNA isolation and cDNA 
synthesis 
GDNA and RNA isolation from tissue samples and cell lines was carried out using 
Tri reagent (Sigma-Aldrich, Dorset, UK) according to the manufacturer’s 
instructions. The final RNA or gDNA samples were quantified using a 
spectrophotometer (WPA UV 1101, Biotech, Cambridge, UK) and then 
standardised. Reverse transcription of RNA was carried out to produce cDNA 
using GoScript™ Reverse Transcription kit (Promega, Madison, USA). 
7.2.5. QPCR 
QPCR was performed as previously described (section 2.5.6) to quantify the level 
of nWASP transcripts in the samples (shown as copies/μl from internal standard 
normalised to housekeeping gene actin) which was then and correlated with 
patient’s pathological and clinical information. 
7.2.6. PCR and Gel Electrophoresis 
PCR was carried out using the following cycling conditions: 94°C for 5 minutes, 
then 32 cycles of 94°C for 30 s, 55°C for 40 s, 72°C for 60 s with a final extension of 
10 minutes at 72°C. Primers used in this study are detailed in Table 2.3. Full 
protocol detailed in sections 2.5.5 and 2.5.7. 
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7.2.7. Reagents and treatments 
Wiskostatin (Enzo Life Sciences, Exeter, UK) was dissolved in 30% dimethyl 
sulfoxide (DMSO, Sigma-Aldrich) in normal cell culture medium to a stock 
concentration of 300µM.  
7.2.8. Protein extraction, SDS-PAGE and Western blot 
Lysis buffer was used to extract protein from cells which was then used for SDS-
PAGE. Proteins were transferred onto Immobilon® PVDF membranes (Merck 
Millipore, Watford, UK) which were blocked and probed with primary antibodies 
and then incubated with the corresponding peroxidase conjugated secondary 
antibodies (1:1000). Proteins were visualised using EZ-ECL Kit (Biological 
Industries, Israel). 
7.2.9. In vitro growth assay 
Cells were seeded into a 96-well plate with appropriate treatments at a density of 
3,000 cells in each well with 10 replicates per treatment. After 1, 2, and 3-day 
incubation periods, cells were fixed and stained using crystal violet. 
7.2.10. In vitro cell adhesion assay 
8 x 105 cells, which had been incubated overnight in treatments, were seeded 
onto pre-plated Matrigel basement membrane in 200μl of normal medium 
containing treatments with at least 6 replicates per sample and incubated for 25 
minutes. Adherent cells fixed, stained and visualised under the microscope at x5 
magnification. 
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7.2.11. In vitro scratch wounding assay 
7 x 105 cells were seeded in appropriate treatments into each well on a 24-well 
plate with at least 3 replicates per experiment. Upon reaching confluence the 
monolayer was scratched and cells were imaged every 30 minutes in an EVOS® FL 
Auto Imaging System (Life Technologies, Paisley, UK). 
7.2.12. ECIS 
Z-theta models of the ECIS (electric cell-substrate impedance sensing) instruments 
(Applied Biophysics Inc., NJ, USA) were used to electrically monitor coverage of 
gold electrodes on the base of a 96W1E+ arrays by measuring the capacitance at 
64 kHz. The plate was stabilised and 8 x 104 cells/well were seeded in treatments 
where appropriate. At least 4 replicate well were used for each sample in every 
experiment. An electrical wound was applied after 35 hours with settings: 20 
seconds, current of 2400μA and frequency of 60,000Hz.  
7.2.13. Cytodex-2 bead motility assay 
Cells were incubated at a density of 7 x 105 cells/ml in normal culture medium, 
containing 100μl of cytodex-2 beads (Sigma-Aldrich at 20mg/ml in BSS), for 4 
hours to allow the cells to adhere to the beads. Following washes, 100μl of the 
cell/bead suspension was added to a 96-well plate and incubated for 18 hours in 
treatments with 6 replicates. Cells which had migrated from the beads to the 
plate were fixed, stained and counted according to absorbance as above. 
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7.2.14. In vitro invasion assay 
Cell culture inserts (0.8μm pore ThinCert™ 24-well plate inserts, Greiner Bio-One 
GmbH, Austria) were placed into a 24-well plate and coated with Matrigel 
basement membrane matrix (BD Biosciences) at 50μg/ml in normal culture 
medium. Cells were seeded into inserts at a density of 3 x 104 cells per insert in 
200μl containing treatments with 3 replicates. After 3 days, cells which had 
invaded through the Matrigel and migrated through the pores on the inserts were 
fixed, stained and counted according to absorbance as above. 
7.2.15. Immunofluorescence staining 
Cells were cultured in Millicell EZ 8-well chamber slides (Merck Millipore, 
Watford, UK) for 18hours at a seeding density of 5 x 104 cells per well. Cells were 
fixed in ice cold 100% ethanol and permeabilised with 0.1% Triton X 100 (Sigma 
Aldrich). Primary and secondary antibodies are detailed in tables 2.5 and 2.6. 
7.2.16. Statistical analysis 
Statistical analysis of patient qPCR data was performed using SPSS software (SPPS 
Inc.). The relationship between nWASP and patient clinicopathological 
information was assessed using student’s unpaired t-tests. Multivariate analysis 
was carried out using Minitab. Survival curves were produced and analysed using 
the Kaplan-Meier method and Wilcoxon (Gehan) statistics. Other data are 
presented as mean ± SD. Each experiment was conducted at least 3 times and 
representative data are presented. Unpaired t-tests and 2-way ANOVA tests were 
used to statistically analyse other experimental data. A p-value < 0.05 over at least 
3 independent repeats was considered statistically significant. 
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7.3. Results 
7.3.1. nWASP expression correlates with patient survival 
Multivariate analysis and Kaplan-Meier survival curve analysis of various lung 
cancer clinicopathological groups versus survival demonstrated that TNM staging 
and nodal status significantly correlates with patient survival, as expected, Table 
7.1, Figure 7.1B, C. nWASP transcript levels in tumour samples are also shown to 
be a factor that correlates with patient survival, with survival significantly lower in 
patients which exhibit high levels of nWASP expression, Figure 7.1A and Table 7.1. 
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Figure 7.1: Survival of lung cancer patients according to clinicopathological 
parameters. Survival is significantly lower in patients that exhibit high nWASP 
expression in tumours (p=0.01) (A). Survival correlates with TNM staging 
significantly (p-0.001) (B). Survival is significantly lower in patients which exhibit 
nodal activity compared with node negative patient tumour samples (p=0.008) 
(C). 
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Table 7.1: Multivariate analysis of lung cancer categories against overall 
survival. Multivariate analysis was carried out to examine clinicopathological 
parameters against overall survival of the patients. TNM staging was found to be 
significantly linked to patient survival as is expected (p=0.007). Likewise, nodal 
involvement was found to be related to overall survival (p=0.007). nWASP 
expression is also significantly linked to patient survival (p=0.003). 
Variables F value P value 
 Tumour type 0.293 0.590 
Differentiation 0.481 0.490 
Nodal status 7.778 0.007 
TNM staging 7.737 0.007 
nWASP 9.546 0.003 
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7.3.2. nWASP expression correlates with lung cancer 
clinicopathology 
Higher levels of nWASP transcript were detected in squamous carcinoma and 
adenocarcinoma tumour tissues compared with small-cell carcinoma tumour 
samples, Figure 7.2A. nWASP also correlated with lymph node involvement and 
TNM stage with node positive samples having significantly higher levels of nWASP 
expression than node negative samples, Table 7.2 and Figure 7.2B, C. 
7.3.3. nWASP expression in lung tumour tissues and relationship 
with patient smoking habits 
nWASP expression appears to correlate with patient smoking habits with long-
term smokers that have a smoking habit of 20-40 years showing increased nWASP 
levels compared with patients who have smoked for less than 20 years, Table 7.2, 
Figure 7.2D. 
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Figure 7.2: nWASP expression in lung tumour clinical samples. nWASP transcript 
levels normalised to actin according to clinicopathological information. nWASP 
transcript levels are higher in both squamous and adenocarcinoma tumours 
compared with small-cell carcinoma samples (p = 0.18 and p = 0.052 respectively) (A). 
nWASP is expressed at significantly higher levels in tumour tissues which exhibit nodal 
activity compared with lymph node-negative tumours (p=0.042) (B). nWASP transcript 
expression increases according to tumour grade, p=0.094 for TNM1 vs. TNM3 (C). 
nWASP expression is higher in lung tumours where patients have a long-term smoking 
habit. Mean ± SEM are shown (D). 
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Table 7.2: Levels of nWASP transcripts in lung tumour tissues. Mean nWASP 
transcript expression normalised to actin, SEM and number of patients in category 
is shown. Expression is presented according to tumour type, level of 
differentiation, nodal involvement, tumour stage and patient smoking habit. 
Category N nWASP level (mean) SEM 
Tumour Type 
Squamous carcinoma 51 32.6 23 
Adenocarcinoma 68 32.1 15.3 
Small-cell carcinoma 3 1.615 0.886 
Differentiation 
High 7 42.8 42.6 
Medium High 16 18.84 9.69 
Medium 50 45.8 25.1 
Medium/low 23 35.5 30.1 
Low 16 5.13 3.78 
Nodal status 
Negative 70 8.37 2.9 
Positive 62 62.3 25.7 
TNM staging 
stage-1 39 3.12 1.33 
stage-2 31 32.8 23.4 
stage-3 52 48 26.2 
Period as smoker 
<5 years 2 0.57724 0.0007 
5-10 years 6 7 6.39 
10-20 years 19 0.521 0.217 
20-30 years 29 47.4 30.6 
30-40 years 21 49.0 35.9 
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7.3.4. Characterisation of A-549 and SK-MES-1 lung cancer cell 
lines  
Since nWASP transcript expression is elevated in adenocarcinoma and squamous 
carcinoma cell lines (Figure 2A), A-549 and SK-MES-1 cell lines were selected as 
models of these lung cancer sub-types respectively in order to examine the role of 
nWASP in lung cancer cell behaviour. Before experiments commenced using these 
cell lines, they were validated using STR profiling. Examining the STR profile of SK-
MES-1 and A-549 lung cancer cell lines revealed that the results matched the 
expected outcome from the STR profile database (see Table 2.2), Figure 7.3A and 
B respectively. Therefore, further experiments could be carried out with peace of 
mind knowing the identity of these cells. 
7.3.5. Knockdown of nWASP in A-549 and SK-MES-1 cell lines 
nWASP siRNA was used to significantly knockdown nWASP after 24 hours at gene 
transcript level, Figure 7.4B. This knockdown is still found 48 hours after 
treatment and is shown at both gene and protein level as demonstrated by qPCR, 
PCR (Figure 7.4A, C) and Western blot (Figure 7.4D, E). 
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Figure 7.3: Validation of SK-MES-1 and A-549 cell lines. SK-MES-1 (A) and A-549 (B) lung carcinoma cell lines were validated through examination of the 
STR profile through PCR. Expected band sizes of the STR sites for each cell line can be found in Table 2.2. 
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Figure 7.4: Generation of nWASP knockdown cell lines. A-549 and SK-MES-1 cells 
were treated with nWASP siRNA/non-targeting siRNA (NT) at 0.5µg/ml and then 
analysed for nWASP expression after 24 and 48 hours. (A) QPCR analysis of nWASP 
transcript expression demonstrates a significant decrease in expression in siRNA 
treated cells after 48 hours, n=4 replicates. (B, C) PCR also demonstrates a decrease in 
nWASP expression in siRNA treated cells 24 and 48 hours after treatment, 
respectively. (D) Quantitative analysis of Western blots (n=4) shows significant 
decrease in nWASP protein expression in both A-549 and SK-MES1 cell lines after 
48hours siRNA treatment. (E) Representative image showing knockdown of nWASP at 
protein level in siRNA treated cells at 48hours. 
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7.3.6. MTT analysis of wiskostatin and 187-1 in lung cancer cell 
lines 
In order to examine the effect of nWASP inhibitors on the inhibition of growth in 
both lung cancer cell lines used in this study, and to aid in the selection of 
inhibitor concentrations to use for further functional assays using these cell types, 
MTT analysis was carried out. In vitro MTT assays using a range of nWASP 
inhibitor treatments showed that wiskostatin has a dose dependent effect on 
inhibiting cell growth in both A-549 and SK-MES-1 cells over a 92-hour incubation 
period, Figure 7.5A, B respectively. Sigmoidal dose-response curves were used to 
calculate the IC50, the concentration of wiskostatin that is required to achieve 50% 
growth inhibition compare with the growth of the untreated cells, for each 
independent experiment. The mean IC50 over the three independent experiments 
was calculated and used to estimate the IC50 for each cell type. The IC50 values 
were calculated at 6.2µM in SK-MES-1 cells and 10.2µM in A-549 cells. These 
results suggest that nWASP inhibition is inhibitory to lung cancer cell growth in a 
dose-dependent manner and that nWASP may be more important for the 
proliferation of the squamous carcinoma SK-MES-1 cells, rather than in the 
adenocarcinoma A-549 cells due to the lower comparative IC50 value. 
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Figure 7.5: The effect of wiskostatin on the inhibition of growth in A-549 and SK-
MES-1 cells. Representative growth inhibition curves from MTT assays using A-
549 cells (A) and SK-MES-1 cells (B) treated with wiskostatin show that wiskostatin 
has a dose dependent effect on inhibiting cell growth over a 92-hour incubation 
period. The IC50 of wiskostatin in SK-MES-1 cells was lower, at 6.2μM, than in A-
549 cells, which had an IC50 of 10.2µM. 
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7.3.7. ECIS analysis of A-549 and SK-MES-1 cells following 
wiskostatin treatment 
ECIS analysis of A-549 and SK-MES-1 cell lines following wiskostatin treatment at 
10µM showed that the capacitance following seeding was significantly increased 
compared with the controls in both cell lines, Figure 7.6A, C respectively. This 
suggests that the initial attachment and spreading behaviour of these cells is 
impaired by nWASP inhibition. This impairment in the initial attachment and 
spreading of both cell types may also be influenced by the decrease in 
proliferation which is found in nWASP inhibitor treated cells (section 7.3.6). The 
influence of cell proliferation over this shorter time-scale (up to 24 hours) and at 
the higher seeding density used for ECIS assays will minimise the influence from 
cell proliferation and is discussed later in this chapter (section 7.3.9). Following an 
electrical wounding, SK-MES-1 cells are found to have a significantly increased 
capacitance following nWASP inhibitor treatment, Figure 7.6D. No significant 
difference between the capacitance of the wiskostatin treated and control A-549 
cells is detected, Figure 7.6B. This suggests that the invasive/migratory capacity of 
SK-MES-1 cells following an electrical wounding is impaired by nWASP inhibition 
but not in A-549 cells. 
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Figure 7.6: The effect of wiskostatin on A-549 and SK-MES-1 cell behaviour 
monitored using ECIS. (A) Wiskostatin treatment significantly increases the 
capacitance of A-549 cells following seeding. (B) No significant effect is detected 
following wounding in A-549 cells. (C) Wiskostatin also causes a significant 
increase in capacitance following seeding in SK-MES-1 cells. (D) A significant 
increase in capacitance is also detected in SK-MES-1 cells following an electrical 
wounding in wiskostatin treated cells. Significant differences between samples are 
represented by * (p<0.05), etc. over the appropriate time points. 
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7.3.8. ECIS analysis of nWASP knockdown A-549 and SK-MES-1 
cells following an electrical wounding 
ECIS analysis of the healing of an electrical wound using A-549 and SK-MES-1 
nWASP knockdown cell lines demonstrates that capacitance is significantly 
increased in both cell lines following siRNA treatment, Figure 7.7A, B respectively. 
Figure 7.7C shows that nWASP knockdown is still present in both cell lines 96 
hours after siRNA treatment, the time period over which the ECIS assay takes 
place. 
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Figure 7.7: The effect of nWASP knockdown on A-549 and SK-MES-1 cell 
behaviour monitored using ECIS. nWASP knockdown causes a significant increase 
in capacitance following an electrical wounding in A-549 and SK-MES-1 cells (A, B 
respectively). (C) PCR using A-549 and SK-MES-1 nWASP knockdown cells 
following ECIS demonstrates that decreased nWASP expression in siRNA treated 
cells is still present at 96 hours compared with cells treated with the non-targeting 
control siRNA. Significant differences between samples are represented by * 
(p<0.05), etc. over the appropriate time points. 
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7.3.9. nWASP affects in vitro growth of lung cancer cells 
10µM wiskostatin treatment was seen to significantly inhibit cell growth over 3 
days in vitro in both A-549 and SK-MES-1 cells according to the absorbance, Figure 
7.8A, B respectively. Growth appeared to be affected by nWASP inhibition more 
so in SK-MES-1 cells where cell number according to absorbance was significantly 
reduced after 24 hours, whereas only after 48 hours is a significant effect on the 
inhibition of growth observed in A-549 wiskostatin-treated cells. This effect on 
growth was also shown in nWASP knockdown A-549 and SK-MES-1 cell lines, with 
a significant difference in absorbance detected over 3 days, Figure 7.8C, D 
respectively. 
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 Figure 7.8: nWASP activity affects A-549 and SK-MES-1 cell growth. Growth 
according to absorbance at 540nm is shown over 1, 2 and 3 days. (A, B) nWASP 
inhibition using 10µM wiskostatin treatment significantly impairs the growth of A-549 
and SK-MES-1 cells, respectively. (C, D) A significant effect on growth is also evident 
after 3 days in nWASP knockdown A-549 and SK-MES-1 cells, respectively, when 
compared to non-targeting control treated cells. Mean ± SD shown, n=10 replicates. 
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7.3.10. In vitro motility, migration and adhesion of A-549 
cells are reduced following wiskostatin treatment 
Motility and migration in A-549 cells was seen to be significantly reduced 
following 10µM wiskostatin treatment according to the number of motile cells, 
measured according to the absorbance following crystal violet staining of cells in a 
cytodex-2 motility assay, and the rate of scratch wound closure, Figure 7.9B, C 
respectively. Although motility was consistently reduced, no significant difference 
in motility or migration was found between wiskostatin treated and control SK-
MES-1 cells, Figure 7.9B, C. Example images taken during the closure of a scratch 
wound in A-549 and SK-MES-1 cells treated with wiskostatin are shown in Figure 
7.10. The level of adhesion, according to the cell coverage in the images captured 
of adherent, crystal violet-stained cells, was consistently reduced in both cell 
types when treated with wiskostatin; however this finding was only consistently 
significant in A-549 cells, Figure 7.9A. 
7.3.11. In vitro invasion of SK-MES-1 cells is affected by 
wiskostatin treatment 
The invasive capacity of A-549 and SK-MES-1 cells was reduced following 
wiskostatin treatment according to the number of invasive cells, measured by 
absorbance, Figure 7.9D, but only significantly over all repeats with SK-MES-1 
cells. Representative images of inserts following invasion assay are shown in 
Figure 7.10. ECIS experiments support this finding where the capacitance is 
increased significantly in SK-MES-1 nWASP knockdown and wiskostatin treated 
cells following electrical wounding, Figure 7.7B and Figure 7.6D respectively. 
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Figure 7.9: In vitro effect of wiskostatin on A-549 and SK-MES-1 invasion, 
adhesion, motility and migration. (A) Wiskostatin treatment impairs the ability of 
A-549 and SK-MES-1 to adhere to a Matrigel basement membrane over a 25-
minute period although only with significance in the former cell line. (B) From 
cytodex-2 motility assays, A-549 cell motility found to be significantly impaired by 
wiskostatin treatment but SK-MES-1 motility is not significantly affected. (C) The 
rate of closure of a scratch wound is reduced in A-549 cells following wiskostatin 
treatment but no significant effect on the rate of migration is seen in SK-MES-1 
cells. (D) The capacity of A-549 and SK-MES-1 cells to invade through pores on a 
Matrigel lined insert is impaired by wiskostatin treatment but only significantly in 
SK-MES-1 cells. Representative data and mean ± SD shown. 
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Figure 7.10: Representative images from scratch and invasion assays. Representative images taken during the closure of a scratch wound using SK-MES-1 
and A-549 cells treated with 10µM wiskostatin compared with controls are shown in grayscale on the left of the figure. The right-hand panel are 
representative images of the base of the inserts used in the in vitro invasion assays where the pores (appear as small circles) and cells stained with crystal 
violet (blue) which have successfully invaded through the pores are shown. Images taken at x 20 zoom. 
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7.3.12. Focal adhesions are affected by nWASP activity 
Having identified that nWASP inhibitor treatment and knockdown can significantly 
impair several key functional behaviours of lung cancer cell models including 
attachment and spreading, invasion, adhesion, motility and migration, this study 
then examined the effect of nWASP inhibition and knockdown on proteins that 
have previously been implicated in these cell functions. Focal adhesion formation 
and turnover is critical for cell adhesion, migration and invasion as has been 
previously described and as such, the effect of nWASP inhibitors on several 
common focal adhesion proteins was examined. Paxillin activity was considerably 
altered following wiskostatin treatment and nWASP knockdown with fewer 
paxillin rich adhesions on the perimeter of the treated cells compared with the 
controls, Figure 7.11A. A decrease in paxillin activity which correlates with nWASP 
activity has also been shown through Western blot analysis of A-549 and SK-MES-
1 knockdown cells after 48 hours of siRNA treatment, Figure 7.12. Paxillin 
expression was quantified by measuring the integrated density and found to be 
significantly reduced in A-549 and SK-MES-1 siRNA treated cells compared with 
the non-targeting control treated cells, Figure 7.11B. This decrease in paxillin 
expression at the focal points on the cell periphery in cells where nWASP activity 
is reduced could explain the effect on cell behaviour that was observed earlier in 
this chapter. In addition, FAK activity was examined in response to nWASP 
knockdown. FAK and pFAK was reduced in A-549 nWASP siRNA treated cells 
compared with the control cell line, Figure 7.11A, C and Figure 7.12. FAK and pFAK 
(Tyr 925) levels seemed lower in SK-MES-1 cells and were not significantly 
affected by nWASP activity, Figure 7.11 A, B and Figure 7.12. 
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Figure 7.11: Protein changes in response to nWASP inhibition and knockdown. 
(A) Immunofluorescence staining for paxillin, FAK, pFAK and nWASP in response to 
nWASP knockdown and the effect on paxillin in wiskostatin treated A-549 and SK-
MES-1 cells. Arrows point to paxillin rich adhesions. (B, C) Quantitative analysis of 
immunofluorescence staining in A-549 and SK-MES-1 nWASP knockdown cells for 
paxillin and FAK respectively, (mean + SD, n=10 replicates). 
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Figure 7.12: Paxillin and FAK expression in nWASP knockdown lung cancer cell 
lines. Western blot demonstrating the effect on paxillin and FAK expression in 
response to nWASP knockdown (siRNA) and non-targeting control (NT) A-549 and 
SK-MES-1 cell lines. 
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7.4. Discussion 
Analysis of nWASP transcript expression highlights several interesting correlations 
between nWASP levels and clinical observations of lung cancer, particularly with 
phenotypes indicative of invasive and advanced cancers. Survival has been shown 
to correlate with TNM staging and nodal involvement as expected (Ries LAG, Last 
accessed online October 2016), with prognosis lower in patients with node 
positive and high TNM stage cancers. Additionally, nWASP activity has been 
shown to correlate with patient survival with significantly poorer prognosis for 
patients who are found to have high levels of nWASP transcript expression. 
Furthermore, nWASP transcript expression levels are shown to correlate with 
TNM stage and lymph node involvement highlighting nWASP as a potential 
biomarker of more aggressive lung cancers phenotypes. These findings suggest 
that nWASP may be involved in the invasion of cancer cells to the lymph nodes 
and the development of more advanced lung cancers, and hence has a significant 
correlation with patient survival. 
This study has demonstrated that nWASP levels in tumours may correlate with 
patient smoking habits. This is an interesting finding given that smoking is 
recognised as a factor related to lung cancer incidence and development. The 
results from this study infer that the elevated nWASP activity detected in tumours 
of patients who are long-term smokers may be related to the development of 
particular types of cancer that are more prevalent in tobacco users. 
nWASP levels are elevated in non-small cell carcinoma lung cancer tissues 
compared with small-cell carcinomas. As such, A-549 and SK-MES-1 cell lines were 
selected as models for the adenocarcinoma and squamous carcinoma lung cancer 
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sub types respectively in order to carry out further assays to investigate the role 
of nWASP in non-small cell lung cancer cell behaviour. 
Several in vitro studies were carried out to examine the effect of nWASP 
inhibition, using the agent wiskostatin, and knockdown, using siRNA, on the 
behaviour of the A-549 adenocarcinoma cell line and the SK-MES-1 squamous 
carcinoma cell line. Growth was significantly impaired in both lung cancer cell 
lines by nWASP inhibitor treatment and knockdown. Furthermore, invasion of SK-
MES-1 cell lines is significantly affected in both in vitro invasion assays and as 
shown through ECIS analysis where the healing of an electrical wound is impaired 
by nWASP inhibition and knockdown. This healing of an electrical wound is likely 
to require elements of invasion because following an electrical wounding the 
electrode is still covered by dead cells and cell debris. Wiskostatin appears not to 
have an effect on the invasion of A-549 cells in in vitro invasion assays but ECIS 
analysis using A-549 nWASP knockdown cells appears to demonstrate that nWASP 
activity does affect the invasive/migratory properties of A-549 cells following an 
electrical wounding. This difference could perhaps be because the inhibitor may 
not be fully effective on inhibiting nWASP in the cells after the length of the ECIS 
experiment or perhaps by a change in the attachment behaviour of the A-549 
cells, as shown in the Matrigel adhesion assay, which could account for the 
change in the capacitance. The motility and migratory properties of A-549 cells 
appear to be significantly impaired by nWASP inhibition. These properties are 
affected over short time periods of less than 24 hours, at which point no 
significant effect on A-549 growth following wiskostatin treatment is seen, so this 
effect on cell behaviour is considered to be independent of changes to cell 
proliferation. A reduction in the adhesive properties of both lung cancer cell types 
in response to nWASP inhibition was suggested too, although more significantly in 
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A-549 cells. This effect on the adhesive and spreading properties is also 
highlighted in both cell lines through ECIS. Together, these experimental results 
demonstrate that nWASP activity has a role in controlling the invasive and 
migratory behaviour of cancer cells, which is supported by previous studies 
(Frugtniet et al., 2015, Fernando et al., 2009, Albiges-Rizo et al., 2009, Kurisu and 
Takenawa, 2010, Yamaguchi et al., 2005), and that the response to nWASP 
inhibition is varied between the adenocarcinoma and squamous carcinoma cell 
lines used in this study. The differences observed in behaviour of these cells lines 
in response to nWASP inhibition and knockdown could be explained by the origins 
of the A-549 and SK-MES-1 cell lines. Squamous carcinoma cell types are more 
invasive and migratory compared with adenocarcinoma cells (Jang et al., 2012). It 
has been shown here that nWASP expression correlates with more advanced lung 
cancer phenotypes and in particular lymph node metastasis. As such, the effect of 
nWASP inhibition and knockdown on invasive cell behaviours may be more 
apparent in the more invasive SK-MES-1 squamous carcinoma cell line.  
A possible explanation for the effect on adhesion and other behaviours observed 
in the A-549 and SK-MES-1 cell lines following nWASP inhibition is provided 
through immunofluorescence studies. These demonstrate fewer paxillin rich 
adhesions are found on the periphery of both cell types following nWASP 
inhibition and knockdown. Paxillin is a key protein which localises to site of focal 
adhesions between the cell and its surroundings and an increase in paxillin 
signalling has been linked to enhanced metastatic potential (Rodina et al., 1999, 
Azuma et al., 2005, Turner, 2000). FAK activity, another molecule which forms and 
integral part of focal adhesions and has also been highlighted as a key molecule in 
lung cancer invasion and migration (Shen et al., 2012, Meng et al., 2009), is also 
affected by nWASP activity in A-549 cells. FAK phosphorylation at tyrosine 925, 
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which is decreased in nWASP knockdown A-549 cells, has also been implicated in 
the control of FAK-mediated cell migration and cell protrusion, further 
highlighting a role of nWASP in cell migration (Deramaudt et al., 2011). The 
observation of loss of paxillin and FAK activity following nWASP inhibition is 
therefore indicative of a reduction in invasive potential. Previous reports agree 
with this conclusion which implicates nWASP in the control of membrane 
protrusion formation and structure in cancer cells (Gligorijevic et al., 2012, Lorenz 
et al., 2004, Yu et al., 2012). Furthermore, nWASP has been linked to the activity 
of integrins in a number of contexts, including chemotaxis and contraction (King 
et al., 2011, Sturge et al., 2002, Zhang et al., 2007) which are critical in the sensing 
and coordination of cellular adhesion. This link with integrin activity highlights an 
avenue which can further be explored as a potential mechanism through which 
nWASP activity may affect focal adhesion protein expression and hence the 
functional changes observed in lung cancer cells in this study. This study has 
identified a possible link between nWASP and the control of focal adhesions but 
direct signalling mechanisms linking them in the context of lung cancer invasion 
are yet to be identified and require further investigation. 
The findings presented in this study suggest that nWASP inhibition in lung cancer 
cell types does in fact alter cell morphology with respect to the level of paxillin-
rich membrane structures the cells are able to produce. This is may be due to the 
role of nWASP in the organisation of the actin cytoskeleton. Since the importance 
of actin-rich membrane protrusions in cell movement and cancer invasion is well 
understood (Ridley, 2011, Insall and Machesky, 2009), it is clear that nWASP is a 
key molecule of interest with respect to controlling these cell behaviours. From 
the results of the functional assays it is even more apparent that nWASP activity is 
important in the control of cellular movement and, when considered alongside 
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findings showing elevated nWASP levels in metastatic and advanced stage lung 
cancer tissues, this study concludes that nWASP is a key molecule of interest with 
respect to lung cancer invasion.  
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Chapter 8: General 
Discussion 
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8.1. Study aims, key findings and future work 
Chronic wounds represent a significant problem for thousands of patients, who 
suffer with daily pain, difficulties with mobility and have a severe impact on the 
quality of life due to the ongoing nature of their wounds. The non-healing 
characteristics of these wounds means that patients need frequent dressing 
changes, contact time with healthcare professionals and treatments that are 
often ineffective and so healthcare systems are also under stress because of the 
problem of chronic wounds in the UK (Posnett and Franks, 2008). As such there is 
a pressing need to identify novel therapies to address the problem of chronic, 
non-healing wounds, a goal that this study has addressed. Through examining 
gene expression in chronic wound tissues, nWASP was identified as a novel 
therapeutic target which could affect the healing of chronic wounds. This study 
therefore examined the use of nWASP inhibitors and knockdown cell models to 
begin to elucidate the role of nWASP in the context of the skin and wounds. 
Although this study has taken the initial steps towards investigating the role of 
nWASP in the context of the skin and wound healing, many questions remain 
unanswered and many new avenues of future research have been uncovered. The 
main findings of this piece of work and areas that have been identified for future 
study have been summarised as follows. 
8.1.1. nWASP as a prognostic indicator and therapeutic target 
for chronic wound healing 
This study examined the transcript expression of nWASP in wound tissue samples 
from two cohorts of patients with venous leg ulcers. nWASP transcript expression 
was found to be significantly higher in non-healing chronic wound samples 
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compared with those that healed or reduced in size in the follow-up period after 
tissue collection. nWASP was therefore highlighted as a prognostic indicator for 
the healing of chronic wounds and as a potential therapeutic target to encourage 
healing of human chronic wounds. Chronic wounds can be classified into several 
categories including venous leg ulcers, diabetic foot ulcers and pressure ulcers 
and the occurrence of these wounds is often related to other conditions such as 
venous disease and diabetes. The physical symptoms and underlying molecular 
mechanisms of venous leg ulcers are very similar to other chronic wound types 
despite their differing underlying pathophysiology (Frykberg and Banks, 2015). 
Currently treatment strategies for these different wound types are also similar 
with debridement, dressing and compression being the standard practise. This 
study therefore highlighted nWASP as a novel marker of the healing behaviour of 
venous leg ulcers but also possibly of other chronic wound types. This is 
supported by the use of a diabetic mouse model, which is discussed later. 
However, examining the expression of nWASP in other wound types is important 
to understand whether the aberrant expression of nWASP in non-healing venous 
leg ulcers is conserved across all non-healing wounds. Furthermore, the wound 
environment is complex and contains many cell types which all have a role in the 
coordination of the wound healing process. The qPCR analysis which highlighted 
nWASP as a key molecule in the control of chronic wound healing does not allow 
analysis of the specific cell types which are exhibiting aberrant nWASP activity 
within the wound environment. As such, further spatial studies using 
immunohistochemical staining or other methods to explore nWASP protein 
expression in the various cell types present in chronic wounds needs to be 
explored in future studies. 
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8.1.2. nWASP activity alters the function of keratinocyte and 
vascular endothelial cells 
To examine how nWASP activity may be related to the healing behaviour of 
chronic wounds, the effect of nWASP inhibitors, wiskostatin and 187-1, and 
knockdown of nWASP, was examined in various cell models. HaCaT keratinocytes 
and HECV vascular endothelial cells were selected as cell models that represent 
those critical to the proliferation and reepithelialisation stage of wound healing, 
the stages that are impaired in non-healing wounds. The attachment and 
spreading of keratinocytes and the angiogenic behaviour of vascular endothelial 
cells was found to be significantly affected by changes to nWASP activity. The 
attachment and spreading behaviour of keratinocytes is critical for their function 
in reepithelialisation as attachment and spreading plays an important role in the 
process of cell migration (Parsons et al., 2010). The angiogenic behaviour of 
vascular endothelial cells is also vital for the progression of wound healing but the 
effect of nWASP microtubule formation and angiogenesis has not previously been 
studied in depth. However, the fact that these cell behaviours are affected by 
nWASP activity is unsurprising due to the known involvement of nWASP in control 
of the actin cytoskeleton and in cell morphology (Derivery and Gautreau, 2010) 
and hence motility which are all critical for the proper functioning of cells during 
migration and angiogenesis. The fact that nWASP activity can affect these cell 
behaviours may go some way towards explaining how altered expression of 
nWASP in chronic wounds can affect their healing. However, due to the complex 
nature of the wound healing process, it is unclear how the changes in cell 
behaviour detected through these in vitro assays will translate into the in vivo 
wound environment. Furthermore, the change in the function of the cell types 
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used in this study in response to varied nWASP inhibitor concentrations and 
knockdown was not consistent. This highlights why it is critical to understand 
what underlying signalling mechanisms are affected by the inhibitor treatments 
and how the signalling mechanisms may vary at different levels of inhibition in 
order to predict how nWASP inhibitors may affect cell behaviour in vivo. 
Additionally, as previously discussed in section 3.4, this study has been unable to 
demonstrate which cell types exhibit the aberrant nWASP expression in the 
patient chronic wound samples. As such, which cell types are responsible for 
wound chronicity and which will be the desired target for inhibitor treatment is 
unknown. nWASP has been shown to have roles in the function of numerous cell 
types involved in the skin function and wound healing process including B cells 
(Liu et al., 2013), hair follicle progenitor cells (Lyubimova et al., 2010) and 
fibroblasts (King et al., 2011). Further investigation into the effect of nWASP 
inhibitors on the function of other cell types that are critical in the wound healing 
process, particularly in cells involved in inflammation, should also therefore be 
done to further assess the possible effects of using nWASP inhibitors as potential 
wound healing therapies.  
8.1.3. nWASP inhibition effectively encourages wound healing in 
vivo 
To begin to investigate whether nWASP inhibitors represent a viable treatment 
option to encourage chronic wound healing in humans, this study employed a 
diabetic mouse model that exhibits an impaired wound healing phenotype to 
observe the effect of systemic and topical application of wiskostatin and 187-1 in 
vivo. Topical and systemic application of nWASP inhibitors was found to 
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encourage the healing of hole punch wounds in the ears in vivo without significant 
side effects. Topical application of nWASP inhibitors in a carrier gel as part of the 
routine dressing changes that patients with a chronic wound regularly undergo 
may be a viable treatment method which would not require significant changes to 
the current wound care system. One study has recently demonstrated that 
conditional nWASP knockout in mouse fibroblasts lead to keratinocyte 
hyperproliferation and enhanced wound closure (Jain et al., 2016) which supports 
the results from this in vivo work and the concept that nWASP inhibition may be 
able to encourage wound healing. This study by Jain et al. highlights the interplay 
between different cell types in wound healing and the importance of considering 
the effect of nWASP inhibitors on the whole wound environment when 
considering their use as a potential therapy for chronic, non-healing wounds, as 
has been done here. There were some drawbacks in the experimental design of 
this process as discussed in chapter 5 and as such, further in vivo studies should 
be carried out to confirm the effect of nWASP inhibitors on the healing of wounds 
in mice. Despite these, the promising findings resulting from this experiment 
supports the use of nWASP inhibitors as a potential therapy for the treatment of 
chronic wounds and agrees with previous studies (Jain et al., 2016) that indicate 
that nWASP activity can have significant bearing on wound healing in vivo. 
8.1.4. nWASP and TrkB activity are linked 
A novel link between nWASP activity and TrkB signalling has been highlighted in 
keratinocytes and could have a role in the control of keratinocyte behaviour in the 
chronic wound environment. TrkB signalling in HaCaT keratinocytes has been 
found to be incredibly sensitive to numerous factors including culture conditions 
and treatments with inhibitors of nWASP and Grb2 activity, and also BDNF. This 
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finding highlights several new areas of research which can be pursued. Elucidating 
how nWASP activity can alter the signalling of TrkB is the primary unanswered 
question that needs to be addressed. Whether this is through a shared interaction 
partner, such as Grb2 as some of the results of this study could allude to, or 
through the control of trafficking or even a BDNF-dependent mechanism, is yet to 
be confirmed. nWASP has previously been shown to be involved in receptor 
trafficking of EGFR (Kessels and Qualmann, 2002) through endocytosis. Examining 
whether this mechanism may be affecting TrkB signalling in keratinocytes is one 
area that should be explored in future work. TrkB and BDNF signalling, and other 
signalling mechanisms that are affected by nWASP activity, in keratinocytes and 
other cell models, must also be explored in future work to fully understand how 
nWASP inhibition may alter cellular function and act to encourage chronic wound 
healing in vivo.  
Since the relationship between nWASP and TrkB has been highlighted in this study 
which focusses on the context of the skin and chronic wounds, the role of TrkB 
and its ligand BDNF must also be elucidated in the control of skin cell behaviour. 
Although neurotrophins and their receptors have previously been shown to have 
a role in skin cell function (Botchkarev et al., 2006), TrkB and BDNF are relatively 
unexplored in this context. This study has demonstrated that TrkB activity in basal 
keratinocytes of non-healing chronic wounds is increased and suggests that there 
may be a link between downstream signalling pathways and keratinocyte 
differentiation. Significant further study will be required to explore TrkB activity 
and the link between nWASP and TrkB in the context of chronic wounds. 
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8.1.5. nWASP is a novel regulator of lung cancer progression 
nWASP has also been identified a novel regulator of lung cancer cell behaviour 
and correlates with aspects of lung cancer progression and survival. Although 
nWASP has been identified as a regulator of cell function in the context of cancer 
and its activity has also been shown to correlate with some aspects of cancer 
progression previously (Frugtniet et al., 2015), the role of nWASP in lung cancer 
remains largely unexplored. This study has begun to explore the potential 
importance of nWASP as a regulator of lung cancer progression and cell behaviour 
and has added to the growing body of research that highlights nWASP as an 
important molecule in cell functions in a range of context. This study has 
demonstrated that nWASP inhibitors can alter cell functions, such as invasion and 
migration in various lung cancer cell models and the effects on cell behaviour 
appears to vary with the aggressiveness of the cell type. This perhaps implies a 
varied role of nWASP in squamous carcinomas and adenocarcinomas which 
already exhibit varied phenotypes. Paxillin and FAK activity was altered by nWASP 
inhibition in both of these cell types. This may go some way towards explaining 
how nWASP inhibitors are able to affect cell function as both paxillin and FAK are 
known to affect cell adhesion and hence migration and invasion in a variety of cell 
types (Hu et al., 2014). The more that is understood about how nWASP can affect 
lung cancer cell activity and how these findings may translate to an in vivo setting, 
the closer the development of therapies and interventions that may be able to act 
to alter aspects of nWASP activity in a therapeutic capacity becomes. 
This study has explored nWASP and the effect of knockdown and inhibitor 
treatment in both the context of wound healing and lung cancer. As was discussed 
in section 1.4, there are many parallels that can be drawn between cancer 
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progression and the process of wound healing including the importance of cell 
migration/invasion, inflammation and angiogenesis. Several signalling pathways 
and molecules that control these cell functions, particular growth factor signals, 
have also been found to be active in both wound healing and cancer progression, 
with the activity of nWASP being one of them. The focus of this study has not 
been to directly compare the effects of nWASP inhibition/knockdown between 
the setting of skin and lung cancer cells but to consider the role of nWASP in these 
contexts separately. In doing so, nWASP activity has been shown to be able to 
alter the function of lung cancer and skin cell lines. The effects of nWASP 
inhibition and knockdown vary between the two lung cancer cell lines examined 
(SK-MES-1 and A-549 cells) and so it is unsurprising that the functional changes in 
the skin cell models are not conserved, especially considering the different 
inhibitor levels applied. Whether the underlying molecular pathways that were 
found to be affected by nWASP inhibition and knockdown these two contexts are 
conserved was not explored. The TrkB tyrosine 816 site that was found to be 
extremely sensitive to nWASP activity in keratinocytes was also found to be active 
in both lung cancer cell lines (data not shown, n=1). Whether this pathway is 
sensitive to nWASP activity in these lung cancer cell types is yet to be studied. 
TrkB has previously been linked to tumour growth and metastasis in several 
cancers including prostate, neuroblastoma and recently lung cancer with TrkB 
activation by BDNF linked to NSCLC proliferation (Chen et al., 2016), knockdown 
of TrkB leading to a decrease in the metastatic behaviour of lung adenocarcinoma 
cell lines and TrkB expression correlating with metastasis in lung cancer patients 
(Sinkevicius et al., 2014). The relationship between nWASP and TrkB discovered in 
keratinocytes, and the importance of nWASP in the function of lung cancer cells, 
shown in this study therefore point to an area of further research where the role 
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of nWASP signalling and the control of TrkB activity in lung cancer can be 
explored. Likewise, the changes to paxillin and FAK expression detected by this 
study in lung cancer cells in response to nWASP inhibition and knockdown should 
be further explored in the context of skin cells and may offer some explanation for 
the change in skin cell function observed following changes to nWASP activity.  
8.2. Conclusions and future directions 
In summary, this body of work has demonstrated that nWASP activity has the 
capacity to alter cell behaviour in a range of contexts from a skin and wound 
setting to the context of lung cancer. Novel potential signalling pathways that are 
affected by nWASP activity in keratinocytes have been identified and the use of 
nWASP inhibitors as a potential therapy for the treatment of chronic wounds has 
been explored. Future studies to elucidate the effect of nWASP inhibitor 
treatment on the function of, and signalling changes in, other cell types that are 
active in the wound healing process, particularly immune cells and fibroblasts will 
complement the findings from this study using keratinocyte and vascular 
endothelial cell lines. Consideration of the global effect of nWASP inhibition in the 
wound environment, through further in vivo studies and a more detailed 
understanding of the downstream signalling changes that occur following nWASP 
inhibition and knockdown, are also necessary. Further work as detailed above 
may be able to confirm whether nWASP inhibition will prove to be an effective 
means of encouraging chronic wound healing in humans in the future. 
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